Composition comprising a biologically pure culture of bacillus spp. strain nrrlb-67746, method for treating a plant to increase plant growth, and coated seed

Abstract

Bacillus strain and methods of its use for plant growth promotion. The present invention relates to a composition comprising a biologically pure culture of Bacillus spp. strain NRRL B-67746 and mutants of that strain possessing all the identifying characteristics of the strain. The present invention also provides a method for promoting plant growth, wherein the method comprises applying such strain or mutants to the plant, to a part of the plant and / or to a locus of the plant.

Description

1 / 98 COMPOSITION COMPRISING A BIOLOGICALLY PURE CULTURE OF BACILLUS SPP. STRAIN NRRL B-67746, METHOD FOR TREATING A PLANT TO INCREASE PLANT GROWTH, AND COATED SEED CROSS-REFERENCE TO RELATED REQUESTS

[0001] This application claims priority for the Patent Application Provisional Serial No. US 62 / 865,823, filed on June 24, 2019, the contents of which are incorporated herein by reference in their entirety. REFERENCE TO THE ELECTRONICALLY SUBMITTED SEQUENCE LISTING

[0002] The official copy of the sequence listing is submitted electronically via EFS-Web as an ASCII-formatted sequence listing with a file named BCS199001_WO_ST25.txt created on June 3, 2020, and having a size of 3 kilobytes, and is archived concurrently with the specification. The ASCII-formatted sequence listing contained in this document is part of the specification and is incorporated herein by reference in its entirety. TECHNICAL FIELD

[0003] The present invention relates to the field of bacterial strains and their ability to improve plant health, including yield. BACKGROUND

[0004] In crop protection, there is an ongoing need for applications that improve plant health. Healthier plants generally result in higher yields and / or better quality of a plant or its products. In addition, due to their greater vigor, healthier plants exhibit better resistance to biotic and / or abiotic stress. Petition 870260055028, dated 08 / 06 / 2026, page 8 / 321 2 / 98

[0005] In order to promote plant health, fertilizers are used worldwide, based on inorganic and organic substances. A fertilizer can be a single substance or a combination and is used to supply nutrients to plants. A major advance in fertilizer application was the development of nitrogen-based fertilizers by Justus von Liebig around 1840. Fertilizers, however, can lead to soil acidification and destabilization of the nutrient balance in the soil, including mineral depletion and enrichment of salt and heavy metals. Furthermore, excessive fertilizer use can lead to changes in soil fauna, as well as contaminate surface and groundwater. Additionally, substances harmful to health, such as nitrates, can be added to plants and fruits.

[0006] A possible alternative to fertilizer for advancing plant growth is plant-associated bacteria, such as rhizobacteria. These bacteria are associated with many, if not all, plant species. The mechanism behind the effect of plant-associated bacteria on plant growth is still open to speculation. Ryu, et al., (Proc. Natl. Acad. Sci. USA

[2003] 100, 4927-4932) suggested that among rhizobacteria that colonize roots, some strains regulate plant growth through the release of 2,3-butanediol and / or acetoin.

[0007] The need remains to provide alternative means to promote plant growth and improve its health. This includes the need for highly effective plant growth-promoting rhizobacteria and related fermentation products. SUMMARY

[0008] To meet this need, the Applicants have developed a plant growth-promoting rhizobacterium with excellent plant growth-promoting abilities: Petition 870260055028, dated 08 / 06 / 2026, p. 9 / 321 3 / 98 Bacillus spp. NRRL B-67746. The present invention is directed to compositions comprising Bacillus spp. NRRL B-67746. The invention also encompasses mutants of such strain exhibiting all the identifying characteristics of the parental strain. Such compositions are biologically pure cultures of the parental or mutant strain. In some cases, such mutants have improved plant growth-promoting ability compared to the Bacillus spp. NRRL B-67746 strain.

[0009] In certain aspects, the mutant strains exhibit sequence identity of more than 90% to the Bacillus spp. NRRL B-67746 strain. In other aspects, the mutant strains exhibit at least approximately 98% sequence identity with the 16S rRNA sequence of B-67746.

[0010] In some cases, the compositions are fermentation products of Bacillus spp. NRRL B-67746 strain or mutants thereof. In other cases, the fermentation product is a freeze-dried powder or a spray-dried powder.

[0011] In certain aspects, the fermentation product also comprises a formulation ingredient. The formulation ingredient may be a wetting agent, extender, solvent, spontaneity promoter, emulsifier, dispersant, freeze protectant, osmoprotectant, thickener, spore-starting nutrient and / or an adjuvant. In one embodiment, the formulation ingredient is a thickener. In yet another aspect, the fermentation product is a fluid suspension.

[0012] The present invention also provides a method of treating a plant to improve plant growth, including increasing plant yield, by applying to the plant, a part of the plant and / or a location on the plant the strain Bacillus spp. B-67746 or a mutant thereof or a composition comprising the strain Petition 870260055028, dated 08 / 06 / 2026, p. 10 / 321 4 / 98 Bacillus spp. B-67746 or a mutant thereof. The composition may be a fermentation product of Bacillus spp. strain B-67746 or a mutant thereof. In yet another aspect of this embodiment, the composition also comprises an agriculturally acceptable carrier, such as a formulation ingredient.

[0013] In other embodiments, the method involves applying the composition to the seed of a plant.

[0014] In other respects, useful plants are selected from the group consisting of soybeans, corn, sorghum, cotton, wheat, canola (rapeseed), and sugar beets.

[0015] In yet another aspect, the composition comprises a seed of a useful plant coated with Bacillus spp. strain B-67746 or a mutant thereof. In one embodiment, the strain is applied at about 1 χ 105 to about 1 χ 1010 colony forming units (CFU) per seed of Bacillus spp. strain B-67746 or a mutant thereof. DETAILED DESCRIPTION

[0016] Bacillus spp. NRRL B-67746 is a rhizobacterium that was isolated from field trials testing disease management in cotton in the USA. Bacillus spp. NRRL B-67746 is also known as AP211. Standard assays were conducted to determine that NRRL B-67746 produces siderophores and indoleacetic acid, improves nitrogen assimilation and absorption, and is present in soybean nodules. These properties are indicative of plant growth-promoting properties. For example, siderophore production may cause increased iron availability in plants associated with the bacterium, as siderophores can complex iron, thus making it available for plant uptake. Furthermore, plants use phytohormones, such as auxins, including IAA, to influence cell function. Some studies have shown a positive correlation between Petition 870260055028, dated 08 / 06 / 2026, page 11 / 321 5 / 98 a produção microbiana de IAA e o crescimento da planta. Ver Shahab, S., et al., Indole Acetic Acid Production and Enhanced Plant Growth Promotion by Indigenous PSBs, African Journal of Agricultural Research, Vol. 4 (11), (Novembro de 2009), 1312-1316; ver também Marques, A., et al., Assessment of the Plant Growth Promotion Abilities of Six Bacterial Isolates Using Zea mays as Indicator Plant, Soil Biology and Biochemistry, 42 (2010), 1229-1235.

[0017] NRRL B-67746 was identified as a Bacillus strain by 16S ribosomal RNA sequencing. The 16S ribosomal DNA sequence for NRRL B-67746 is provided as SEQ ID NO: 1. Whole genome sequence analyses for NRRL B-67746 revealed that the strain is part of the Bacillus amyloliquefaciens operational group, as described in Fan, B., et al., Bacillus amyloliquefaciens, Bacillus velezensis, and Bacillus siamensis form an Operational Group B. amyloliquefaciens within the B. subtilis Species Complex, Front Microbiol, vol. 8, p. 22 (2017). It was also determined based on whole genome sequencing that NRRL B-67746 is a Bacillus velezensis.

[0018] NRRL B-67746 was cultivated in the laboratory and the resulting fermentation product was tested against fermentation products of several other rhizobacteria. Compositions based on NRRL B67746 possess unique and superior plant growth-promoting properties compared to other Bacillus spp. strains of the Bacillus amyloliquefaciens operational group and were therefore selected for further development. The examples section provides details of such assays and comparisons.

[0019] The term plant growth promotion or plant growth promotion, as used herein, refers to the ability of a microorganism to exert a beneficial effect on plant growth, development, or crop yield. By Petition 870260055028, dated 08 / 06 / 2026, page 12 / 321 6 / 98 For example, this may be related to increased length, increased total surface area, volume, and / or fresh and / or dry weight of roots and shoots of treated plants or crops compared to untreated plants or crops. Other indications of a beneficial effect on plant growth include enhanced nodulation in soybean grains, an overall increase in the total number of finer roots, and an increased number of branched roots.

[0020] Plant growth promotion may also be characterized by improved plant vigor, including the following: (a) improved plant vitality, (b) improved plant and / or plant product quality, for example, improved protein content, (c) improved visual appearance, (d) delayed senescence, (e) increased root growth and / or more developed root system (e.g., determined by root dry mass), change in root architecture, (f) increased nodulation, in particular rhizobia nodulation, (g) longer panicles, (h) larger leaf blade, (i) fewer dead basal leaves, (j) increased chlorophyll content, (k) increased nitrogen balance index, (l) decreased anthocyanins, (m) prolonged photosynthetically active period, (n) increased or improved plant stand density, (o) less plant back (housing), (p) increased plant weight, (q) increased plant height increased,(r) increased tillering,(s) stronger and / or more productive tillers, (t) less productive tillers, (u) enhanced photosynthetic activity and / or enhanced pigment content and therefore greener leaf color, (v) earlier and / or improved germination, (w) improved and / or more uniform and / or earlier emergence, (x) increased shoot growth, (y) earlier flowering, (z) earlier fruiting, (aa) earlier grain maturity, (ab) less fertilizer needed, (ac) fewer seeds needed per plant area, (ad) improved association with beneficial symbionts, Petition 870260055028, dated 08 / 06 / 2026, p. 13 / 321 7 / 98 such as mycorrhizae, (ae) improved grain size and / or fill, such as in maize or wheat, (af) enhanced tolerance to environmental or nutritional stress, and (ag) improved plant nutrition and / or water uptake.

[0021] According to the present invention, increased yield of a plant, in particular of an agricultural, forestry and / or ornamental plant, means that the economic yield of a product of the respective plant (seed, tuber, leaf, flower) is increased by a measurable amount over the yield of the same product from the plant produced under the same conditions, but without the application of the composition of the invention or without the application of a parental bacterial strain, such as Bacillus spp. NRRL B-67746 or a mutant thereof. According to the present invention, it is preferred that the yield be increased by at least 0.5%, or at least 1%, or at least 2%, or at least 4%, or at least 5%, or at least 10% when compared with appropriate controls.

[0022] Plant growth-promoting ability refers to the ability of a strain to improve one of the above properties of a plant after application to a plant, plant part, or plant site compared to a plant that has not been treated with the plant growth-promoting strain. In one embodiment, the strains of the present invention increase plant yield or total weight by at least about 0.5%, or at least about 1%, or at least about 2%, or at least about 3%, or at least about 4%, or at least about 5%, or at least about 6%, or at least about 7%, or at least about 8%, or at least about 9%, or at least about 10%, or at least about 11%, or by at least about 12% when compared to plants produced under the same conditions but without treatment by a plant growth-promoting strain or without Petition 870260055028, dated 08 / 06 / 2026, p. 14 / 321 8 / 98 the application of Bacillus spp. NRRL B-67746 or a mutant thereof.

[0023] The present invention also provides mutants of Bacillus spp. strain NRRL B-67746 with enhanced plant growth-promoting properties and for methods of generating, screening and developing such mutants.

[0024] The term mutant refers to a genetic variant derived from Bacillus spp. strain NRRL B-67746. In one embodiment, the mutant has one or more or all of the identifying (functional) characteristics of Bacillus spp. strain NRRL B-67746. In a particular case, the mutant or a fermentation product thereof enhances plant health, including yield. Such mutants may be genetic variants possessing a genomic sequence with more than about 85%, more than about 90%, more than about 95%, more than about 96%, greater than about 97%, more than about 98%, or more than about 99% sequence identity with NRRL B-67746. Alternatively, such mutants may exhibit a 16SrDNA sequence with at least approximately 98%, at least approximately 99%, or at least approximately 100% sequence identity to the 16SrDNA sequence of NRRL B-67746.

[0025] The mutant strain may be any mutant strain that has one or more or all of the identifying characteristics of Bacillus spp. strain NRRL B-67746 and, in particular, plant growth-promoting activity that is better than that of one or more of such strains. In yet another embodiment, the mutant produces more indoleacetic acid (IAA) than the parental strain.

[0026] Mutants can be obtained by treating Bacillus spp. strain NRRL B-67746 with chemicals or irradiation or by selecting spontaneous mutants from a population of such Bacillus spp. strain NRRL B-67746 (as resistant mutants to Petition 870260055028, dated 08 / 06 / 2026, p. 15 / 321 9 / 98 phages or antibiotic-resistant), by genome entanglement, as described below, or by other means well known to practitioners of the technique, such as gene editing.

[0027] Genome entanglement between Bacillus strains can be facilitated through the use of a process called protoplast fusion. The process begins with the formation of protoplasts from vegetative bacillary cells. Removal of the peptidoglycan cell wall, typically using lysozyme and an osmotic stabilizer, results in the formation of a protoplast. This process is visible under a light microscope with the appearance of spherical cells. The addition of polyethylene glycol (PEG) then induces fusion between the protoplasts, allowing the genetic contents of two or more cells to come into contact, facilitating recombination and genome entanglement. The fused cells then partition and are recovered in a solid growth medium. During recovery, the protoplasts rebuild the peptidoglycan cell walls, transitioning back to the bacillary form. See Schaeffer, et al., (1976) PNAS USA, vol. 73, 6:2151-2155).

[0028] In one embodiment, the method of obtaining mutants includes generating mutants and then screening such mutants for increased plant growth promotion compared with the parental strain. In one embodiment, the plant yield, crop, fruit or vegetable yield or plant mass of materials treated with the mutant strain is increased by about 1% to about 10%, by about 2% to about 15%, by about 2% to about 20% compared with the plant yield, crop, fruit or vegetable yield or plant mass of materials treated with the parental strain. In yet another aspect, the plant yield, crop, fruit or vegetable yield of materials treated with the mutant strain is increased by about 1%, about 2%, about 3%, about 4%, about 5%, about 10%, Petition 870260055028, dated 08 / 06 / 2026, p. 16 / 321 10 / 98 approximately 20%, approximately 30%, compared to an untreated plant, crop, fruit or vegetable or compared to a plant, crop, fruit or vegetable treated with the wild type strain.

[0029] In another embodiment, such mutants can then be screened for enhanced production of various plant growth regulators, such as IAA, gibberellin, or cytokinin; enhanced production or activity of 1-aminocyclopropane-1-carboxylate (ACC) deaminase or superoxide dismutase; enhanced production of bacterial compounds that contribute to systemic resistance induced in plants, such as siderophores, salicylic acid, and lipopolysaccharides; and / or enhanced ability to promote plant growth compared to parental strains. Multiple rounds of mutagenesis, with and without screening between rounds, can be used to generate and screen mutants. Fermentation products of mutants possessing one or more enhanced attributes can be produced and applied to plants to promote plant growth.

[0030] In a method according to the invention, a composition containing Bacillus spp. NRRL B-67746 or a plant growth-promoting mutant of the aforementioned strain can be applied to any plant or any part of any plant grown in any type of medium used to grow plants (e.g., soil, vermiculite, shredded cardboard and water) or applied to plants or parts of plants grown aerially, such as orchids or staghorn ferns. The composition can, for example, be applied by spraying, atomizing, vaporizing, dispersing, dusting, watering, squirting, sprinkling, pouring or fumigating. As already indicated above, the application can be carried out in any desired location where the plant of interest is positioned, such as agriculture, horticulture, forestry, plantation, orchard, nursery, organically grown crops, Petition 870260055028, dated 08 / 06 / 2026, page 17 / 321 11 / 98 grass and urban environments.

[0031] The strains and compositions of the present invention can be applied to seeds, plants, or plant parts as a powder, aqueous or non-aqueous solution. The powders can be dry, wettable powders, or water-dispersible granules. In some embodiments, the spore-forming bacteria is a solution, emulsifiable concentrate, wettable powder, suspension concentrate, soluble powder, granules, suspension-emulsion concentrate, natural and synthetic materials impregnated with active compounds, and fine-controlled release capsules. The strains and compositions of the present invention in liquid or dry form can be mixed into the soil before, at the time of, or after planting. In one embodiment, the composition is in the liquid state mixed with the soil before or at the time of planting.

[0032] Compositions of the present invention include biologically pure cultures of the strains described herein. Biologically pure cultures of Bacillus spp. NRRL B-67746 and mutants derived therefrom can be obtained according to methods well known in the art, including using the medium and other methods described below.

[0033] Conventional large-scale microbial culture processes include submerged fermentation, solid-state fermentation, or liquid surface culture. During fermentation, as nutrients are depleted, cells begin the transition from the growth phase to the sporulation phase, so the end product of fermentation is largely spores, metabolites, and residual fermentation medium. Sporulation is part of the natural life cycle of Bacillus spp. and is usually initiated by the cell in response to nutrient limitation. Fermentation is set up to obtain high levels of colony-forming units and to promote sporulation. Bacterial cells, spores, and metabolites in culture media resulting from fermentation can be used directly. Petition 870260055028, dated 08 / 06 / 2026, page 18 / 321 12 / 98 or concentrated by conventional industrial methods, such as centrifugation or filtration, such as tangential flow filtration or depth filtration and evaporation.

[0034] The compositions of the present invention include the products of the microbial culture processes described herein. In embodiments where submerged fermentation is used as the culture process, the product is referred to as a fermentation broth. This broth can be concentrated, as described above. The concentrated fermentation broth can be washed, for example, by means of a diafiltration process, to remove residual fermentation broth and metabolites. The term broth concentrate, as used herein, refers to fermentation broth that has been concentrated by conventional industrial methods, as described above, but remains in liquid form.

[0035] The fermentation broth or broth concentrate can be dried with or without the addition of carriers using conventional drying processes or methods, such as spray drying, freeze drying, tray drying, fluidized bed drying, drum drying or evaporation.

[0036] The resulting dry products can be further processed, such as by grinding or granulation, to achieve a specific particle size or physical shape. The carriers, described below, can also be added after drying.

[0037] The term fermentation product, as used herein, refers to fermentation broth, broth concentrate and / or fermentation broth or dry broth concentrate, referred to herein as dry fermentation broth.

[0038] Cell-free fermentation broth preparations of the strains of the present invention can be obtained by any means known in the art, such as extraction, centrifugation and / or filtration of Petition 870260055028, dated 08 / 06 / 2026, page 19 / 321 13 / 98 Fermentation broth. Those skilled in the art will appreciate that so-called cell-free preparations may not be cell-free, but rather are largely cell-free or essentially cell-free, depending on the technique used (e.g., centrifugation speed) to remove the cells. The resulting cell-free preparation can be dried and / or formulated with components that aid in its application to plants or plant growth media. Concentration methods and drying techniques described above for fermentation broth are also applicable to cell-free preparations.

[0039] In one embodiment, the fermentation product comprises at least about 1 x 10⁵ colony-forming units (CFU) of the microorganism (e.g., Bacillus spp. NRRL B-67746, or a plant growth-promoting or plant health-promoting mutant strain thereof) / mL of broth. In another embodiment, the fermentation product comprises at least about 1 x 10⁶ CFU of the microorganism (e.g., Bacillus spp. NRRL B-67746 or a plant growth-promoting mutant strain thereof) / mL of broth. In yet another embodiment, the fermentation product comprises at least about 1 x 10⁷ CFU of the microorganism (e.g., Bacillus spp. NRRL B-67746 or a plant growth-promoting mutant strain thereof) / mL of broth. In another embodiment, the fermentation product comprises at least about 1 x 108 CFU of the microorganism (e.g., Bacillus spp. NRRL B-67746 or a plant growth-promoting mutant strain thereof) / mL of broth.In another embodiment, the fermentation product comprises at least about 1 x 10⁹ CFU of the microorganism (e.g., Bacillus spp. NRRL B-67746 or a plant growth-promoting mutant strain thereof) / mL of broth. In another embodiment, the fermentation product comprises at least about... Petition 870260055028, dated 08 / 06 / 2026, p. 20 / 321 14 / 98 of 1x1010 CFU of the microorganism (e.g., Bacillus spp. NRRL B67746 or a plant growth-promoting mutant strain thereof) / mL of broth. In another embodiment, the fermentation product comprises at least about 1 x 1011 CFU of the microorganism (e.g., Bacillus spp. NRRL B-67746 or a plant growth-promoting mutant strain thereof) / mL of broth.

[0040] In another embodiment, the fermentation product is a broth concentrate or a dry broth comprising at least about 1 x 10⁸ colony-forming units (CFU) of the microorganism (e.g., Bacillus spp. NRRL B-67746 or a plant health-enhancing mutant strain thereof) / mL of broth. In another embodiment, the fermentation product is a broth concentrate or a dry fermentation broth comprising at least about 1 x 10⁹ CFU of the microorganism (e.g., Bacillus spp. NRRL B67746 or a plant health-enhancing mutant strain thereof) / mL of broth. In another embodiment, the fermentation product is a broth concentrate or a dry fermentation broth comprising at least about 1 x 1010 CFU of the microorganism (e.g., Bacillus spp. NRRL B-67746 or a plant health-enhancing mutant strain thereof) / mL of broth.In another embodiment, the fermentation product is a broth concentrate or a dry fermentation broth comprising at least about 1 x 10¹¹ CFU of the microorganism (e.g., Bacillus spp. NRRL B-67746 or a plant health-enhancing mutant strain thereof) / mL of broth. In another embodiment, the fermentation product is a broth concentrate or a dry fermentation broth comprising at least about 1 x 10¹² CFU of the microorganism (e.g., Bacillus spp. NRRL B-67746 or a plant health-enhancing mutant strain thereof) / mL of broth. In another embodiment, the fermentation product is a broth concentrate or a dry fermentation broth that... Petition 870260055028, dated 08 / 06 / 2026, p. 21 / 321 15 / 98 comprises at least about 1 χ¹⁰¹³ CFU of the microorganism (e.g., Bacillus spp. NRRL B-67746 or a plant health-enhancing mutant strain thereof) / mL of broth. In another embodiment, the fermentation product is a broth concentrate or a dry fermentation broth comprising at least about 1 χ¹⁰¹⁴ CFU of the microorganism (e.g., Bacillus spp. NRRL B67746 or a plant health-enhancing mutant strain thereof) / mL of broth. In another embodiment, the fermentation product is a broth concentrate or a dry fermentation broth comprising from about 1 χ¹⁰⁸ CFU to about 1χ¹⁰¹⁴ CFU of the microorganism (e.g., Bacillus spp. NRRL B-67746 or a plant health-enhancing mutant strain thereof) / mL of broth. In another embodiment, the fermentation product is a broth concentrate or a dry fermentation broth comprising about 1 χ 109 CFU to about 1 χ 1013 CFU of the microorganism (e.g., Bacillus spp.).NRRL B-67746 or a plant health-enhancing mutant strain thereof) / mL of broth. In another embodiment, the fermentation product is a broth concentrate or a dry fermentation broth comprising about 1 χ 1010 CFU to about 1 χ 1012 CFU of the microorganism (e.g., Bacillus spp. NRRL B-67746 or a plant health-enhancing mutant strain thereof) / mL of broth.

[0041] In another embodiment, the fermentation product comprises about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 15%, about 20%, or about 25% of fermentation solids. Fermentation solids include spores, vegetative cells, and unspent fermentation media. In certain respects, the fermentation product comprises from about 1% to about 60% fermentation solids, for example, any range within 1% to 60%, such as 1% to 50%, 1% to 40%. Petition 870260055028, dated 08 / 06 / 2026, p. 22 / 321 16 / 98 1% to 30%, 1% to 25%, 1% to 20%, 1% to 15%, 1% to 10%, 30% to 60%, 40% to 60%, etc. In certain aspects, the fermentation product comprises about 1% to about 25% fermentation solids, about 1% to about 20% fermentation solids, about 1% to about 15% fermentation solids, or about 1% to about 10% fermentation solids.

[0042] The inventive compositions may be used as such or, depending on their particular physical and / or chemical properties, in the form of their formulations or in forms of use prepared from them, such as aerosols, capsule suspensions, cold misting concentrates, hot misting concentrates, encapsulated granules, fine granules, fluid concentrates for seed treatment, ready-to-use solutions, sprayable powders, emulsifiable concentrates, oil-in-water emulsions, water-in-oil emulsions, macrogranules, microgranules, oil-dispersible powders, oil-miscible fluid concentrates, oil-miscible liquids, gas (under pressure), gas-generating product, foams, pastes, pesticide-coated seeds, suspension concentrates, oil dispersion, suspoemulsion concentrates, soluble concentrates, suspensions, including encapsulated suspensions, where, for example, an oil dispersion containing particles solids are encapsulated in water.Wettable powders, soluble powders, powders and granules, water-soluble and water-dispersible granules or tablets, water-soluble and water-dispersible powders for seed treatment, wettable powders, natural products and synthetic substances impregnated with active ingredient, microdispersions, and also microencapsulations in polymeric substances and in seed coating materials, and also ULV cold spray and hot spray formulations.

[0043] In a certain aspect, biologically Petition 870260055028, dated 08 / 06 / 2026, page 23 / 321 17 / 98 pure or related fermentation products of the present invention are combined with an agriculturally acceptable carrier. These agriculturally acceptable carriers may be the formulation inerts described below.

[0044] In a particular aspect, the compositions of the present invention are formulated for seed treatment as sprayable dry powders, fluid suspensions or suspension concentrates, liquid solutions, water-soluble powders or water-dispersible powders.

[0045] In some embodiments, the inventive compositions are liquid formulations. Non-limiting examples of liquid formulations include suspension concentrates and oil dispersions. In other embodiments, the inventive compositions are solid formulations. Non-limiting examples of liquid formulations include freeze-dried powders and spray-dried powders.

[0046] The composition of the present invention may include formulation inerts added to compositions comprising cells, cell-free preparations, or metabolites to improve efficacy, stability, and usability and / or to facilitate processing, packaging, and end-use application in agriculture. Such inerts and formulation ingredients may include carriers, stabilizing agents, nutrients, or physical property modifying agents, which may be added individually or in combination. In some embodiments, the carriers may include liquid materials such as water, oil, and other organic or inorganic solvents and solid materials such as minerals, polymers, or polymer complexes derived biologically or by chemical synthesis. In some embodiments, the carrier is a binder or adhesive that facilitates the adhesion of the composition to a plant part, such as a seed or root. See, for example, Taylor, AG, et al.Concepts and Technologies of Selected Seed Treatments, Annu. Rev. Petition 870260055028, dated 08 / 06 / 2026, p. 24 / 321 18 / 98 Phytopathol. 28: 321-339 (1990). Stabilizing agents may include anti-caking agents, antioxidants, desiccants, protectants, or preservatives. Nutrients may include sources of carbon, nitrogen, and phosphorus, such as sugars, polysaccharides, oil, proteins, amino acids, fatty acids, and phosphates, or micronutrients such as manganese. Modifiers of physical properties may include bulking agents, wetting agents, thickeners, pH modifiers, rheology modifiers, dispersants, adjuvants, surfactants, antifreeze agents, or colorants. In some embodiments, the composition comprising cells, cell-free preparation, or metabolites produced by fermentation may be used directly with or without water as the diluent without any further formulation preparation. In some embodiments, the formulation inerts are added after concentration of the fermentation broth and during and / or after drying.

[0047] In certain respects, the fermentation product further comprises a formulation ingredient. The formulation ingredient may be a wetting agent, diluent, solvent, spontaneity promoter, emulsifier, dispersant, freeze protectant, thickener and / or an adjuvant. In one embodiment, the formulation ingredient is a wetting agent.

[0048] The composition of the present invention may include formulation ingredients added to the composition of the present invention to improve recovery, efficacy or physical properties and / or to aid in processing, packaging and administration. These formulation ingredients may be added individually or in combination.

[0049] The ingredients of the formulation may be added to compositions comprising cells, cell-free preparations and / or metabolites to improve efficacy, stability and properties. Petition 870260055028, dated 08 / 06 / 2026, page 25 / 321 19 / 98 physical properties, usability, and / or to facilitate processing, packaging, and end-use application. Such formulation ingredients may include carriers, inerts, stabilizing agents, preservatives, nutrients, or physical property modifying agents, which may be added individually or in combination. In some embodiments, the carriers may include liquid materials such as water, oil, and other organic or inorganic solvents and solid materials such as minerals, polymers, or polymer complexes derived biologically or by chemical synthesis. In some embodiments, the formulation ingredient is a binder, adjuvant, or adhesive that facilitates the adhesion of the composition to a plant part such as leaves, seeds, or roots. See, for example, Taylor, AG, et al., Concepts and Technologies of Selected Seed Treatments, Annu. Rev. Phytopathol., 28: 321-339 (1990).Stabilizing agents may include anti-caking agents, antioxidants, anti-settling agents, anti-foaming agents, desiccants, protectants, or preservatives. Nutrients may include sources of carbon, nitrogen, and phosphorus, such as sugars, polysaccharides, oil, proteins, amino acids, fatty acids, phosphates, macronutrients, and micronutrients. Macronutrients include nitrogen, phosphorus, potassium, calcium, sulfur, and magnesium. Micronutrients include zinc, boron, manganese, iron, copper, sodium, molybdenum, and nickel, typically in small amounts. Modifiers of physical properties may include bulking agents, wetting agents, thickeners, pH modifiers, rheology modifiers, dispersants, adjuvants, surfactants, film formers, hydrotropic agents, builders, antifreeze agents, or colorants.In some embodiments, the composition comprising cells, cell-free preparations and / or metabolites produced by fermentation can be used directly with or without water as the diluent without any other. Petition 870260055028, dated 08 / 06 / 2026, page 26 / 321 20 / 98 formulation preparation. In a particular embodiment, a wetting agent, or a dispersant, is added to a dry broth concentrate, such as a freeze-dried or spray-dried powder. A wetting agent increases the spreading and penetration properties, or a dispersant increases the dispersibility and solubility of the active ingredient (once diluted) when applied to surfaces. Exemplary wetting agents are known to those skilled in the art and include sulfosuccinates and derivatives, such as MULTIWET™ MO-70R (Croda Inc., Edison, NJ); siloxanes such as BREAK-THRU® (Evonik, Germany); nonionic compounds, such as ATLOX™ 4894 (Croda Inc., Edison, NJ); alkyl polyglucosides, such as TERWET® 3001 (Huntsman International LLC, The Woodlands, Texas); C12-C14 alcohol ethoxylate, such as TERGITOL® 15-S-15 (The Dow Chemical Company, Midland, Michigan); phosphate esters, such as RHODAFAC® BG-510 (Rhodia, Inc.); and alkyl ether carboxylates, such as EMULSOGEN™LS (Clariant Corporation, North Carolina).

[0050] The present invention provides combinations of active compounds comprising (a) Bacillus spp. strain NRRL B-67746 or a plant growth-promoting mutant of this strain and (b) at least one other active compound active against at least one plant pathogen and / or plant pest or active in promoting plant growth, including fungicides, insecticides, nematicides and microbial-based products.

[0051] Chemical fungicide mixing partner (b)

[0052] In one embodiment, the combinations of active compounds according to the invention comprise as compound (b) at least one other active compound selected from the following groups (1) ergosterol synthesis inhibitors, (2) respiratory chain inhibitors in complex I or II, (3) respiratory chain inhibitors in complex III, Petition 870260055028, dated 08 / 06 / 2026, p. 27 / 32121 / 98 (4) inhibitors of mitosis and cell division, (5) compounds capable of having a multi-site action, (6) compounds capable of inducing a host defense, (7) inhibitors of amino acid and / or protein biosynthesis, (8) inhibitors of ATP production, (9) inhibitors of cell wall synthesis, (10) inhibitors of lipid and membrane synthesis, (11) inhibitors of melanin biosynthesis, (12) inhibitors of nucleic acid synthesis, (13) inhibitors of signal transduction, (14) compounds capable of acting as an uncoupler, (15) other fungicides selected from the group consisting of (15.001) abscisic acid, (15.002) bentiazole, (15.003) betoxazine, (15.004) capsimycin, (15.005) carvone, (15.006) quinomethionate,(15.007) cufraneb, (15.008) ciflufenamide, (15.009) cymoxanil, (15.010) cyprosulfamide, (15.011) flutianil, (15.012) fosetyl-aluminum, (15.013) fosetyl-calcium,(15.014) fosetyl-sodium, (15.015) methyl isothiocyanate, (15.016) metrafenone, (15.017) moderiomycin, (15.018) natamycin, (15.019) dimethyldithiocarbamate de níquel, (15.020) nitrotal-isopropila, (15.021) oxamocarbe, (15.022) oxatiapiprolina, (15.023) oxyphentynine, (15.024) pentachlorophenol e sais, (15.025) phosphorous acid and other substances, (15.026) propamocarbe-fosetilato, (15.027) pyriofenona (clazafenona), (15.028) tebufloquina, (15.029) tecloftalam, (15.030) tolnifanida, (15.031) 1 -(4-{4-[(5R)-5-(2,6-difluorophenyl)-4,5-dihydro-1,2-oxazol-3-yl]-1,3-thiazol-2-yl}piperidin-1-yl)-2-[5-methyl-3(trifluoromethyl)-1H-pyrazol-1 -yl]etanone, (15.032) 1 -(4-{4-[(5S)-5-(2,6-difluorophenyl)-4,5-dihydro-1,2-oxazol-3-yl]-1,3-thiazol-2-yl}piperidin-1 -yl)-2[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1 -yl]etanone, (15.033) 2-(6benzylpyridin-2-yl)quinazoline, (15.034) dipimetitrone, (15.035) 2-[3,5bis(difluoromethyl)-1H-pyrazol-1 -yl]-1 -[4-(4-{5-[2-(prop-2-in-1-yloxy)phenyl]-4,5. Petition 870260055028, 08 / 06 / 2026, pág. 28 / 321 22 / 98 dihydro-1,2-oxazol-3-yl}-1,3-thiazol-2-yl)piperidin-1 -yl]ethanone, (15,036) 2[3,5-bis(difluoromethyl)-1H-pyrazol-1-yl]-1 -[4-(4-{5-[2-chloro-6-(prop-2-in-1 iloxy)phenyl]-4,5-di-hydro-1,2-oxazol-3-yl}-1,3-thiazol-2-yl)piperidine-1yl]ethanone, (15,037) 2-[3,5-bis(difluoromethyl)-1H-pyrazol-1-yl]-1 -[4-(4-{5-[2fluoro-6-(prop-2-in-1 -yloxy)phenyl]-4,5-di-hydro-1,2-oxazol-3-yl-thyl}-naydine]1,3-peridine (15,038) 2-[6-(3-fluoro-4-methoxyphenyl)-5methylpyridine-2-yl]quinazoline, (15,039) 2-{(5R)-3-[2-(1-{[3,5-bis(difluoromethyl)-1H-pyrazol-1 -yl]acetyl}piperidine-4-yl)-1,3-thiazol-4-yl]-4,5-di-hydro-1,2oxazol-5-yl}-3-chlorophenyl methanosulfonate, (15,040) 2-{(5S)-3-[2-(1-oromethyl(){dizol-1,5bis -yl]acetyl}piperidin-4-yl)-1,3-thiazol-4-yl]-4,5-dihydro-1,2-oxazol-5-yl}-3-chlorophenyl methanosulfonate, (15,041) ipflufenoquine, (15,042) 2-{2-fluoro-6-[(8-fluoro-2-methylquinolin-3yl)oxy]phenyl}propan-2-ol, (15,043) fluoxapiproline, (15.044) 2-{3-[2-(1-{[3,5bis(difluoromethyl)-1H-pyrazol-1 -yl]acetyl}piperidin-4-yl)-1,3-thiazol-4-yl]-4,5-dihydro-1,2-oxazol-5-yl}phenyl methanesulfonate, (15.045) 2-phenylphenol e sais, (15.046) 3-(4,4,5-trifluoro-3,3-dimethyl-3,4-di-hidroisoquinolin-1 yl)quinoline, (15.047) quinofumeline, (15.048) 4-amino-5-fluoropirimidin-2-ol (tautomeric form: 4-amino-5-fluoropirimidin-2(1H)-one), (15.049) ácido 4-oxo-4-[(2-phenylethyl)amino]butanoic acid, (15.050) 5-amino-1,3,4thiadiazol-2-thiol, (15.051) 5-chloro-N'-phenyl-N'-(prop-2-in-1 -yl)thiophene-2-sulfonohydrazide, (15.052) 5-fluoro-2-[(4-fluorobenzyl) óxi]pyrimidin-4-amine, (15.053) 5-fluoro-2-[(4-methylbenzyl) óxi]pyrimidin-4-amine, (15.054) 9-fluoro-2,2-dimethyl-5-(quinolin-3-yl)-2,3-di-hydro-1,4benzoxazepine, (15.055) but-3-in-1-yl {6-[({[(Z)-(1-methyl-1H-tetrazol-5yl)(phenyl)methylene] amino}óxi)methyl]pyridin-2-yl}carbamate, (15.056) ethyl (2Z)-3-amino-2-cyano-3-phenylacrylate, (15.057) phenazine-1carboxylic acid, (15.058) propyl 3,4,5-tri-hidroxybenzoate, (15.059) quinolin-8ol, (15,060) quinolin-8-ol sulfate (2:1), (15,061) tert-butyl {6-[({[(1-methyl1H-tetrazol-5-yl)(phenyl)methylene]amino}oxy)methyl]carba (15mato-2,2-yl} 5-fluoro-4-imino-3-methyl-1-[(4-methylphenyl)sulfonyl]-3,4-di. Petition 870260055028, dated 08 / 06 / 2026, p. 29 / 321 23 / 98 hydropyrimidin-2(1H)-one, (15.063) aminopyrifeno, (15.064) (N'-[2-chloro-4(2-fluorophenoxy)-5-methylphenyl]-N-ethyl-N-methylimidoformamida), (15.065) (N'(2-chloro-5-methyl-4-phenoxyphenyl)-N-ethyl-N-methylimidoformamida), (15.066) (2{2-[(7,8-difluoro-2-metilquinolin-3-yl)oxy]-6-fluorofenyl}propan-2-ol), (15.067) (5-bromo-1 -(5,6-dimetilpiridin-3-yl)-3,3-dimetil-3,4-dihidroisoquinolina), (15.068) (3-(4,4-difluoro-5,5-dimetil-4,5-dihidrotieno[2,3-c]piridin-7-yl)quinolina), (15.069) (1 -(4,5-dimetil-1Hbenzimidazol-1-yl)-4,4-difluoro-3,3-dimetil-3,4-dihidroisoquinolina), (15.070) 8-fluoro-3-(5-fluoro-3,3-dimetil-3,4-dihidroisoquinolin-1 yl)quinolona, ​​(15.071) 8-fluoro-3-(5-fluoro-3,3,4,4-tetrametil-3,4-dihidroisoquinolin-1-yl)quinolona, ​​(15.072) 3-(4,4-difluoro-3,3-dimethyl-3,4-dihydroisoquinolin-1-yl)-8-fluoroquinoline, (15.073) (N-methyl-N-phenyl-4-[5(trifluoromethyl)-1,2,4-oxadiazol-3-yl]benzamida), (15.074) methyl {4-[5(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl}carbamate, (15.075) (N-{4-[5(trifluorometil)-1,2,4-oxadiazol-3-il]benzil}ciclopropanocarboxamida), (15.076) N-metil-4-(5-(trifluorometil)-1,2,4-oxadiazol-3-il]benzamida, (15.077) N-[(E)-metoxiiminometil]-4-[5-(trifluorometil)-1,2,4-oxadiazol-3il]benzamida, (15.078) N-[(Z)-metoxiiminometil]-4-[5-(trifluorometil)1,2,4-oxadiazol-3-il]benzamida, (15.079) N-[4-[5-(trifluorometil)-1,2,4oxadiazol-3-il]fenil]ciclopropanocarboxamida, (15.080) N-(2-fluorofenil)4-[5-(trifluorometil)-1,2,4-oxadiazol-3-il]benzamida, (15.081) 2,2-difluoroN-metil-2-[4-[5-(trifluorometil)-1,2,4-oxadiazol-3-il]fenil]acetamida, (15.082) N-alil-N-[[4-[5-(trifluorometil)-1,2,4-oxadiazol-3il)fenil]metil]acetamida, (15.083) N-[(E)-N-metóxi-C-metil-carbonimidoil]4-(5-(trifluorometil)-1,2,4-oxadiazol-3-il]benzamida, (15.084) N-[(Z)-Nmetóxi-C-metil-carbonimidoil]-4-[5-(trifluorometil)-1,2,4-oxadiazol-3il]benzamida, (15.085) N-alil-N-[[4-[5-(trifluorometil)-1,2,4-oxadiazol-3il]fenil]metil]propanamida, (15.086) 4,4-dimethyl-1-[[4-[5-(trifluoromethyl)1,2,4-oxadiazol-3-yl]phenyl]methyl]pyrrolidin-2-one, (15,087) N-methyl-4-[5(trifluoromethyl)-1,2,4-oxadiazol-3-yl]benzenecarbothioamide, (15,088) 5. Petition 870260055028, dated 08 / 06 / 2026, page 30 / 321 24 / 98 methyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]pyrrolidin-2-one, (15.089) N-((2,3-difluoro-4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]-3,3,3-trifluoro-propanamide, (15.090) 1-methoxy-1-methyl-3-[[4[5-(trifluoromethyl}-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, (15.091) 1,1 -diethyl3-[[4-[5-(trifluoromethyl}-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, (15.092) N[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide, (15.093) N-methoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]cyclopropanecarboxamide, (15.094) 1 -methoxy-3-methyl-1 -[[4-[5(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, (15.095) N-methoxy-N[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl)cyclopropanecarboxamide, (15.096) N,2-dimethoxy-N-[[4-[5(trifluoromethyl}-1,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide, (15.097) Nethyl-2-methyl-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3yl)phenyl]methyl]propanamide, (15.098) 1-methoxy-3-methyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, (15.099) 1,3-dimethoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, (15.100) 3-ethyl-1-methoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, (15.101) 1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]piperidin-2one, (15.102) 4,4-dimethyl-2-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]isoxazolidin-3-one, (15.103) 5,5-dimethyl-2-[[4-[5(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]isoxazolidin-3-one, (15.104) 3,3-dimethyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]piperidin-2-one, (15.105) 1 -[[3-fluoro-4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]azepan-2-one, (15.106) 4,4-dimethyl-2-[[4-(5-(trifluoromethyl)1,2,4-oxadiazol-3-yl]phenyl]methyl]isoxazolidin-3-one, (15.107) 5,5-dimethyl-2[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]isoxazolidin-3-one, (15.108)108) etil 1-{4-[5-(trifluorometil)-1,2,4-oxadiazol-3-il]benzil}-1H-pirazol4-carboxilato, (15.109) N,N-dimetil-1-{4-[5-(trifluorometil)-1,2,4- oxadiazol-3-il]benzil}-1H-1,2,4-triazol-3-amina, (15.110) N-{2,3-difluoro4-[5-(trifluorometil)-1,2,4-oxadiazol-3-il]benzil}butanamida, (15.111) NPetição 870260055028, de 08 / 06 / 2026, pág. 31 / 321. 25 / 98 (1-methylcyclopropyl)-4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]benzamida, (15.112) N-(2,4-difluorophenyl)-4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3yl]benzamida, (15.113) 1-(5,6-dimethylpyridin-3-yl)-4,4-difluoro-3,3-dimethyl3,4-di-hydroisoquinoline, (15.114) 1-(6-(difluoromethyl)-5-methyl-pyridin-3-yl)4,4-difluoro-3,3-dimethyl-3,4-di-hydroisoquinoline, (15.115) 1-(5(fluoromethyl)-6-methyl-pyridin-3-yl)-4,4-difluoro-3,3-dimethyl-3,4-dihydroisoquinoline, (15.116) 1-(6-(difluoromethyl)-5-methoxy-pyridin-3-yl)-4,4difluoro-3,3-dimethyl-3,4-dihydroisoquinoline, (15.117) 4-[5-(trifluoromethyl)1,2,4-oxadiazol-3-yl]phenyl dimethylcarbamate, (15.118) N-{4-[5(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl}propanamida, (15.119) 3-[2-(1{[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]acetyl}piperidin-4-yl)-1,3-thiazol-4yl]-1,5-di-hidro-2,4-benzodioxepin-6-ylmethanesulfonate, (15.120) 9fluoro-3-[2-(1-{[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]acetyl}piperidin-4yl)-1,3-thiazol-4-yl]-1,5-di-hidro-2,4-benzodioxepin-6-ylmethanesulfonate, (15.121) 3-[2-(1-{[3,5-bis(difluoromethyl)-1H-pyrazol-1-yl]acetyl}piperidin-4yl)-1,3-thiazol-4-yl]-1,5-di-hidro-2,4-benzodioxepin-6-ylmethanesulfonate, (15,122) 3-[2-(1-{[3,5-bis(difluoromethyl)-1H-pyrazol-1-yl]acetyl}piperidin-4yl)-1,3-thiazol-4-yl]-9-fluoro-1,5-di-hidro-2,4-benzodioxepin-6ylmethanesulfonate, (15.123) 1 -(6,7-dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4difluoro-3,3-dimethyl-3,4-di-hidroisoquinoline, (15.124) 8-fluoro-N-(4,4,4trifluoro-2-methyl-1 -phenylbutan-2-yl)quinoline-3-carboxamide, (15.125) 8fluoro-N-[(2S)-4,4,4-trifluoro-2-methyl-1-phenylbutan-2-yl]quinoline-3carboxamidae, (15,126) N-(2,4-dimethyl-1-phenylpentan-2-yl)-8fluoroquinoline-3-carboxamidae (15,127) N-[(2S)-2,4-dimethyl-1phenylpentan-2-yl]-8-fluoroquinoline-3-carboxamida.

[0053] Compound (B) is preferably selected from:

[0054] Selected ergosterol synthesis inhibitors from the group consisting of (1.001) ciproconazole, (1.002) difenoconazole, (1.003) epoxiconazole, (1.004) phenhexamide, (1.005) phenpropidine, (1.006) phenpropimorph, (1.007) phenpyrazamine, (1.008) fluquinconazole, (1.009) Petition 870260055028, dated 08 / 06 / 2026, page 32 / 321 26 / 98 flutriafol, (1.010) imazalil, (1.011) imazalylsulfato, (1.012) ipconazole, (1.013) metconazole, (1.014) myclobutanil, (1.015) paclobutrazol, (1.016) prochloraz, (1.017) propiconazole, (1.018) prothioconazole, (1.019) pyrisoxazole, (1.020) spiroxamine, (1.021) tebuconazole, (1.022) tetraconazole, (1.023) triadimenol, (1.024) tridemorpho, (1.025) triticonazole, (1.026) (1R,2S,5S)-5-(4-chlorobenzyl)-2-(chloromethyl)-2-methyl-1 -(1H-1,2,4triazol-1-ylmethyl)cyclopentanol, (1.027) (1S,2R,5R)-5-(4-chlorobenzyl)-2(chloromethyl)-2-methyl-1-(1H-1,2,4-triazol-1-ylmethyl)cyclopentanol, (1.028) (2R)-2-(1-chlorocyclopropyl)-4-[(1 R)-2,2-dichlorocyclopropyl]-1-(1H-1,2,4triazol-1-yl)butan-2-ol, (1.029) (2R)-2-(1-chlorocyclopropyl)-4-[(1S)-2,2dichlorocyclopropyl]-1-(1H-1,2,4-triazol-1-yl)butan-2-ol, (1.030) (2R)-2-[4-(4chlorophenoxy)-2-(trifluoromethyl)phenyl]-1-(1H-1,2,4-triazol-1-yl)propan-2-ol, (1.031) (2S)-2-(1-chlorocyclopropyl)-4-[(1R)-2,2-dichlorocyclopropyl]-1 -(1 H1,2,4-triazol-1-yl)butan-2-ol, (1.031)032) (2S)-2-(1-chlorocyclopropyl)-4-[(1S)-. 2,2-dichlorocyclopropyl]-1-(1H-1,2,4-triazol-1-yl)butan-2-ol, (1.033) (2S)-2- [4-(4-chlorophenoxy)-2-(trifluoromethyl)phenyl]-1 -(1H-1,2,4-triazol-1 -yl)propan-2ol, (1,034) (R)-[3-(4-chloro-2-fluorophenyl)-5-(2,4-difluorophenyl)-1,2-oxazol-4yl](pyridine-3-yl)methanol, (1.035) (S)-[3-(4-chloro-2-fluorophenyl)-5-(2,4difluorophenyl)-1,2-oxazol-4-yl](pyridine-3-yl)methanol, (1,036) [3-(4-chloro-2fluorophenyl)-5-(2,4-difluorophenyl)-1,2-oxazol-4-yl](pyridine-3-yl)methanol, (1.037) 1-({(2R,4S)-2-[2-chloro-4-(4-chlorophenoxy)phenyl]-4-methyl-1,3-dioxolan2-yl}methyl)-1H-1,2,4-triazole, (1,038) 1 -({(2S,4S)-2-[2-chloro-4-(4chlorophenoxy)phenyl]-4-methyl-1,3-dioxolan-2-yl}methyl)-1H-1,2,4-triazole, (1,039) 1 -{[3-(2-chlorophenyl)-2-(2,4-difluorophenyl)oxiran-2-yl]methyl}-1H-1,2,4-triazol-5ylthiocyanate, (1,040) 1-{[rel(2R,3R)-3-(2-chlorophenyl)-2-(2,4difluorophenyl)oxiran-2-yl]methyl}-1H-1,2,4-triazol-5-ylthiocyanate, (1,041) 1 {[rel(2R,3S)-3-(2-chlorophenyl)-2-(2,4-difluorophenyl)oxiran-2-yl]methyl}-1H1,2,4-triazol-5-ylthiocyanate, (1.042) 2-[(2R,4R,5R)-1-(2,4-dichlorophenyl)-5hydroxy-2,6,6-trimethyl-heptan-4-yl]-2,4-di-hydro-3H-1,2,4-triazole-3-thione, (1.043) 2-[(2R,2,5S)-1 -(2,4-dichlorophenyl)-5-hydroxy-2,6,6-trimethyl-heptanePetition 870260055028, of 08 / 06 / 2026, p. 33 / 321. 27 / 98 4-yl]-2,4-di-hydro-3H-1,2,4-triazol-3-thione, (1,044) 2-[(2R,4S,5R)-1-(2,4dichlorophenyl)-5-hydroxy-2,6,6-trimethyl-heptan-4-yl]-2,4-di-hydro-3H-1,2,4triazol-3-thione, (1,045) 2-[(2R,4S,5S)-1-(2,4-dichlorophenyl)-5-hydroxy-2,6,6trimethyl-heptan-4-yl]-2,4-di-hydro-3H-1,2,4-triazol-3-thione, (1,046) 2[(2S,4R,5R)-1-(2,4-dichlorophenyl)-5-hydroxy-2,6,6-trimethyl-heptan-4-yl]-2,4-dihydro-3H-1,2,4-triazol-3-thione, (1,047) 2-[(2S),4R -(2,4-dichlorophenyl)5-hydroxy-2,6,6-trimethyl-heptan-4-yl]-2,4-di-hydro-3H-1,2,4-triazol-3-thione, (1,048) 2-[(2S,4S,5R)-1 -(2,4-dichlorophenyl)-5-hydroxy-2,6,6-trimethyl-heptane4-yl]-2,4-di-hydro-3H-1,2,4-triazol-3-thione, (1,049) 2-[(2S,4S,5S)-1-(2,4dichlorophenyl)-5-hydroxy-2,6,6-trimethyl-heptan-4-yl]-2,4-di-hydro-3H-1,2,4triazol-3-thione, (1,050) 2-[1-(2,4-dichlorophenyl)-5-hydroxy-2,6,6-trimethylheptan-4-yl]-2,4-di-hydro-3H-1,2,4-triazol-3-thione, (1,051) 2-[2-chloro-4(2,4)-dichlorophen(2,4)-oxychlorophene H-1,2,4-triazol-1 -yl)propane-2-ol, (1.052) 2-[2chloro-4-(4-chlorophenoxy)phenyl]-1-(1H-1,2,4-triazol-1-yl)butan-2-ol, (1.053) 2[4-(4-chlorophenoxy)-2-(trifluoromethyl)phenyl]-1-(1H-1,2,4-triazol-1-yl)butan-2-ol, (1.054) 2-[4-(4-chlorophenoxy)-2-(trifluoromethyl)phenyl]-1-(1H-1,2,4-triazol-1yl)pentan-2-ol, (1.055) mefentrifluconazole, (1.056) 2-{[3-(2-chlorophenyl)-2(2,4-difluorophenyl)oxiran-2-yl]methyl}-2,4-dihydro-3H-1,2,4-triazol-3-thione, (1.057) 2-{[rel(2R,3R)-3-(2-chlorophenyl)-2-(2,4-difluorophenyl)oxiran-2yl]methyl}-2,4-dihydro-3H-1,2,4-triazole-3-thione, (1.058) 2-{[rel(2R,3S)-3-(2chlorophenyl)-2-(2,4-difluorophenyl)oxiran-2-yl]methyl}-2,4-dihydro-3H-1,2,4triazole-3-thione, (1.059) 5-(4-chlorobenzyl)-2-(chloromethyl)-2-methyl-1 -(1H1,2,4-triazol-1-ylmethyl)cyclopentanol, (1.060) 5-(allylsulfanyl)-1 -{[3-(2chlorophenyl)-2-(2,4-difluorophenyl)oxiran-2-yl]methyl}-1H-1,2,4-triazole, (1.061) 5(allylsulfanyl)-1-{[rel(2R,3R)-3-(2-chlorophenyl)-2-(2,4-difluorophenyl)oxiran-2-yl]methyl}-1H-1,2,4-triazole, (1.061)062) 5-(allylsulfanyl)-1-{[rel(2R,3S)-3-(2chlorophenyl)-2-(2,4-difluorophenyl)oxiran-2-yl]methyl}-1H-1,2,4-triazole, (1.063) N'-(2,5-dimethyl-4-{[3-(1,1,2,2-tetrafluoroethoxy)phenyl]sulfanyl}phenyl)-N-ethyl-Nmethylimidoformamide, (1,064) N'-(2,5-dimethyl-4-{[3-(2,2,2-trifluoroethoxy)phenyl]sulfanyl}phenyl)-N-ethyl-N-methylimidoformamide, (1,065) N'-(2,5-dimethyl. Petition 870260055028, dated 08 / 06 / 2026, p. 34 / 321 28 / 98 4-{[3-(2,2,3,3-tetrafluoropropoxy)phenyl]sulfanyl}phenyl)-N-ethyl-N-methylimidoformamide, (1.066) N'-(2,5-dimethyl-4-{[3-(pentafluoroethoxy)phenyl]sulfanyl}phenyl)-N-ethyl-N-methylimidoformamide, (1.067) N'-(2,5-dimethyl4-{3-[(1,1,2,2-tetrafluoroethyl)sulfanyl]phenoxy}phenyl)-N-ethyl-N-methylimidoformamide, (1.068) N'-(2,5-dimethyl-4-{3-[(2,2,2-trifluoroethyl)sulfanyl]phenoxy}phenyl)-N-ethyl-N-methylimidoformamide, (1.069) N'-(2,5-dimethyl-4-{3-[(2,2,3,3-tetrafluoropropyl)sulfanyl]phenoxy}phenyl)-N-ethyl-N-methylimidoformamide, (1.070) N'-(2,5-dimethyl-4-{3-[(pentafluoroethyl)sulfanyl]phenoxy}phenyl)-N-ethyl-N-methylimidoformamide, (1.071) N'-(2,5-dimethyl-4-phenoxyphenyl)-N-ethyl-N-methylimidoformamide, (1.072) N'-(4-{[3(difluoromethoxy)phenyl]sulfanyl}-2,5-dimethylphenyl)-N-ethyl-N-methylimidoformamide, (1.073) N'-(4-{3-[(difluoromethyl)sulfanyl]phenoxy}-2,5dimethylphenyl)-N-ethyl-N-methylimidoformamide, (1.074) N'-[5-bromo-6-(2,3-dihydro-1H-inden-2-yloxy)-2-methylpyridin-3-yl]-N-ethyl-N-methylimidoformamide, (1.075) N'-{4-[(4,5-dichloro-1,3-thiazol-2-yl)oxy]-2,5-dimethylphenyl}-N-ethyl-N-methylimidoformamide, (1.076) N'-{5-bromo-6-[(1R)-1-(3,5difluorophenyl)ethoxy]-2-methylpyridin-3-yl}-N-ethyl-N-methylimidoformamide, (1.077) N'-{5-bromo-6-[(1S)-1-(3,5-difluorophenyl)ethoxy]-2-methylpyridin-3-yl}N-ethyl-N-methylimidoformamide, (1.078) N'-{5-bromo-6-[(cis-4isopropylcyclohexyl)oxy]-2-methylpyridin-3-yl}-N-ethyl-N-methylimidoformamide, (1.079) N'-{5-bromo-6-[(trans-4-isopropylcyclohexyl)oxy]-2-methylpyridin-3yl}-N-ethyl-N-methylimidoformamide, (1.080) N'-{5-bromo-6-[1-(3,5difluorophenyl)ethoxy]-2-methylpyridin-3-yl}-N-ethyl-N-methylimidoformamide, (1.081) ipfentrifluconazole, (1.082) 2-[4-(4-chlorophenoxy)-2(trifluoromethyl)phenyl]-1-(1H-1,2,4-triazol-1-yl)propan-2-ol, (1.083) 2-[6-(4bromophenoxy)-2-(trifluoromethyl)-3-pyridyl]-1-(1,2,4-triazol-1-yl)propan-2-ol, (1.084) 2-[6-(4-chlorophenoxy)-2-(trifluoromethyl)-3-pyridyl]-1-(1,2,4-triazol-1yl)propan-2-ol, (1.085) 3-[2-(1-chlorocyclopropyl)-3-(3-chloro-2-fluoro-phenyl)-2hidróxi-propyl]imidazol-4-carbonitrila, (1.086) 4-[[6-[rac-(2R)-2-(2,4difluorophenyl)-1,1-difluoro-2-hidróxi-3-(5-thioxo-4H-1,2,4-triazol-1-yl)propyl]Petition 870260055028, of 06 / 08 / 2026, pág. 35 / 321. 29 / 98 3-pyridyl]óxi]benzonitrila, (1.087) N-isopropyl-N'-[5-metóxi-2-methyl-4-(2,2,2trifluoro-1-hidróxi-1-phenylethyl)phenyl]-N-methylimidoformamida, (1.088) N'-{5bromo-2-methyl-6-[(1-propoxypropan-2-yl)óxi]pyridin-3-yl}-N-ethyl-Nmethylimidoformamida, (1.089) hexaconazol, (1.090) penconazole (1.091) fenbuconazol;

[0055] Respiratory chain inhibitors in complex I or II selected from the group consisting of (2.001) benzovindiflupir, (2.002) bixafen, (2.003) boscalide, (2.004) carboxin, (2.005) fluopiram, (2.006) flutolanil, (2.007) fluxapyroxad, (2.008) furomethpyr, (2.009) isofetamide, (2.010) isopyrazam (antiepimeric enantiomer 1R, 4S, 9S), (2.011) isopyrazam (antiepimeric enantiomer 1S, 4R, 9R), (2.012) isopyrazam (antiepimeric racemate 1RS, 4SR, 9SR), (2.013) isopyrazam (racemate mixture) syn-epimeric 1RS,4SR,9RS antiepimeric eracemate 1RS,4SR,9SR), (2.014) isopyrazam (syn-epimeric enantiomer 1R,4S,9R), (2,015) isopyrazam (syn-epimeric enantiomer 1S,4R,9S), (2,016) isopyrazam (syn-epimeric racemate 1RS,4SR,9RS), (2,017)penflufene, (2,018) penthio18 pidiflumetofen, (2,020) pyraziflumide, (2,021) sedaxano, (2,022) 1,3-dimethyl-N-(1,1,3-trimethyl-2,3di-hydro-1H-inden-4-yl)-1H-pyrazol-4-carboxamide,) 1,3-dimethyl-N[(3R)-1,1,3-trimethyl-2,3-di-hydro-1H-inden-4-yl]-1H-pyrazol-4-carboxamide, (2,024) 1,3-dimethyl-N-[(3S)-1,1,3-trimethyl-2,3-di-hydro-1H-inden-4-yl]-1Hpyrazol-4-carboxamide, (2,025) 1-methyl-3-(trifluoromethyl)-N-[2'(trifluoromethyl)biphenyl-2-yl]-1H-pyrazol-4-carboxamide, (2,026) 2-fluoro-6(trifluoromethyl)-N-(1,1,3-trimethyl)indenza-n-2,3-da-H-di- (2,027) 3-(difluoromethyl)-1-methyl-N-(1,1,3-trimethyl-2,3-di-hydro-1H-inden-4yl)-1H-pyrazol-4-carboxamide, (2,028) impirfluxam, (2,029) 3(difluoromethyl)-1-methyl-N-[(3S)-1,1,3-trimethyl-2,3-di-hydro-1H-inden-4-yl]1H-pyrazol-4-carboxamide, (2,030) fluindapyr, (2.031) 3-(difluoromethyl)-N[(3R)-7-fluoro-1,1,3-trimethyl-2,3-di-hydro-1H-inden-4-yl]-1-methyl-1H-pyrazol4-carboxamide, (2,032) 3-(difluoromethyl)-N-[(3S)-7-fluoro-1,1,3-trimethylPetition 870260055028, dated 08 / 06 / 2026, p. 36 / 321. 30 / 98 2,3- dihydro-1H-inden-4-yl]-1 -methyl-1H-pyrazol-4-carboxamide, (2,033) 5,8- difluoro-N-[2-(2-fluoro-4-{[4-(trifluorometil)piridin-2-il]óxi}fenil) etil]quinazolin-4-amina, (2.034) N-(2-ciclopentil-5-fluorobenzil)-Nciclopropil-3-(difluorometil)-5-fluoro-1-metil-1H-pirazol-4-carboxamida, (2.035) N-(2-terc-butil-5-metilbenzil)-N-ciclopropil-3-(difluorometil)-5fluoro-1-metil-1H-pirazol-4-carboxamida, (2.036) N-(2-terc-butilbenzil)-Nciclopropil-3-(difluorometil)-5-fluoro-1-metil-1H-pirazol-4-carboxamida, (2.037) N-(5-cloro-2-etilbenzil)-N-ciclopropil-3-(difluorometil)-5-fluoro-1metil-1H-pirazol-4-carboxamida, (2.038) isoflucipram, (2.039) N[(1R,4S)-9-(diclorometileno)-1,2,3,4-tetrahidro-1,4-metanonaftalen-5-il]3-(difluorometil)-1 -metil-1H-pirazol-4-carboxamida, (2.040) N-[(1S,4R)-9(diclorometileno)-1,2,3,4-tetrahidro-1,4-metanonaftalen-5-il]-3(difluorometil)-1-metil-1H-pirazol-4-carboxamida, (2.041) N-[1 -(2,4diclorofenil)-1-metoxipropan-2-il]-3-(difluorometil)-1-metil-1H-pirazol-4carboxamida, (2.042) N-[2-cloro-6-(trifluorometil)benzil]-N-ciclopropil-3(difluorometil)-5-fluoro-1-metil-1H-pirazol-4-carboxamida, (2.043) N-[3cloro-2-fluoro-6-(trifluorometil)benzil]-N-ciclopropil-3-(difluorometil)-5fluoro-1-metil-1H-pirazol-4-carboxamida, (2.044) N-[5-cloro-2(trifluorometil)benzil]-N-ciclopropil-3-(difluorometil)-5-fluoro-1-metil-1Hpirazol-4-carboxamida, (2.045) N-ciclopropil-3-(difluorometil)-5-fluoro-1metil-N-[5-metil-2-(trifluorometil)benzil]-1H-pirazol-4-carboxamida, (2.046) N-ciclopropil-3-(difluorometil)-5-fluoro-N-(2-fluoro-6isopropilbenzil)-1-metil-1H-pirazol-4-carboxamida, (2.047) N-ciclopropil3-(difluorometil)-5-fluoro-N-(2-isopropil-5-metilbenzil)-1-metil-1H-pirazol4-carboxamida, (2.048) N-ciclopropil-3-(difluorometil)-5-fluoro-N-(2isopropilbenzil)-1-metil-1H-pirazol-4-carbotioamida, (2.049) Nciclopropil-3-(difluorometil)-5-fluoro-N-(2-isopropilbenzil)-1-metil-1Hpirazol-4-carboxamida, (2.050) N-cyclopropyl-3-(difluoromethyl)-5-fluoro-N(5-fluoro-2-isopropylbenzyl)-1-methyl-1H-pyrazole-4-carboxamide, (2.051) Ncyclopropyl-3-(difluoromethyl)-N-(2-ethyl-4,5-dimethylbenzyl)-5-fluoro-1-methyl Petition 870260055028, dated 08 / 06 / 2026, page 37 / 321. 31 / 98 1H-pirazol-4-carboxamida, (2.052) N-ciclopropil-3-(difluorometil)-N-(2etil-5-fluorobenzil)-5-fluoro-1 -metil-1H-pirazol-4-carboxamida, (2.053) Nciclopropil-3-(difluorometil)-N-(2-etil-5-metilbenzil)-5-fluoro-1-metil-1Hpirazol-4-carboxamida, (2.054) N-ciclopropil-N-(2-ciclopropil-5fluorobenzil)-3-(difluorometil)-5-fluoro-1-metil-1H-pirazol-4-carboxamida, (2.055) N-ciclopropil-N-(2-ciclopropil-5-metilbenzil)-3-(difluorometil)-5fluoro-1-metil-1H-pirazol-4-carboxamida, (2.056) N-ciclopropil-N-(2ciclopropilbenzil)-3-(difluorometil)-5-fluoro-1-metil-1H-pirazol-4carboxamida, (2.057) pirapropoína, (2.058) N-[rac-(1S,2S)-2-(2,4diclorofenil)ciclobutil]-2-(trifluorometil)nicotinamida, (2.059) N-[(1S,2S)-2(2,4-diclorofenil)ciclobutil]-2-(trifluorometil)nicotinamida;

[0056] Respiratory chain inhibitors in complex III selected from the group consisting of (3.001) ametoctradine, (3.002) amisulbrom, (3.003) azoxystrobin, (3.004) coumetoxystrobin, (3.005) coumoxystrobin, (3.006) ciazofamide, (3.007) dimoxystrobin, (3.008) enoxastrobin, (3.009) famoxadone, (3.010) fenamidone, (3.011) flufenoxystrobin, (3.012) fluoxastrobin, (3.013) cresoxim-methyl, (3.014) metominostrobin, (3.015) orisastrobin, (3.016) picoxystrobin, (3.017) pyraclostrobin, (3.018) pyramethostrobin, (3.019) pyroxystrobin, (3.020) trifloxystrobin, (3.021) (2E)-2-{2-[ ( { [(1E)-1-(3-{[(E)-1-fluoro-2phenylvinyl] oxy}phenyl)ethylidene]amino}oxy)methyl]phenyl}-2-(methoxyimino)-Nmethylacetamide, (3.022) (2E,3Z)-5-{[1-(4-chlorophenyl)-1H-pyrazol-3-yl]oxy}-2(methoxyimino)-N,3-dimethylpent-3-enamide, (3.023) (2R)-2-{2-[(2,5dimethylphenoxy)methyl]phenyl}-2-methoxy-N-methylacetamide, (3.024) (2S)-2-{2[(2,5-dimethylphenoxy)methyl]phenyl}-2-methoxy-N-methylacetamide, (3.025) fenpicoxamide, (3.026) mandestrobine, (3.027) N-(3-ethyl-3,5,5trimethylcyclohexyl)-3-formamido-2-hydroxybenzamide, (3.028) (2E,3Z)-5{[1-(4-chloro-2-fluorophenyl)-1H-pyrazol-3-yl]oxy}-2-(methoxyimino)-N,3dimethylpent-3-enamide, (3.029) methyl {5-[3-(2,4-dimethylphenyl)-1H-pyrazol-1yl]-2-methylbenzyl}carbamate, (3.030) methyltetraprol, (3.031). Petition 870260055028, de 08 / 06 / 2026, pág. 38 / 321 32 / 98 florilpicoxamide;

[0057] Selected mitosis and cell division inhibitors from the group consisting of (4.001) carbendazim, (4.002) diethofencarb, (4.003) etaboxam, (4.004) fluopicolide, (4.005) pencicuron, (4.006) thiabendazole, (4.007) thiophanate-methyl, (4.008) zoxamide, (4.009) pyridaclomethyl, (4.010) 3-chloro-5-(4-chlorophenyl)-4-(2,6-difluorophenyl)-6-methylpyridazine, (4.011) 3-chloro-5-(6-chloropyridin-3-yl)-6-methyl-4-(2,4,6-trifluorophenyl)pyridazine, (4.012) 4-(2-bromo-4-fluorophenyl)-N-(2,6difluorophenyl)-1,3-dimethyl-1H-pyrazol-5-amine, (4.013) 4-(2-bromo-4fluorophenyl)-N-(2-bromo-6-fluorophenyl)-1,3-dimethyl-1H-pyrazol-5-amine, (4.014) 4-(2-bromo-4-fluorophenyl)-N-(2-bromophenyl)-1,3-dimethyl-1H-pyrazol5-amine, (4.015) 4-(2-bromo-4-fluorophenyl)-N-(2-chloro-6-fluorophenyl)-1,3dimethyl-1H-pyrazol-5-amine, (4.016) 4-(2-bromo-4-fluorophenyl)-N-(2chlorophenyl)-1,3-dimethyl-1H-pyrazol-5-amine, (4.017) 4-(2-bromo-4fluorophenyl)-N-(2-fluorophenyl)-1,3-dimethyl-1H-pyrazol-5-amine, (4.018) 4-(2chloro-4-fluorophenyl)-N-(2,6-difluorophenyl)-1,3-dimethyl-1H-pyrazol-5-amine, (4.019) 4-(2-chloro-4-fluorophenyl)-N-(2-chloro-6-fluorophenyl)-1,3-dimethyl-1H-pyrazol-5-amine, (4.020) 4-(2-chloro-4-fluorophenyl)-N-(2-chlorophenyl)-1,3-dimethyl-1H-pyrazol-5-amine, (4.021) 4-(2-chloro-4-fluorophenyl)-N-(2fluorophenyl)-1,3-dimethyl-1H-pyrazol-5-amine, (4.022) 4-(4-Chlorophenyl)-5-(2,6difluorophenyl)-3,6-dimethylpyridazine, (4.023) N-(2-bromo-6-fluorophenyl)-4-(2chloro-4-fluorophenyl)-1,3-dimethyl-1H-pyrazol-5-amine, (4.024) N-(2bromophenyl)-4-(2-chloro-4-fluorophenyl)-1,3-dimethyl-1H-pyrazol-5-amine, (4.025) N-(4-chloro-2,6-difluorophenyl)-4-(2-chloro-4-fluorophenyl)-1,3-dimethyl1H-pyrazol-5-amine, (4.026) fluopimomida;.

[0058] Compounds capable of having a multisite action selected from the group consisting of (5.001) Bordeaux mixture, (5.002) captafol, (5.003) captan, (5.004) chlorothalonil, (5.005) copper hydroxide, (5.006) copper naphthenate, (5.007) copper oxide, (5.008) copper oxychloride, (5.009) copper(2+) sulfate, (5.010) dithianon, (5.011) dodine, Petition 870260055028, dated 08 / 06 / 2026, page 39 / 321 33 / 98 (5.012) folpet, (5.013) mancozeb, (5.014) maneb, (5.015) metiram, (5.016) metiram zinc, (5.017) copper oxine, (5.018) propineb, (5.019) sulfur and sulfur preparations, including calcium polysulfide, (5.020) thiram, (5.021) zineb, (5.022) ziram, (5.023) 6-ethyl-5,7-dioxo-6,7dihydro-5H-pyrrolo[3',4':5,6][1,4]dithiino[2,3-c][1,2]thiazol-3-carbonitrile;

[0059] Compounds capable of inducing a host defense selected from the group consisting of (6.001) acibenzolar-S-methyl, (6.002) isothianyl, (6.003) probenazole, (6.004) thiadyl;

[0060] Inhibitors of amino acid and / or protein biosynthesis selected from the group consisting of (7.001) cyprodinil, (7.002) kasugamycin, (7.003) kasugamycin hydrochloride hydrate, (7.004) oxytetracycline, (7.005) pyrimethanil, (7.006) 3-(5-fluoro-3,3,4,4-tetramethyl-3,4-dihydroisoquinolin-1-yl)quinoline;

[0061] Selected ATP production inhibitors from the group consisting of (8.001) silthiofam;

[0062] Cell wall synthesis inhibitors selected from the group consisting of (9,001) bentiavalicarb, (9,002) dimethomorph, (9,003) flumorph, (9,004) iprovalicarb, (9,005) mandipropamide, (9,006) pyrimorph, (9,007) valifenalate, (9,008) (2E)-3-(4-tert-butylphenyl)-3-(2chloropyridin-4-yl)-1-(morpholin-4-yl)prop-2-en-1-one, (9.009) (2Z)-3-(4-tertbutylphenyl)-3-(2-chloropyridin-4-yl)-1-(morpholin-4-yl)prop-2-en-1-one;

[0063] Selected lipid and membrane synthesis inhibitors from the group consisting of (10.001) propamocarb, (10.002) propamocarb hydrochloride, (10.003) tolclofos-methyl;

[0064] Selected melanin biosynthesis inhibitors from the group consisting of (11.001) tricyclazole, (11.002) tolprocarb;

[0065] Selected nucleic acid synthesis inhibitors from the group consisting of (12.001)benalaxil, (12.002)benalaxil-M (kiralaxil), (12.003)metalaxil, (12.004)metalaxil-M (mefenoxam);

[0066] Selected signal transduction inhibitors from the group that Petition 870260055028, dated 08 / 06 / 2026, page 40 / 321 34 / 98 consists of (13,001) fludioxonil, (13,002) iprodione, (13,003) procymidone, (13,004) proquinazide, (13,005) quinoxyfene, (13,006) vinclozolin;

[0067] Compounds capable of acting as uncouplers selected from the group consisting of (14.001) fluazinam and (14.002) meptylidinocap;

[0068] Other fungicides selected from the group consisting of (15,001) abscisic acid, (15,002) bentiazole, (15,003) betoxazine, (15,004) capsimycin, (15,005) carvone, (15,006) quinomethionate, (15,007) cufraneb, (15,008) ciflufenamide, (15,009) cymoxanil, (15,010) cyprosulfamide, (15,011) flutianil, (15,012) fosetyl-aluminum, (15,013) fosetyl-calcium, (15,014) fosetyl-sodium, (15,015) methyl isothiocyanate, (15,015) 15,016) metrafenone, (15,017) mildiomycin, (15,018) natamycin, (15,019) nickel dimethyldithiocarbamate, (15,020) nitrothalisopropyl, (15,021) oxamocarb, (15,022) oxathiapiproline, (15,023) oxyphenthyin, (15,024) pentachlorophenol and salts, (15,025) phosphorous acid and its salts, (15,026) propamocarb-fosetylate, (15,027) pyriofenone (clazafenone), (15,028) tebufloquine, (15,029) teclophthalam, (15,030) tolnifanide, (15.031) 1 -(4-{4-[(5R)-5-(2,6-difluorophenyl)-4,5-di-hydro-1,2oxazol-3-yl]-1,3-thiazol-2-yl}piperidine-1 -yl-yl)-2-[5-methyl-3-)(trianol-Horomethyl] (15,032) 1 -(4-{4-[(5S)-5-(2,6-difluorophenyl)-4,5-dihydro-1,2-oxazol-3-yl]-1,3-thiazol-2-yl}piperidin-1-yl)-2-[5-methylHorone-methyl-3(zoyl-1-trifluo) (15,033) 2-(6-benzylpyridine-2yl)quinazoline, (15,034) dipimethitrone, (15,035) 2-[3,5-bis(difluoromethyl)1H-pyrazol-1-yl]-1-[4-(4-{5-[2-(prop-2-in-1-yloxy)phenyl]-4,5-di-hydro-1,2oxazol-3-yl}-1,3-thiazol)15periethyl-ano.2-yl-yl) 2-[3,5bis(difluoromethyl)-1H-pyrazol-1-yl]-1-[4-(4-{5-[2-chloro-6-(prop-2-in-1yloxy)phenyl]-4,5-di-hydro-1,2-oxazol-3-yl}-1,3-dine-thiazole] (15,037) 2-[3,5-bis(difluoromethyl)-1H-pyrazol-1-yl]-1 -[4-(4-{5-[2fluoro-6-(prop-2-in-1 -yloxy)phenyl]-4,5-di-hydro-1,2-ylpethiazol-3-3 870260055028, of 08 / 06 / 2026, pp. 41 / 321. 35 / 98 l)piperidin-1-yl]ethanone, (15,038) 2-[6-(3-fluoro-4-methoxyphenyl)-5methylpyridine-2-yl]quinazoline, (15,039) 2-{(5R)-3-[2-(1-oromethyl-bis{()zodiflu-H5-H -yl]acetyl}piperidine-4-yl)-1,3-thiazol-4-yl]-4,5-di-hydro-1,2oxazol-5-yl}-3-chlorophenylmethanosulfonate, (15,040) 2-{(5S)-3-[2-(1-oromethyl -{zof-Hu-3,5 -yl]acetyl}piperidine-4-yl)-1,3-thiazol-4-yl]-4,5-dihydro-1,2-oxazol-5-yl}-3-chlorophenylmethanosulfonate, (15,041) ipflufenoquine, (15,042) 2-{2-fluoro-6-[(8-fluoro-2-methylquinolin-3-yl)oxy] phenyl}propan-2-ol, (15,043) fluoxapiproline, (15,044) 2-{3-[2-(1-{[[3,5bis(difluoromethyl))-1H-pyrazol-1-yl]acetyl}piperidine-4-yl)-1,3-thiazol-4-yl]-4,5-dihydro-1,2-oxazol-5-yl}phenylmethanesulfonyl and 2.saiphenyl,5, (5 (15,046) 3-(4,4,5-trifluoro-3,3-dimethyl-3,4-di-hydroisoquinolin-1 il)quinoline, (15,047) quinofumelin, (15,048) 4-amino-5-fluoropyrimdin2-ol (tautomeric form 4-amino-5-fluoropyrimidine-2(1H)-one), (15.049) 4-oxo-4-[(2-phenylethyl)amino]butanoic acid, (15.050) 5-amino-1,3,4thiadiazole-2-thiol, (15.051) 5-chloro-N'-phenyl-N'-(prop-2-in-1-yl)thiophene-2-sulfonohydrazide, (15.052) 5-fluoro-2-[(4-fluorobenzyl)óxi]pyrimidin-4-amine, (15.053) 5-fluoro-2-[(4-methylbenzyl)óxi]pyrimidin-4-amine, (15.054) 9-fluoro-2,2-dimethyl-5-(quinolin-3-yl)-2,3-di-hydro-1,4-benzoxazepine, (15.055) but-3-in-1 -yl {6-[({[(Z)-(1 -methyl-1H-tetrazol-5-yl)(phenyl)methyleno] amino}óxy)metil]pyridin-2-yl}carbamate, (15.056) ethyl (2Z)-3-amino-2cyano-3-phenylacrylate, (15.057) phenazine-1-carboxylic acid, (15.058) propyl 3,4,5-trihydroxybenzoate, (15.059) quinolin-8-ol, (15.060) quinolin8-ol sulfate (2:1), (15.061) tert-butyl {6-[({[(1-methyl-1H-tetrazol-5yl)(phenyl)methyleno]amino}óxi)metil]pyridin-2-yl}carbamate, (15.062) 5-fluoro4-imino-3-metil-1-[(4-metilfenil)sulfonyl]-3,4-dihidropyrimidin-2(1H)-one, (15.063) aminopirifeno, (15.064) (N'-[2-chloro-4-(2-fluorofenóxi)-5metilfenil]-N-ethyl-N-metilimidoformamide), (15.065) (N'-(2-chloro-5-methyl-4phenoxyphenyl)-N-ethyl-N-methylimidoformamide), (15,066) (2-{2-[(7,8-difluoro2-methylquinolin-3-yl)oxy]-6-fluorophenyl}6)(5.0-ol (5-bromo-1(5,6-dimethylpyridine-3-yl)-3,3-dimethyl-3,4-di-hydroisoquinoline), (15,068) (3Petition 870260055028, dated 08 / 06 / 2026, p. 42 / 321 36 / 98 (4,4-difluoro-5,5-dimetil-4,5-di-hidrotieno[2,3-c]piridin-7-yl)quinolina), (15.069) (1-(4,5-dimetil-1H-benzimidazol-1-yl)-4,4-difluoro-3,3-dimetil3,4-di-hidroisoquinolina), (15.070) 8-fluoro-3-(5-fluoro-3,3-dimetil-3,4-dihidroisoquinolin-1-yl)quinolona, ​​(15.071) 8-fluoro-3-(5-fluoro-3,3,4,4tetrametil-3,4-di-hidroisoquinolin-1-yl)quinolona, ​​(15.072) 3-(4,4-difluoro3,3-dimethyl-3,4-di-hidroisoquinolin-1-yl)-8-fluoroquinoline, (15,073) (Nmethyl-N-phenyl-4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]benzamida), (15,074) methyl {4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl}carbamate, (15.075) (N-{4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]benzyl}cyclopropanecarboxamida), (15.076) N-methyl-4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3yl]benzamida, (15,077) N-[(E)-methoxiiminomethyl]-4-[5-(trifluoromethyl)1,2,4-oxadiazol-3-yl]benzamida, (15,078) N-[(Z)-methoxiiminomethyl]-4-[5(trifluoromethyl)-1,2,4-oxadiazol-3-yl]benzamida, (15.079) N-[4-[5(trifluorometil)-1,2,4-oxadiazol-3-il]fenil]ciclopropanocarboxamida, (15.080) N-(2-fluorofenil)-4-[5-(trifluorometil)-1,2,4-oxadiazol-3il]benzamida, (15.081) 2,2-difluoro-N-metil-2-[4-[5-(trifluorometil)-1,2,4oxadiazol-3-il]fenil]acetamida, (15.082) N-alil-N-[[4-[5-(trifluorometil)1,2,4-oxadiazol-3-il)fenil]metil]acetamida, (15.083) N-[(E)-N-metóxi-Cmetil-carbonimidoil]-4-(5-(trifluorometil)-1,2,4-oxadiazol-3-il]benzamida, (15.084) N-[(Z)-N-metóxi-C-metil-carbonimidoil]-4-[5-(trifluorometil)1,2,4-oxadiazol-3-il]benzamida, (15.085) N-alil-N-[[4-[5-(trifluorometil)1,2,4-oxadiazol-3-il]fenil]metil]propanamida, (15.086) 4,4-dimetil-1 -[[4-[5(trifluorometil)-1,2,4-oxadiazol-3-il]fenil]metil]pirrolidin-2-ona, (15.087) Nmetil-4-[5-(trifluorometil)-1,2,4-oxadiazol-3-il]benzenocarbotioamida, (15.088) 5-metil-1 -[[4-[5-(trifluorometil)-1,2,4-oxadiazol-3-il]fenil] metil]pirrolidin-2-ona, (15.089) N-((2,3-difluoro-4-[5-(trifluoromethyl)-1,2,4oxadiazol-3-yl]phenyl]methyl]-3,3,3-trifluoropropanamide, (15.090) 1-methoxy1-methyl-3-[[4-[5-(trifluoromethyl}-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, (15.091) 1,1-diethyl-3-[[4-[5-(trifluoromethyl}-1,2,4-oxadiazol-3-yl] phenyl]methyl]urea, (15.092) N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3. Petition 870260055028, de 08 / 06 / 2026, p. 43 / 321 37 / 98 yl]phenyl]methyl]propanamide, (15.093) N-methoxy-N-[[4-[5-(trifluoromethyl)1,2,4-oxadiazol-3-yl]phenyl]methyl]cyclopropanecarboxamide, (15.094) 1 methoxy-3-methyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, (15.095) N-methoxy-N-[[4-[5-(trifluoromethyl)-1,2,4oxadiazol-3-yl]phenyl]methyl)cyclopropanecarboxamide, (15.096) N,2-dimethoxy-N-[[4-[5-(trifluoromethyl}-1,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide, (15.097) N-ethyl-2-methyl-N-[[4-[5-(trifluoromethyl)1,2,4-oxadiazol-3-yl)phenyl]methyl]propanamide, (15.098) 1-methoxy-3-methyl-1[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, (15.099) 1,3dimethoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, (15.100) 3-ethyl-1 -methoxy-1 -[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, (15.101) 1 -[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]piperidin-2-one, (15.102) 4,4-dimethyl-2-[[4-[5-(trifluoromethyl)1,2,4-oxadiazol-3-yl]phenyl]methyl]isooxazolidin-3-one, (15.103) 5,5-dimetil2-[[4-[5-(trifluorometil)-1,2,4-oxadiazol-3-il]fenil]metil]isoxazolidin-3-ona, (15.104) 3,3-dimetil-1-[[4-[5-(trifluorometil)-1,2,4-oxadiazol-3il]fenil]metil]piperidin-2-ona, (15.105) 1 -[[3-fluoro-4-(5-(trifluorometil)1,2,4-oxadiazol-3-il]fenil]metil]azepan-2-ona, (15.106) 4,4-dimetil-2-[[4(5-(trifluorometil)-1,2,4-oxadiazol-3-il]fenil]metil]isoxazolidin-3-ona, (15.107) 5,5-dimetil-2-[[4-[5-(trifluorometil)-1,2,4-oxadiazol-3-il]fenil]metil]isoxazolidin-3-ona, (15.108) etil 1-{4-[5-(trifluorometil)-1,2,4oxadiazol-3-il]benzil}-1H-pirazol-4-carboxilato, (15.109) N,N-dimetil-1-{4[5-(trifluorometil)-1,2,4-oxadiazol-3-il]benzil}-1H-1,2,4-triazol-3-amina, (15.110) N-{2,3-difluoro-4-[5-(trifluorometil)-1,2,4-oxadiazol-3il]benzil}butanamida, (15.111) N-(1-metilciclopropil)-4-[5-(trifluorometil)1,2,4-oxadiazol-3-il]benzamida, (15.112) N-(2,4-difluorofenil)-4-[5(trifluorometil)-1,2,4-oxadiazol-3-il]benzamida, (15.(113) 1 -(5,6dimethylpyridine-3-yl)-4,4-difluoro-3,3-dimethyl-3,4-di-hydroisoquinoline, (15,114) 1-(6-(difluoromethyl)-5-methyl-pyridine-3-yl)-4,4-difluoro-3,3-dimethyl3,4-di-hydroisoquinoline, (15,115) 1-(5-(fluoromethyl)-6-methyl-pyridine-3-yl,0 de75026o)Petição 08 / 06 / 2026, p. 44 / 321. 38 / 98 4,4-Difluoro-3,3-dimethyl-3,4-dihydroisoquinoline, (15.116) 1-(6(difluoromethyl)-5-methoxy-pyridin-3-yl)-4,4-difluoro-3,3-dimethyl-3,4-dihydroisoquinoline, (15.117) 4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl dimethylcarbamate, (15.118) N-{4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3yl]phenyl}propanamide, (15.119) 3-[2-(1-{[5-methyl-3-(trifluoromethyl)-1Hpirazol-1-yl]acetyl}piperidin-4-yl)-1,3-thiazol-4-yl]-1,5-di-hidro-2,4benzodioxepin-6-ylmethanesulfonate, (15,120) 9-fluoro-3-[2-(1-{[5-methyl3-(trifluoromethyl)-1H-pyrazol-1-yl]acetyl}piperidin-4-yl)-1,3-thiazol-4-yl]-1,5-dihydro-2,4-benzodioxepin-6-ylmethanesulfonate, (15.121) 3-[2-(1-{[3,5bis(difluoromethyl)-1H-pyrazol-1 -yl]acetyl}piperidin-4-yl)-1,3-thiazol-4-yl]-1,5-dihydro-2,4-benzodioxepin-6-ylmethanesulfonate, (15.122) 3-[2-(1 -{[3,5bis(difluoromethyl)-1H-pyrazol-1 -yl]acetyl}piperidin-4-yl)-1,3-thiazol-4-yl]-9fluoro-1,5-di-hidro-2,4-benzodioxepin-6-ylmethanesulfonate, (15.123) 1 (6,7-dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4-difluoro-3,3-dimethyl-3,4-dihydroisoquinoline, (15,124) 8-fluoro-N-(4,4,4-trifluoro-2-methyl-1-phenylbutan-2-yl)quinoline-3-carboxamide, (15,125) 8-fluoro-N-[(2S)-4,4,4trifluoro-2-methyl-1-phenylbutan-2-yl]quinoline-3-carboxamide, (15,126) N(2,4-dimethyl-1-phenylpentan-2-yl)-8-fluoroquinoline-3-carboxamide and (15,127) N-[(2S)-2,4-dimethyl-1-phenylpentan-2-yl]-8-fluoroquinoline-3carboxamide. Chemical pesticide mixing partner (b)

[0069] The active compounds identified here by their common names are known and described, for example, in the pesticide manual (The Pesticide Manual 16th Ed., British Crop Protection Council 2012) or can be found on the Internet (e.g., http: / / www.alanwood.net / pesticides). The classification is based on the current IRAC mode of action classification scheme at the time of filing of this patent application.

[0070] In a further embodiment of the invention, the combinations of active compounds comprise (a) Bacillus spp. strain NRRL B. Petition 870260055028, dated 08 / 06 / 2026, page 45 / 321 39 / 98 67746 or a plant growth-promoting mutant of this strain and at least one compound (b) selected from the following groups.

[0071] (1) Acetylcholinesterase (AChE) inhibitors, preferably selected carbamates dealanicarb, aldicarb, bendiocarb, benfuracarb, butocarboxim, butoxycarboxim, carbaryl, carbofuran, carbosulfan, etiofencarb, fenobucarb, formetanate, furatiocarb, isoprocarb, methiocarb, methomyl, metolcarb, oxamyl, pirimicarb, propoxur, thiodicarb, thiofanox, triazamate, trimetacarb, XMC and xylylcarb, or selected organophosphates of methyl acetate, azamethifos, azinfos-ethyl, cadinfos, azinfo-ethyl, chlorfenvinfos, chlormefos, chlorpyrifos-methyl, coumafos, cyanophos, demetone-S-methyl, diazinon, dichlorvos / DDVP, dicrotophos, dimethoate, dimethylvinphos, disulfotone, EPN, ethione, etoprofos, fanfur, fenostamifos, fenitrothione, fenton, fosthiazate, heptenofos, imiciafos, isofenfos, isopropyl O(methoxyaminothiophosphoryl) salicylate, isoxathione, malathione, mecarbam, methamidophos, methidathione, mevinfos, monocrotofos, naled, omethoate, oxidemeton-methyl, parathion-methyl, fentoate, phorate,fosalone, phosmet, phosphamidone, foxim, pirimiphos-methyl, profenofos, pirimiphos-methyl, profenofos, pyridafenthionine, quinalfos, sulfotepe, tebupirinfos, temefos, terbufos, tetrachlorvinfos, thiomethone, triazofos, trichlorfona and vamidothionine.

[0072] (2) GABA-blocked chloride channel blockers, preferably cyclodiene-organochlorides selected from chlordane and endosulfan, or phenylpyrazoles (fiprols) selected from etiprol and fipronyl.

[0073] (3) Sodium channel modulators, preferably pyrethroids selected from acrinathrin, allethrin, d-cis-trans allethrin, d-trans allethrin, bifenthrin, bioallethrin, s-cyclopentenyl bioallethrin isomer, bioresmethrin, cycloprothrin, cyfluthrin, beta-cyfluthrin, cyhalothrin, lambda-cyhalothrin, gamma-cyhalothrin, cypermethrin, alpha-cypermethrin, beta-cypermethrin, theta-cypermethrin, zeta-cypermethrin, cyfenothrin [(1R)-trans-isomer], deltamethrin, empentrin [(EZ)-(1R) Petition 870260055028, dated 08 / 06 / 2026, page 46 / 321 40 / 98 isomer], esfenvalerate, etofenprox, fenpropathrin, fenvalerate, flucitrinate, flumethrin, tau-fluvalinate, halfenprox, imiprothrin, kadethrin, monofluorothrin, permethrin, phenothrin [(1R)-trans-isomer], prallethrin, pyrethrins (pyrethrum), resmethrin, silafluophen, tefluthrin, tetramethrin, tetramethrin [(1R)-isomer)], tralomethrin and transfluthrin, or DDT or methoxychlor.

[0074] (4) Competitive modulators of the nicotinic acetylcholine receptor (nAChR), preferably neonicotinoids selected from acetamipride, clothianidin, dinotefuran, imidacloprid, nitenpyram, thiacloprid and thiamethoxam, or nicotine, or sulfoximines selected from sulfoxaflor, or butenolides selected from flupiradifurone, or mesoionics selected from triflumezopirim.

[0075] (5) Allosteric modulators of the nicotinic acetylcholine receptor (nAChR) (Site I), preferably spinosyns selected from spinetoram and spinosad.

[0076] (6) Allosteric modulators of the glutamate-gated chloride channel (GluCl), preferably avermectins / milbemycins selected from abamectin, emamectin benzoate, lepimectin and milbemectin.

[0077] (7) Youth hormone mimics, preferably youth hormone analogues selected from hydroprene, quinoprene and methoprene, or fenoxycarb or pyriproxyfen.

[0078] (8) Non-specific heterogeneous inhibitors (multi-site), preferably alkyl halides selected from methyl bromide and other alkyl halides, or chloropicrin or sulfuryl fluoride or borax or tartar emetic or methylisocyanate generators selected from diazomide and metam.

[0079] (9) Chordotonal organ TRPV channel modulators, preferably pyridine azomethanes selected from pimetrozine and pirifluquinazone, or pyropenes selected from afidopyropene. Petition 870260055028, dated 08 / 06 / 2026, page 47 / 321 41 / 98

[0080] (10) Mite growth inhibitors affecting CHS1 selected from clofentezine, hexithiazox, diflovidazine and ethoxazole.

[0081] (11) Microbial disruptors of insect intestinal membranes selected from Bacillus thuringiensis subspecies israelensis, Bacillus sphaericus, Bacillus thuringiensis subspecies aizawai, Bacillus thuringiensis subspecies kurstaki, Bacillus thuringiensis subspecies tenebrionis, and selected Bt plant proteins from Cry1Ab, Cry1Ac, Cry1Fa, Cry1A.105, Cry2Ab, Vip3A, mCry3A, Cry3Ab, Cry3Bb and Cry34Ab1 / 35Ab1.

[0082] (12) Mitochondrial ATP synthase inhibitors, preferably ATP disruptors selected from diafenthiurone, or organotin compounds selected from azocyclotine, ciexatine and fenbutatine oxide, or propargite or tetradiphone.

[0083] (13) Uncouplers of oxidative phosphorylation by means of proton gradient disruption selected from chlorfenapyr, DNOC and sulfluramide.

[0084] (14) Selected nicotinic acetylcholine receptor channel blockers of bensultap, cartap hydrochloride, thiocilam and thioultap-sodium.

[0085] (15) Chitin biosynthesis inhibitors affecting CHS1, preferably benzoylureas selected from bistriflurone, chlorfluazurone, diflubenzurone, flucicloxurone, flufenoxurone, hexaflumurone, lufenurone, novalurone, noviflumurone, teflubenzurone and triflubenzurone.

[0086] (16) Chitin biosynthesis inhibitors, type 1 selected from buprofezin.

[0087] (17) Molt disruptor (in particular for diptera, i.e., diptera) selected from cyromazine.

[0088] (18) Ecdysone receptor agonists, preferably diacylhydrazines selected from cromofenozide, halofenozide, Petition 870260055028, dated 08 / 06 / 2026, page 48 / 321 42 / 98 methoxyfenozide and tebufenozide.

[0089] (19) Selected amitraz octapamine receptor agonists.

[0090] (20) Selected mitochondrial complex III electron transport inhibitors of hydramethylnon, acequinocil, fluacripyrim and bifenazate.

[0091] (21) Mitochondrial inhibitors of complex I electron transport, preferably METI acaricides and insecticides selected from phenazaquine, fenpyroximate, pirimidifen, pyridaben, tebufenpyrad and tolfenpyrad, or rotenone (Derris).

[0092] (22) Voltage-dependent sodium channel blockers, preferably oxadiazines selected from indoxacarb, or semicarbazones selected from metaflumizone.

[0093] (23) Acetyl CoA carboxylase inhibitors, preferably tetronic and tetramic acid derivatives selected from spirodiclofen, spiromesifene, spiropidion and spirotetramat.

[0094] (24) Inhibitors of mitochondrial complex IV electron transport, preferably selected phosphides of aluminum phosphide, calcium phosphide, phosphine and zinc phosphide, or selected cyanides of calcium cyanide, potassium cyanide and sodium cyanide.

[0095] (25) Mitochondrial electron transport inhibitors of complex II, preferably beta-ketonitrile derivatives selected from cyenopyrafene and cyflumethophene, or carboxanilides selected from piriflubumide.

[0096] (28) Ryanodine receptor modulators, preferably diamides selected from chlorantraniliprole, cyantraniliprole, cyclaniliprol, flubendiamide and tetraniliprol.

[0097] (29) Chordotonal organ modulators (with undefined target site) selected from flonicamide. Petition 870260055028, dated 08 / 06 / 2026, page 49 / 321 43 / 98

[0098] (30) Allosteric modulators of GABA-controlled chloride channels, preferably meta-diamides selected from broflanilide, or isoxazoles selected from fluxamethamide.

[0099] (31) Baculovirus, preferably Granuloviruses (GVs) selected from Cydiapomonella GV and Thaumatotibialeucotreta (GV), or Nucleopolyhedroviruses (NPVs) selected from Anticarsiagemmatalis MNPV and Helicoverpa armigera NPV.

[00100] (32) Selected allosteric modulators of nicotinic acetylcholine receptors (Site II) from the GS-omega / kappa HXTXHv1a peptide.

[00101] (33) Other selected active compounds from Acinonapir, Afoxolaner, Azadirachtin, Benclotiaz, Benzoximate, Benzpirimoxan, Bromopropylate, Quinomethionate, Chlorprolethrin, Cryolite, Cyclobutrifluram or Cyclobutrifen (CAS 1460292-16-3), Cicloxaprid, Cietpirafen, Cyhalodiamide, Dichloromezothiaz, Dicofol, Dimpropyridaz, epsilon-Metofluthrin, epsilon-Monfluthrin, Flomethoquine, Fluazaindolizine, Fluensulfone, Flufenerim, Fluphenoxystrobin, Flufiprol, Fluhexafon, Fluopyram, Flupyrimine, Fluralaner, Fufenozide, Fupentiofenox (CAS 1472050-04-6), Guadipyr, Heptafluthrin, Imidaclotiz, Iprodione, Isocycloseram, Kappa-Bifenthrin, Kappa-Tefluthrin, Lotilaner, Meperfluthrin, Oxazosulfyl, Paichongding, Pyridalila, Pyriflurquinazon, Pyriminostrobin, Spirobudiclofen, Tetramethylfluthrin, Tetrachlorantraniliprole, Tigolaner, Thioxazaphene, Thiofluoximate, Iodomethane, Triflupentoxide (CAS 1472050-04-6); In addition, preparations based on Bacillus firmus (I-1582, BIONEEM®, VOTIVO®), and also the following compounds: 1-{2-fluoro-4-methyl-5-[(2,2,2-trifluoroethyl)sulfinyl]phenyl}-3-(trifluoromethyl)-1H-1,2,4-triazol-5-amine (known from WO 2006 / 043635) (CAS 885026-50-6), {1'-[(2E)-3-(4chlorophenyl)prop-2-en-1-yl]-5-fluorospiro[indol-3,4'-piperidin]-1(2H)-yl}(2chloropyridin-4-yl)methanone (known from WO 2003 / 106457) (CAS Petition 870260055028, dated 08 / 06 / 2026, page 50 / 321 44 / 98 637360-23-7), 2-chloro-N-[2-{1-[(2E)-3-(4-chlorophenyl)prop-2-en-1-yl]piperidin-4-yl}-4-(trifluoromethyl)phenyl]isonicotinamide (known from WO 2006 / 003494) (CAS 872999-66-1), 3-(4-chloro-2,6-dimethylphenyl)-4-hydroxy-8-methoxy-1,8-diazaspiro[4.5]dec-3-en-2-one (known from WO 2010 / 052161) (CAS 1225292-17-0), 3-(4-chloro-2,6-dimethylphenyl)-8-methoxy-2-oxo-1,8-diazaspiro[4,5]dec-3-en-4-ylethyl carbonate (known from EP2647626) (CAS 1440516-42-6), 4-(but-2-yn-1-yloxy)-6-(3,5-dimethylpiperidin-1-yl)-5-fluoropyrimidine (known from WO 2004 / 099160) (CAS 792914-58-0), PF1364 (known from JP2010 / 018586) (CAS 1204776-60-2), (3E)-3-[1-[(6-chloro-3-pyridyl)methyl]-2-pyridilidene]-1,1,1-trifluoro-propan-2-one (known from WO 2013 / 144213) (CAS 146174315-6), , N-[3-(benzylcarbamoyl)-4-chlorophenyl]-1-methyl-3-(pentafluoroethyl)-4(trifluoromethyl)-1H-pyrazol-5-carboxamide (known as WO 2010 / 051926) (CAS 1226889-14-0), 5-bromo-4-chloro-N-[4-chloro-2-methyl6-(methylcarbamoyl)phenyl]-2-(3-chloro-2-pyridyl)pyrazol-3-carboxamida (conhecido de CN103232431) (CAS 1449220-44-3), 4-[5-(3,5dichlorophenyl)-4,5-di-hidro-5-(trifluoromethyl)-3-isoxazolyl]-2-methyl-N-(cis-1oxido-3-thietanyl)-benzamida, 4-[5-(3,5-dichlorophenyl)-4,5-di-hydro-5(trifluoromethyl)-3-isoxazolyl]-2-methyl-N-(trans-1-oxido-3-tietanil)benzamidae 4-[(5S)-5-(3,5-dichlorophenyl)-4,5-di-hydro-5-(trifluoromethyl)-3isoxazolyl]-2-methyl-N-(cis-1-oxido-3-tietanil)benzamida (conhecido de WO 2013 / 050317 A1) (CAS 1332628-83-7), N-[3-chloro-1-(3-pyridinyl)-1Hpyrazol-4-yl]-N-ethyl-3-[(3,3,3-trifluoropropyl)sulfinyl]-propanamida, (+)-N-[3chloro-1-(3-pyridinyl)-1H-pyrazol-4-yl]-N-ethyl-3-[(3,3,3-trifluoropropyl)sulfinyl]propanamidae (-)-N-[3-chloro-1-(3-pyridinyl)-1H-pyrazol-4-yl]-N-ethyl-3-[(3,3,3trifluoropropyl)sulfinyl]-propanamida (conchecido de WO 2013 / 162715 A2, WO 2013 / 162716 A2, Publication of Patent Application NorteAmericana No.2014 / 0213448 A1) (CAS 1477923-37-7), 5-[[(2E)-3chloro-2-propen-1-yl]amino]-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-4[(trifluoromethyl)sulfinyl]-1H-pyrazol-3-carbonitrile (known from CN. Petition 870260055028, dated 08 / 06 / 2026, p. 51 / 321 45 / 98 101337937 A) (CAS 1105672-77-2), 3-bromo-N-[4-chloro-2-methyl-6[(methylamino)thioxomethyl]phenyl]-1-(3-chloro-2-pyridinyl)-1H-pyrazol-5-carboxamide, (Liudaibenjiaxuanan, known from CN 103109816 A) (CAS 1232543-85-9); N-[4-chloro-2-[[(1,1-dimethylethyl)amino]carbonyl]-6-methylphenyl]-1-(3-chloro-2-pyridinyl)-3-(fluoromethoxy)-1H-pyrazol-5-carboxamide (known from WO 2012 / 034403 A1) (CAS 1268277-22-0), N-[2-(5-amino-1,3,4-thiadiazol-2-yl)-4-chloro-6-methylphenyl]-3-bromo-1-(3-chloro-2-pyridinyl)-1H-pyrazol-5-carboxamide (known from WO 2011 / 085575 A1) (CAS 1233882-22-8), 4-[3-[2,6-dichloro-4-[(3,3-dichloro-2-propen-1-yl)oxy]phenoxy]propoxy]-2-methoxy-6-(trifluoromethyl)-pyrimidine (known from CN 101337940 A) (CAS 1108184-52-6); (2E)- and 2(Z)-2[2-(4-cyanophenyl)-1-[3-(trifluoromethyl)phenyl]ethylidene]-N-[4-(difluoromethoxy)phenyl]-hydrazinecarboxamide (known from CN 101715774 A) (CAS 1232543-85-9);3-(2,2-dichloroethenyl)2,2-dimethyl-4-(1H-benzimidazol-2-yl)phenylcyclopropanecarboxylic acid ester (known from CN 103524422 A) (CAS 1542271-46-4); (4aS)-7-chloro-2,5-dihydro-2-[[(methoxycarbonyl)[4[(trifluoromethyl)thio]phenyl]amino]carbonyl]-indeno[1,2-e][1,3,4]oxadiazine4a(3H)-carboxylic acid methyl ester (known from CN 102391261 A) (CAS 1370358-692); 6-deoxy-3-O-ethyl-2,4-di-O-methyl-, 1-[N-[4-[1-[4-(1,1,2,2,2-pentafluoroethoxy)phenyl]-1H-1,2,4-triazol-3-yl]phenyl]carbamate]-α-L-manopyranose (known from U.S. Patent Application Publication No. 2014 / 0275503 A1) (CAS 1181213-14-8);8-(2cyclopropylmethoxy-4-trifluoromethyl-phenoxy)-3-(6-trifluoromethyl-pyridazin-3-yl)3-aza-bicyclo[3,2,1]octane(CAS 1253850-56-4), (8-anti)-8-(2cyclopropylmethoxy-4-trifluoromethyl-phenoxy)-3-(6-trifluoromethyl-pyridazin-3-yl)3-aza-bicyclo[3,2,1]octane(CAS 933798-27-7), (8-syn)-8-(2cyclopropylmethoxy-4-trifluoromethyl-phenoxy)-3-(6-trifluoromethyl-pyridazin-3-yl)3-aza-bicyclo[3,2,1]octane (known from WO 2007 / 040280 A1, WO 2007 / 040282 A1) (CAS 934001-66-8), N-[3-chloro-1-(3-pyridinyl)-1H; Petition 870260055028, dated 08 / 06 / 2026, page 52 / 321 46 / 98 pyrazol-4-yl]-N-ethyl-3-[(3,3,3-trifluoropropyl)thio]-propanamide (known from WO 2015 / 058021 A1, WO 2015 / 058028 A1) (CAS 1477919-27-9) and N[4-(aminothioxomethyl)-2-methyl-6-[(methylamino)carbonyl]phenyl]-3-bromo-1-(3chloro-2-pyridinyl)-1H-pyrazol-5-carboxamide (known from CN 103265527 A) (CAS 1452877-50-7), 5-(1,3-dioxan-2-yl)-4-[[4(trifluoromethyl)phenyl]methoxy]-pyrimidine (known from WO 2013 / 115391 A1) (CAS 1449021-97-9), 3-(4-chloro-2,6-dimethylphenyl)-8-methoxy-1-methyl-1,8-diazaspiro[4,5]decane-2,4-dione (known from WO 2014 / 187846 A1) (CAS 1638765-58-8), ethyl ester of acid 3-(4-chloro-2,6-dimethylphenyl)8-methoxy-1-methyl-2-oxo-1,8-diazaspiro[4,5]dec-3-en-4-yl-carbonic acid (known from WO 2010 / 066780 A1, WO 2011151146 A1) (CAS 1229023-00-0), 4-[(5S)-5-(3,5-dichloro-4-fluorophenyl)-4,5-dihydro-5(trifluoromethyl)-3-isoxazolyl]-N-[(4R)-2-ethyl-3-oxo-4-isoxazolidinyl]-2-methylbenzamide (known from WO 2011 / 067272, WO 2013 / 050302) (CAS 1309959-62-3). Active Biological Compounds as a Mixing Partner (b)

[00102] In a further embodiment of the invention, the combinations of active compounds comprise (a) Bacillus spp. strain NRRL B67746 or a plant growth-promoting mutant of this strain and at least one compound (b) selected from biological active compounds, such as biological fungicides or pesticides or plant growth-promoting compounds. The biological active compounds comprise, in particular, bacteria, fungi, yeasts, plant extracts and products formed by microorganisms, including proteins and secondary metabolites.

[00103] As used herein, the term biological control is defined as the control of harmful organisms, such as phytopathogenic fungi and / or insects and / or mites and / or nematodes, by the use or application of an active compound.

[00104] As used herein, the term active biological compound is Petition 870260055028, dated 08 / 06 / 2026, page 53 / 321 47 / 98 defined as an organism different from the harmful organisms and / or proteins or secondary metabolites produced by such organism for purposes of biological control or plant growth promotion. Mutants of the second organism should be included in the definition of the biological control active compound. The term mutant refers to a variant of the parental strain, as well as to methods of obtaining a mutant or variant in which the pesticidal activity is greater than that expressed by the parental strain. The parental strain is defined here as the parental strain before mutagenesis. To obtain such mutants, the parental strain may be treated with a chemical such as N-methyl-N'-nitro-N-nitrosoguanidine, ethylmethanesulfone, or by irradiation with gamma rays, X-rays or UV, or by other means also known to those skilled in the art.Known mechanisms of active compounds for biological control include enteric bacteria that control root rot caused by fungi that compete for space on the root surface. Bacterial toxins, such as antibiotics, have been used to control pathogens. The toxin can be isolated and applied directly to the plant, or the bacterial species can be administered so that it produces the toxin in situ.

[00105] A variant is a strain with all the identifying characteristics of the NRRL or ATCC accession numbers as indicated in this text and can be identified as possessing a genome that hybridizes under high rigor conditions with the genome of the NRRL or ATCC accession numbers.

[00106] Hybridization refers to a reaction in which one or more polynucleotides react to form a complex that is stabilized by hydrogen bonding between the bases of the nucleotide residues. Hydrogen bonding can occur through Watson-Crick base pairing, Hoogstein bonding, or any other sequence-specific manner. The complex may comprise two Petition 870260055028, dated 08 / 06 / 2026, page 54 / 321 48 / 98 strands forming a duplex structure, three or more strands forming a multi-strand complex, a single self-hybridizing strand, or any combination thereof. Hybridization reactions can be carried out under different severity conditions. In general, a low-severity hybridization reaction is carried out at about 40°C in 10X SSC or an equivalent ionic strength / temperature solution. A moderate-severity hybridization is typically carried out at about 50°C in 6X SSC, and a high-severity hybridization reaction is generally carried out at about 60°C in 1X SSC.

[00107] A variant of the indicated NRRL or ATCC Accession Number may also be defined as a strain exhibiting a genomic sequence that is greater than 85%, more preferably greater than 90%, or most preferably greater than 95% sequence identity with the genome of the indicated NRRL or ATCC accession number. A polynucleotide or polynucleotide region (or a polypeptide or polypeptide region) having a certain percentage (e.g., 80%, 85%, 90%, or 95%) of sequence identity with another sequence means that, when aligned, that percentage of bases (or amino acids) are the same when comparing the two sequences. This alignment and percentage homology or sequence identity can be determined using software programs known in the art, for example, those described in Current Protocols in Molecular Biology (FM Ausubel et al., eds., 1987).

[00108] NRRL is the abbreviation for Agricultural Research Service Culture Collection, an international depository authority for the purposes of depositing strains of microorganisms under the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the purposes of patent proceedings, having the address National Center for Agricultural Utilization Research, Agricultural Research Service, Department of Agriculture of Petition 870260055028, dated 08 / 06 / 2026, page 55 / 321 49 / 98 United States, 1815 North University Street, Peoria, Illinois 61604, USA

[00109] ATCC is the abbreviation for American Type Culture Collection, an international depository authority for the purpose of depositing strains of microorganisms under the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for Purposes of Patent Proceedings, with the address ATCC Patent Depository, 10801 University Boulevard, Manassas, Virginia 10110, USA

[00110] The active biological compound may be a bactericidally active compound. Such bactericidally active biological compounds comprise

[00111] (A1) bacteria, such as (A1.1) Bacillus subtilis, in particular strain QST713 / AQ713 (available as SERENADE® OPTI or SERENADE® ASO from Bayer CropScience LP, US, having Accession Number NRRL B-21661, US Patent No. 6,060,051); (A1.2) Bacillus sp., in particular strain D747 (available as DOUBLE NICKEL® from Kumiai Chemical Industry Co., Ltd.), having Accession Number FERM BP-8234, US Patent No. 7,094,592; (A1.3) Bacillus pumilus, in particular strain BU F-33, having NRRL Accession Number 50185 (available as part of BASF's CARTISSA® product, EPA Reg. No. 71840-19); (A1.4) Bacillus subtilis var. amyloliquefaciens strain FZB24 having DSM Accession Number 10271 (available from Novozymes as TAEGRO® or TAEGRO® ECO (EPA Registration Number 70127-5); (A1.5) Paenibacillus sp. strain having NRRL Accession Number B-50972, or NRRL Accession Number B-67129, WO 2016 / 154297; (A1.6) Bacillus subtilis strain BU1814, (available as VELONDIS® EXTRA from BASF SE); (A1.7) Bacillus mojavensis strain R3B (NCAIM Accession Number (P) B001389) (WO 2013 / 034938) from Certis USA LLC, a. Petition 870260055028, dated 08 / 06 / 2026, page 56 / 321 50 / 98 subsidiary of Mitsui & Co.; (A1.8) Bacillus subtilis CX-9060 from Certis USA LLC, a subsidiary of Mitsui & Co.; (A1.9) Paenibacillus polymyxa, in particular strain AC-1 (e.g., TOPSEED® from Green Biotech Company Ltd.); (A1.10) Pseudomonas proradix (e.g., PRORADIX® from Sourcon Padena); (A1.11) Pantoea agglomerans, in particular strain E325 (Accessory Number NRRL B-21856) (available as BLOOMTIME BIOLOGICAL™ FD BIOPESTICIDE from Northwest Agri Products); and

[00112] (A2) fungi, such as (A2.1) Aureobasidium pullulans strain DSM14940, strain DSM14941 or mixtures of strains DSM14940 and DSM14941 (e.g., BOTECTOR® and BLOSSOM PROTECT® from Bio-Ferm, CH); (A2.2) Pseudozyma aphidis (as disclosed in WO 2011 / 151819 by Yissum Research Development Company of the Hebrew University of Jerusalem); (A2.3) Saccharomyces cerevisiae, in particular strains CNCM No. I-3936, CNCM No. I-3937, CNCM No. I-3938 or CNCM No. I-3939 (WO 2010 / 086790) by Lesaffre et Compagnie, FR.

[00113] The biologically active compound may be a fungicidal biologically active compound or a biologically active compound active against oomycetes. Such biologically active compounds comprise

[00114] (B1) bacteria, for example, (B1.1) Bacillus subtilis, in particular strain QST713 / AQ713 (available as SERENADE®OPTI or SERENADE®ASO from Bayer CropScience LP, US, having Accession Number NRRL B-21661 and described in US Patent No. 6,060,051); (B1.2) Bacillus pumilus, in particular strain QST2808 (available as SONATA® from Bayer CropScience LP, US, having Accession Number NRRL B-30087 and described in US Patent No. 6,245,551); (B1.3) Bacillus pumilus, in particular strain GB34 (available as YIELD SHIELD® from Bayer AG, DE); (B1.4) Bacillus pumilus, in particular strain BU F-33, (having Accession Number Petition 870260055028, dated 08 / 06 / 2026, p. 57 / 321 51 / 98 NRRL 50185 (available as part of the CARTISSA® product from BASF, EPA Reg. No. 71840-19)); (B1.5) Bacillus amyloliquefaciens, in particular strain D747 (available as DOUBLE NICKEL™ from Kumiai Chemical Industry Co., Ltd. Certis, US, possessing FERM accession number BP-8234, and disclosed in US Patent No. 7,094,592); (B1.6) Bacillus subtilis Y1336 (available as BIOBAC® WP from Bion-Tech, Taiwan, registered as a biological fungicide in Taiwan under Registration Numbers 4764, 5454, 5096 and 5277); (B1.7) Bacillus amyloliquefaciens var. (B1.7) Bacillus subtilis strain MBI 600 (available as SUBTILEX® from BASF SE), having Accession Number NRRL B50595, U.S. Patent No. 5,061,495; (B1.8) Bacillus subtilis strain GB03 (available as KODIAK® from Bayer AG, DE); (B1.9) Bacillus subtilis var. amyloliquefaciens strain FZB24 having Accession Number DSM 10271 (available from Novozymes as TAEGRO® or TAEGRO® ECO (EPA Registration Number 70127-5)) (available from Novozymes Biologicals Inc., Salem, Virginia or Syngenta Crop Protection, LLC, Greensboro, North Carolina as the fungicide TAEGRO® or TAEGRO® ECO (EPA Registration Number 70127-5); (B1.10) Bacillus mycoides, J isolate, possessing Accession Number B30890 (available as BMJ TGAI® WG and LIFEGARD™ from Certis USA LLC, a subsidiary of Mitsui & Co.) (available as BMJ TGAI® or WG from Certis USA); (B1.11) Bacillus licheniformis, in particular strain SB3086, having Accession Number ATCC 55406, WO 2003 / 000051 (available as ECOGUARD® and GREEN RELEAF™ Biofungicides from Novozymes); (B1.12) Paenibacillus sp. strain having Accession Number NRRL B-50972, or Accession Number NRRL B67129, and described in International Patent Publication No. WO 2016 / 154297; (B1.13) Bacillus subtilis strain BU1814, (available as VELONDIS® PLUS, VELONDIS® FLEX and VELONDIS® EXTRA from BASF. Petition 870260055028, dated 08 / 06 / 2026, page 58 / 321 52 / 98 SE); (B1.14) Bacillus subtilis CX-9060 from Certis USA LLC, a subsidiary of Mitsui & Co.; (B1.15) Bacillus amyloliquefaciens strain F727 (also known as strain MBI110) (NRRL Accession Number B-50768; WO 2014 / 028521) (STARGUS® from Marrone Bio Innovations); (B1.16) Bacillus amyloliquefaciens strain FZB42, DSM Accession Number 23117 (available as RHIZOVITAL® from ABiTEP, DE); (B1.17) Bacillus licheniformis FMCH001 and Bacillus subtilis FMCH002 (QUARTZO®(WG) and PRESENCE®(WP) from FMC Corporation); (B1.18) Bacillus mojavensis strain R3B (NCAIM Accession Number (P) B001389) (WO 2013 / 034938) from Certis USA LLC, a subsidiary of Mitsui & Co.; (B1.19) Paenibacillus polymyxa ssp. plantarum (WO 2016 / 020371) from BASF SE; (B1.20) Paenibacillus epiphyticus (WO 2016 / 020371) from BASF SE; (B.1.21) Pseudomonas chlororaphis strain AFS009, possessing NRRL Accession Number B50897, WO 2017 / 019448 (e.g., HOWLER™ and ZIO® from AgBiome Innovations, US); (B1.22) Pseudomonas chloropharphis, in particular strain MA342 (e.g., CEDOMON®, CERALL®, and CEDRESS® by Bioagri and Koppert); (B1. 23) Streptomyces lydicus strain WYEC108 (also known as Streptomyces lydicus strain WYCD108US) (ACTINO-IRON® and ACTINOVATE® by Novozymes); (B1. 24) Agrobacterium radiobacter strain K84 (e.g., GALLTROLA® by AgBioChem, CA); (B1. 25) Agrobacterium radiobacter strain K1026 (e.g., NOGALL™ by BASF SE); (B1. 26) Bacillus subtilis strain KTSB (FOLIACTIVE® by Donaghys); (B1.27) Bacillus subtilis IAB / BS03 (AVIV™ from STK Bio-Ag Technologies); (B1.28) Bacillus subtilis strain Y1336 (available as BIOBAC®WP from Bion-Tech, Taiwan, registered as a biological fungicide in Taiwan under registration numbers 4764, 5454, 5096 and 5277); (B1.29) Bacillus amyloliquefaciens B246 alone (e.g., AVOGREEN™ from the University of Pretoria); (B1.30) Bacillus methylotrophicus strain BAC-9912 (from the Chinese Academy of Sciences). Petition 870260055028, dated 08 / 06 / 2026, p. 59 / 321 53 / 98 Institute of Applied Ecology); (B1.31) Pseudomonas proradix (e.g., PRORADIX® by SourconPadena); (B1.32) Streptomyces griseoviridis cepa K61 (also known as Streptomyces galbus cepa K61) (DSM Accession Number 7206) (MYCOSTOP® by Verdera; PREFENCE® by BioWorks; cf. Crop Protection 2006, 25, 468-475); (B1.33) Pseudomonas fluorescens cepa A506 (e.g., BLIGHTBAN® A506 by NuFarm); and.

[00115] (B2) fungi, for example: (B2.1) Coniothyrium minitans strain CON / M / 91-8 (Accession No. DSM-9660; e.g. CONTANS® from Bayer CropScience Biologics GmbH); (B2.2) Talaromyces flavuscepa V117b; (B2.3) Trichoderma atroviride strain CNCM I-1237 (e.g. ESQUIVE® WP from Agrauxine, FR); (B2.4) Gliocladium catenulatum (Synonym: Clonostachys rosea f. catenulate) strain J1446 (e.g. PRESTOP® by Lallemand); (B2.5) Trichoderma viridestrain B35 (Pietr et al., 1993, Zesz. Nauk. AR w Szczecinie 161: 125-137); (B2.6) Metschnikowia fructicola strain NRRL Y-30752; (B2.7) Gliocladium roseum (also known as Clonostachys rosea f. rosea), in particular strain 321U from Adjuvants Plus, strain ACM941 as described in Xue (Efficacy of Clonostachys rosea strain ACM941 and fungicide seed treatments to control pea root complex, Can Jour Plant Sci 83 (3): 519-524), strain IK726 (Jensen, DF, et al. Development of a Biocontrol Active Compound for Plant Disease Control with Special Emphasis on the Near Commercial Fungal Antagonist Strain Clonostachys rosea 'IK726'; Australas Plant Pathol. 2007; 36: 95-101); (B2.8) Trichoderma asperellum cepa SKT-1, having FERM Accession No. P-16510 (e.g., ECOHOPE® from Kumiai Chemical Industry); Trichoderma asperellum T34 (ASPERELLO® from Biobest Group NV and T34 BIOCONTROL® from Biocontrol Technologies SL, ES); (B2.9) Trichoderma asperelloides JM41R (NRRL Accession No. B-50759) (TRICHO PLUS® from BASF SE); Petition 870260055028, dated 08 / 06 / 2026, p. 60 / 321 54 / 98 (B2.10) Trichoderma asperellum strain ICC 012 (Isagro); Trichoderma atroviride strain SC1, with accession No. CBS 122089, WO 2009 / 116106 and U.S. Patent No. 8,431,120, (from Bi-PA), strain 77B (T77 from Andermatt Biocontrol), strain LU132 (e.g., SENTINEL® from Agrimm Technologies Limited), strain having accession No. NMI V08 / 002387, strain having accession No. NMI V08 / 002388, strain having accession No. NMI V08 / 002389, strain having accession No. NMI V08 / 002390, strain having accession No. ATCC 20476 (IMI 206040), strain SKT-1, having accession No. FERM P-16510, JP Patent Publication (Kokai) 11-253151 A, strain SKT-2, having FERM Accession No. P-16511, JP Patent Publication (Kokai) 11-253151 A, strain SKT-3, having FERM Accession No. P-17021, JP Patent Publication (Kokai) 11-253151 A; (B2.11) Trichoderma harzianum strain T-22 (e.g., TRIANUM-P® from Andermatt Biocontrol or Koppert), strain DB 103 (available as TGRO®7456 from Dagutat Biolab); (B2.12) Trichoderma virens (also known as Gliocladium virens), in particular strain GL-21 (e.g., SOILGARD® by Certis, US); (B2. 13) Trichoderma harzianum strain Simb-T5 (from Simbiose Agro); (B2. 14) Aspergillus flavus strain NRRL 21882 (products known as AFLA-GUARD® from Syngenta / ChemChina); (B2. 15) Chaetomium cupreum (CABI Accession No. 353812) (e.g., BIOKUPRUM™ by AgriLife); (B2. 16) Microsphaero psisochracea; (B2. 17) Saccharomyces cerevisiae strain LASO2 (from Agro-Levures et Dérivés), cell wall strain LAS117 (CEREVISANE® from Lesaffre; ROMEO® from BASF SE), strains CNCM No. I-3936, CNCM No. I-3937, CNCM No. I-3938, CNCM No. I3939 (WO 2010 / 086790) by Lesaffre et Compagnie, FR; (B2. 18) Trichoderma virens strain G-41, formerly known as Gliocladium virens (ATCC Accession No. 20906) (e.g., ROOTSHIELD®PLUS WP and TURFSHIELD®PLUS WP from BioWorks,. Petition 870260055028, dated 08 / 06 / 2026, p. 61 / 321 55 / 98 US); (B2.19) Gliocladium roseum strain 321 U, with ATCC accession number 10406, from WF Stoneman Company LLC; (B2.20) Trichoderma hamatum, with ATCC accession number 28012; (B2.21) Trichoderma harzianum strain TH35 (e.g., ROOT-PRO® by Mycontrol); (B2.22) Ampelomyces quisqualis strain AQ10, with CNCM accession number I-807 (e.g., AQ 10® by IntrachemBio Italia); (B2.23) Aureobasidium pullulans with DSM accession number 14940, strain with DSM accession number 14941; (B2.24) Cladosporium cladosporioides strain H39, having accession No. CBS122244, U.S. Patent Application Publication No. 2010 / 0291039 (by Stichting Dienst Landbouwkundig Onderzoek); (B2.25) Lecanicillium longisporum (formerly known as Lecanicillium lecanii and also Verticillium lecanii) strain KV01 (e.g., VERTALEC® by Koppert BV, Netherlands / Arysta); (B2.26) Penicillium vermiculatum; (B2.27) Pichia anomala strain WRL-076, having accession No. NRRL Y-30842, U.S. Patent No. 7.579.183; (B2.28) Trichoderma asperellum cepa kd (e.g., TGRO from Andermatt Biocontrol); (B2.29) Trichoderma polysporum cepa IMI 206039, having accession No. IMI 206039 (e.g., BINAB®TF WP by BINAB Bio-Innovation AB, Sweden); (B2.30) Trichoderma stromaticum, having accession No. Ts3550 (e.g., TRICOVAB® by CEPLAC, Brazil); (B2.31). (B2.31) Ulocladium oudemansii strain U3, with accession number NM 99 / 06216 (e.g., BOTRY-ZEN® by Botry-Zen Ltd, New Zealand and BOTRYSTOP® by BioWorks, Inc.); (B2.32) Verticillium albo-atrum (formerly V. dahliae), with accession number WCS850, deposited at the Central Bureau for Fungi Cultures (e.g., DUTCH TRIG® by Tree Care Innovations); (B2.33) Verticillium chlamydosporium; (B2.34) mixtures of Trichoderma asperellum strain ICC 012 (also known as Trichoderma harzianum ICC012), Petition 870260055028, dated 08 / 06 / 2026, page 62 / 321 56 / 98 possessing CABI CC IMI Accession No. 392716, (B2. 35) Trichoderma gamsii (formerly T. viride) strain ICC 080, possessing IMI Accession No. 392151 (e.g., BIO-TAMTM from Isagro USA, Inc. and BIODERMA® by Agrobiosol de Mexico, SA de CV); (B2. 36) Phlebiopsis gigantea strain VRA 1992 (ROTSTOP® C from Danstar Ferment); (B2. 37) Penicillium steckii (DSM 27859; WO 2015 / 067800) from BASF SE; (B2. 38) Chaetomium globosum (available as RIVADIOM® by Rivale); (B2. 39) Cryptococcus flavescens, strain 3C (NRRL Y-50378); (B2. 40) Dactylaria candida; (B2. 41) Dilophosphora alopecuri (available as TWIST FUNGUS®); (B2. 42) Fusarium oxysporum, strain Fo47 (available as FUSACLEAN® by Natural Plant Protection); (B2. 43) Lecanicillium lecanii (formerly known as Verticillium lecanii) strain KV01 (available as VERTALEC® by Koppert / Arysta); (B2. 44) Penicillium vermiculatum; (B2. 45) Pichia anomala, strain WRL-076 (NRRL Y-30842); (B2.46) Pseudozymaflocculosa, strain PF-A22 UL (available as SPORODEX®L by Plant Products Co., CA); (B2. 47) Trichoderma gamsii (formerly T. viride), strain ICC080 (IMI CC 392151 CABI) (available as BIODERMA® by AGROBIOSOL DE MEXICO, SA DE CV); Trichoderma polysporum, strain IMI 206039 (available as BINAB TF®WP by BINAB Bio-Innovation AB, Sweden); Trichoderma stromaticum (available as TRICOVAB® by Ceplac, Brazil); Tsukamurella paurometabola, strain C-924 (available as HEBERNEM® by Gavac); Ulocladium oudemansii, in particular strain HRU3 (available as BOTRY-ZEN® by Botry-Zen Ltd, NZ); Verticillium albo-atrum (formerly V. dahliae), strain WCS850 (CBS 276.92); Trichoderma fertile (e.g., TRICHOPLUS® product from BASF); Muscodor roseus, in particular strain A3-5 (Accession No. NRRL 30548); mixture of Trichoderma asperellum strain ICC 012 and Trichoderma gamsii strain ICC 080 (e.g., BIO-TAMTM from Isagro USA, Inc. and BIODERMA® by Agrobiosol de Mexico, SA de CV); Petition 870260055028, dated 08 / 06 / 2026, p. 63 / 321 57 / 98 Simplicilliumlanoso niveum.

[00116] The active biological compound may be a plant growth-promoting active compound. Such plant growth-promoting active compounds comprise

[00117] (E1) selected bacteria of (E1.1) Bacillus pumilus, in particular strain QST2808 (having NRRL accession No. B30087) or strain GB34 (e.g., YIELD SHIELD® from Bayer CropScience, DE); (E1. 2) Bacillus subtilis, in particular strain QST713 / AQ713 (having NRRL accession No. B-21661 and described in U.S. Patent No. 6,060,051; available as SERENADE® OPTI or SERENADE® ASO from Bayer CropScience LP, US), strain AQ30002 (having NRRL accession No. B-50421 and described in U.S. Patent Application No. 13 / 330,576), strain AQ30004 (and NRRL B-50455 and described in U.S. Patent Application No. 13 / 330,576), strain MBI 600 (e.g., SUBTILEX® from BASF SE); (E1. 3) Sinorhizobiummeliloti strain NRG-185-1 (NITRAGIN® GOLD from Bayer CropScience); (E1. 4) Bacillus subtilis strain BU1814, (available as TEQUALIS® from BASF SE); (E1. 5) Bacillus subtilis rm303 (RHIZOMAX® from Biofilm Crop Protection); (E1.6) Bacillus amylolique faciens strain pm414 (LOLI-PEPTA® from Biofilm Crop Protection), strain SB3281 (ATCC No. PTA-7542; WO 2017 / 205258), strain TJ1000 (available as QUIKROOTS® from Novozymes), strain IN937a, strain FZB42 (e.g., RHIZOVITAL® from ABiTEP, DE), strain BS27 (NRRL Accession No. B-5015); (E1.7) Bacillus mycoides strain BT155 (NRRL No. B-50921), strain EE118 (NRRL No. B-50918), strain EE141 (NRRL No. B-50916), strain BT46-3 (NRRL No. B-50922), (E1.8) Bacillus cereus family member EE128 (NRRL No. B-50917) or family member EE349 (NRRL No. B-50928), (E1.9)Bacillus thuringiensis. BT013A (NRRL No. B-50924) also known as Bacillus thuringiensis 4Q7, (E1.10) Bacillus firmus, in particular strain CNCM I Emission 870260055028, dated 08 / 06 / 2026, page 64 / 321 58 / 98 1582 (e.g., VOTIVO® from BASF SE); (E1.11) a mixture of Bacillus licheniformis FMCH001 and Bacillus subtilis FMCH002 (available as QUARTZO® (WG), PRESENCE® (WP) from FMC Corporation); (E1.12) Bacillus cereus, in particular strain BP01 (ATCC 55675; e.g., MEPICHLOR® from Arysta Lifescience, US); (E1.13) Bradyrhizobium japonicum (e.g., OPTIMIZE® from Novozymes); (E1.14) Mesorhizobium cicer (e.g., NODULATOR® from BASF SE); (E1.15) Rhizobium leguminosarium biovar viciae (e.g., NODULATOR® from BASF SE); (E1.16) Delftia acidovorans, in particular strain RAY209 (e.g., BIOBOOST® from Brett Young Seeds); (E1.17) Lactobacillus sp. (e.g., LACTOPLANT® from LactoPAFI); (E1.18) Paenibacillus polymyxa, in particular strain AC-1 (e.g., TOPSEED® from Green Biotech Company Ltd.); (E1.19) Pseudomonas proradix (e.g., PRORADIX® from Sourcon Padena); (E1.20) Azospirillum brasilense (e.g., VIGOR® from KALO, Inc.); (E1.21) Azospirillum lipoferum (e.g., VERTEX-IFTM from TerraMax, Inc.); (E1. 22) a mixture of Azotobacter vinelandii and Clostridium pasteurianum (available as INVIGORATE® from Agrinos); (E1. 23) Pseudomonas aeruginosa, in particular strain PN1; (E1. 24) Rhizobium leguminosarum, in particular bv. viceae strain Z25 (CECT Accession No. 4585); (E1. 25) Azorhizobium caulinodans, in particular strain ZB-SK-5; (E1. 26) Azotobacter chroococcum, in particular strain H23; (E1. 27) Azotobacter vinelandii, in particular strain ATCC 12837; (E1. 28) Bacillus siamensis, in particular strain KCTC 13613T; (E1. 29)Bacillus tequilensis, in particular strain NII-0943; (E1. 30) Serratia marcescens, in particular strain SRM (MTCC accession no. 8708); (E1. 31)Thiobacillus sp. (e.g. CROPAID® from Cropaid Ltd UK); (E1. 22) Bacillus megaterium, in particular strain NRRL B-67357 (see WO2018 / 129016); Bacillus psychrosaccharolyticus strain PTA-123720 (see WO2018 / 128986); and. Petition 870260055028, dated 08 / 06 / 2026, p. 65 / 321 59 / 98

[00118] (E2) selected fungi from (E2.1) Purpureocillium lilacinum (previously known as Paecilomyces lilacinus) strain 251 (AGAL 89 / 030550; for example, BIOACT® from Bayer CropScience Biologics GmbH); (E2.2) Penicillium bilaii strain ATCC 22348 (for example, JUMPSTART® from Acceleron BioAg), (E2.3) Talaromyces flavus strain V117b; (E2.4) Trichoderma atroviride strain CNCM I-1237 (e.g., ESQUIVE® WP from Agrauxine, FR), (E2.5) Trichoderma viride, e.g., strain B35 (Pietr et al., 1993, Zesz. Nauk. AR w Szczecinie 161: 125-137); (E2.6) Trichoderma atroviride strain LC52 (also known as Trichoderma atroviride strain LU132; e.g., SENTINEL® from Agrimm Technologies Limited); (E2.7) Trichoderma atroviride strain SC1 described in International Application No. PCT / IT2008 / 000196); (E2.8) Trichoderma asperellum strain kd (e.g., T-GRO® from Andermatt Biocontrol); (E2.9) Trichoderma asperellum strain Eco-T (Plant Health Products, ZA); (E2.10) Trichoderma harzianum strain T-22 (e.g., TRIANUM-P® from Andermatt Biocontrol or Koppert); (E2.11) Myrothecium verrucaria strain AARC-0255 (e.g., DITERA™ from Valent Biosciences); (E2.12) Penicillium bilaii strain ATCC20851; (E2.13) Pythium oligandrum strain M1 (ATCC 38472; e.g., POLYVERSUM®da Bioprepraty, CZ); (E2.14) Trichoderma virens strain GL-21 (e.g., SOILGARD®da Certis, USA); (E2.15) Verticillium albo-atrum (formerly V. dahliae) strain WCS850 (CBS 276.92; e.g.,DUTCH TRIG®da Tree Care Innovations); (E2.16) Trichoderma atroviridae, in particular strain no. V08 / 002387, NMI strain no. V08 / 002388, strain no. NMI No. V08 / 002389, strain no. NMI No. V08 / 002390; (E2.17) Trichoderma harzianum strain ITEM 908, strain TSTh20, strain 1295-22; (E2.18). Pythium oligandrum strain DV74; (E2.19) Rhizopogon amylopogon(for example, comprehended in MYCO-SOL®da Helena Chemical Company); (E2.20) Rhizopogon fulvigleba (for example,understood Petition 870260055028, 08 / 06 / 2026, pág. 66 / 321 60 / 98 em MYCO-SOL® from Helena Chemical Company); (E2.21) Trichoderma koningii; (E2.22) Glomus aggregatum; (E2.23) Glomus clarum; (E2.24) Glomus deserticola; (E2.25) Glomus etunicatum; (E2.26) Glomus intraradices; (E2.27) Glomus monosporum; (E2.28) Glomus mosseae; (E2.29) Laccaria bicolor; (E2.30) Rhizopogon luteolus; (E2.31) Rhizopogon tinctorus; (E2.32) Rhizopogon villosulus; (E2.33) Scleroderma cepa; (E2.34) Suillus granulatus; (E2.35) Suillus punctatapies; (E2.36) Trichoderma virenscepa GI-3; (E2.37) Pseudozyma aphidis (for example, from Yissum Research Development Company from Hebrew University of Jerusalem).

[00119] Active biological compounds that promote plant growth also include (F) bacteria and fungi that can be added as inoculants to plants or plant parts or plant organs and that, by virtue of their particular properties, promote plant growth and health. Examples are: Agrobacterium spp., Azorhizobium caulinodans, Azospirillum spp., Azotobacter spp., Bradyrhizobium spp., Burkholderia spp., in particular Burkholderia cepacia (formerly known as Pseudomonas cepacia), Gigaspora spp., or Gigaspora monosporum, Glomus spp., Laccaria spp., Lactobacillus buchneri, Paraglomus spp., Pisolithustinctorus, Pseudomonas spp., Rhizobium spp., in particular Rhizobium trifolii, Rhizopogon spp., Scleroderma spp., Suillus spp., and Streptomyces spp.; and

[00120] (G) plant extracts and products formed by microorganisms, including proteins and secondary metabolites that can be used as active biological control compounds, such as Allium sativum, Artemisia absinthium, azadirachtin, BIOKEEPER®WP, Cassia nigricans, Celastrusangulatus, Chenopodium anthelminticum, chitin, ARMOUR-ZEN®, Dryopteris filix-mas, Equisetum arvense, FORTUNE AZA®, FUNGASTOP®, HEADS UP®( Petition 870260055028, dated 08 / 06 / 2026, page 67 / 321 61 / 98 Chenopodium quinoa saponin extract), Pyrethrum / Pyrethrins, Quassiaamara, Quercus, Quillaja, Regalia, REQUIEM® insecticide, rotenone, riania / ryanodine, Symphytum officinale, Tanacetum vulgare, thymol, TRIACT® 70, TRICON®, Tropaeulummajus, Urticadioica, VERATRIN®, Viscum album, extract of Brassicaceae, in particular rapeseed powder or mustard powder.

[00121] The biologically active compounds that promote plant growth may also comprise one or more lipochitooligosaccharides (LCOs), chitooligosaccharides (COs) and / or chitinous compounds. LCOs, sometimes referred to as symbiotic nodulation signals (Nod) (or Nod factors) or as Myc factors, consist of an oligosaccharide structure of 3-1,4-linked ((GlcNAc)) N-acetyl-D-glucosamine residues with a condensed N-linked fatty acyl chain at the non-reducing end. As understood in the art, LCOs differ in the number of GlcNAc residues in the structure, the length and degree of saturation of the fatty acyl chain, and the substitutions of reducing and non-reducing sugar residues. See, for example, Denarie et al., Ann. Rev. Biochem. 65: 503 (1996); Diaz et al., Mol. Plant-Microbe Interactions 13: 268 (2000); Hungria et al., Soil Biol. Biochem. 29: 819 (1997); Hamel et al., Plant 232: 787 (2010); and Prome et al., Pure & Appl. Chem.70 (1): 55 (1998), whose contents and descriptions are incorporated herein by reference.

[00122] LCOs can be synthetic or obtained from any suitable source. See, for example, WO 2005 / 063784, WO 2007 / 117500 and WO 2008 / 071674, the contents and descriptions of which are incorporated herein by reference. In some respects, a synthetic LCO may have the basic structure of a naturally occurring LCO, but contains one or more modifications or substitutions, such as those described in Spaink, Crit. Rev. Plant Sci. 54: 257 (2000). LCOs and precursors for the construction of LCOs (e.g., COs, which may be useful as a Petition 870260055028, dated 08 / 06 / 2026, page 68 / 321 62 / 98 biologically active ingredient) can be synthesized by genetically modified organisms. See, for example, Samaine et al., Carbohydrate Res. 302: 35 (1997); Cottaze et al., Meth. Eng. 7 (4): 311 (2005); and Samaine et al., J. Biotechnol. 72:33 (1999) (e.g., Fig. 1 here, which shows structures of COs that can be recombinantly made in E. coli harboring different combinations of nodBCHL genes), the contents and descriptions of which are incorporated herein by reference.

[00123] LCOs (and their derivatives) may be included or used in compositions in various purity forms and may be used alone or in the form of a culture of LCO-producing bacteria or fungi. For example, OPTIMIZE® (commercially available from Monsanto Company (St. Louis, MO)) contains a culture of Bradyrhizobium japonicum that produces LCOs. Methods for providing substantially pure LCOs include removing microbial cells from a mixture of LCOs and the microbe, or proceeding to isolate and purify the LCO molecules via LCO solvent phase separation followed by HPLC chromatography as described, for example, in U.S. Patent No. 5,549,718. Purification can be intensified by repeated HPLC and the purified LCO molecules can be lyophilized for long-term storage.

[00124] In one embodiment, the biological control active compound is selected from Bacillus subtilis strain QST713 / AQ713; a Paenibacillus sp. having NRRL Accession No. B-50972, or NRRL Accession No. B-67129, Bacillus pumilus strain BU F-33; Bacillus subtilis strain BU1814; Bacillus sp. D747; Bacillus subtilis var.amyloliquefaciens strain FZB24; Bacillus mojavensis strain R3B; Bacillus subtilis CX-9060, Bacillus pumilus strain QST2808, Coniothyriumminitans strain CON / M / 918; Talaromyces flavuscepa V117b; Trichoderma atroviridecepa CNCM I1237; Gliocladiumcatenulatum strain J1446; Trichoderma viridecepa. Petition 870260055028, 08 / 06 / 2026, p. 69 / 3 63 / 9 B35; Metschnikowia fructicola strain NRRL Y-30752; Gliocladiumroseum strain 321U, strain ACM941, strain IK726; Trichoderma asperellum strain SKT-1; Trichoderma asperellum T34; Trichoderma asperellum strain T34; Trichoderma asperelloids JM41R; Sinorhizobiummeliloticepa NRG185-1, Purpureocillium lilacinum strain 251, Penicillium bilaii, ATCC strain 22348, Trichoderma atroviride strain LC52; Trichoderma atroviride strain SC1; Trichoderma asperellum strain kd; Trichoderma asperellum strain Eco-T; Trichoderma harzianum strain T-22; Myrothecium verrucaria strain AARC-0255; Penicillium bilaii cepa ATCC20851.

[00125] In another embodiment, the active biological compound is selected from Bacillus subtilis strain QST713 / AQ713; the Paenibacillus sp strain, having NRRL Accession No. B-50972, or NRRL Accession No. B-67129, Bacillus pumilus strain QST2808, Coniothyrium minitans strain CON / M / 91-8; Trichoderma atroviride strain CNCM I-1237; Gliocladium catenulatum strain J1446; Trichoderma viride strain B35, Metschnikowia fructicola strain NRRL Y-30752; Sinorhizobium melilotii strain NRG-185-1, Purpureocillium lilacinum strain 251, Penicillium bilaii, strain ATCC 22348.

[00126] Biologically active compounds comprise bacteria, such as spore-forming bacteria, root-colonizing bacteria, and bacteria that act as biological fungicides, insecticides, acaricides, or nematicides, or as plant growth promoters.

[00127] In another embodiment of the invention, the combinations of active compounds according to the invention comprise (a) Bacillus spp. strain NRRL B-67746 or a plant growth-promoting mutant of this strain, and (b) at least one compound selected from the following groups of bacteria that are used or may be used as biological active compounds:

[00128] Bacillus amyloliquefaciens, strain FZB42 (DSM 231179), Petition 870260055028, dated 08 / 06 / 2026, p. 70 / 321 64 / 98 or Bacillus cereus, in particular B. cereus strain CNCM I-1562 or Bacillus firmus strain I-1582 (CNCM Accession No. I-1582) or Bacillus pumilus, in particular strain GB34 (ATCC Accession No. 700814) and strain QST2808 (NRRL Accession No. B-30087), or Bacillus subtilis, in particular strain GB03 (ATCC Accession No. SD-1397), or Bacillus subtilis strain QST713 (NRRL Accession No. B-21661) or Bacillus subtilis strain OST30002 (NRRL Accession No. B-50421) Bacillus thuringiensis, in particular B. thuringiensis subspecies israelensis (serotype H-14), strain AM65-52 (ATCC Accession No. 1276), or B. thuringiensis subspecies aizawai, in particular strain ABTS-1857 (SD1372), or B. thuringiensis subspecies kurstaki strain HD-1, or B. thuringiensis subspecies tenebrionis strain NB 176 (SD-5428), Pasteuria penetrans, Pasteurias spp.(Rotylenchulus reniformis nematode)-PR3 (ATCC Accession Number SD-5834), Streptomyces microflavus strain AQ6121 (NRRL B-50550), Streptomyces galbus strain AQ6047 (NRRL Accession Number 30232). 1) Fungi and yeasts that are used or can be used as biologically active compounds:

[00129] Beauveria bassiana, in particular strain ATCC 74040, Coniothyrium minitans, in particular strain CON / M / 91-8 (DSM Accession No. 9660), Lecanicillium spp., in particular strain HRO LEC 12, Lecanicillium lecanii (formerly known as Verticillium lecanii), in particular strain KV01, Metarhizium anisopliae, in particular strain F52 (DSM 3884 / ATCC 90448), Metschnikowia fructicola, in particular strain NRRL Y-30752, Paecilomyces fumosoroseus (now: Isaria fumosorosea), in particular strain IFPC 200613, or strain Apopka 97 (ATCC Accession No. 20874), Paecilomyces lilacinus, in particular P. lilacinus strain 251 (AGAL 89 / 030550), Talaromyces flavus, in particular strain V117b, Trichoderma atroviride, in particular strain SC1 (CBS Accession Number 122089), Trichoderma harzianum, Petition 870260055028, dated 08 / 06 / 2026, p. 71 / 321 65 / 98 in particular T. harzianumrifai T39 (CNCM Accession Number I-952).

[00130] 2) Viruses that are used or may be used as biological active compounds:

[00131] Granulosis virus Adoxophyesorana (summer fruit tortrix) (GV), Granulosis virus (GV) Cydiapomonella (moth), Nuclear polyhedrosis virus (NPV), Helicoverpa armigera (cotton bollworm), Spodoptera exigua (sugar beet armyworm) mNPV, Spodoptera frugiperda (fall armyworm) mNPV, Spodoptera littoralis (African cotton bollworm) NPV.

[00132] 3) bacteria and fungi that are added as inoculants to plants or plant parts or plant organs and that, by virtue of their particular properties, promote plant growth and health:

[00133] Agrobacterium spp., Azorhizobiumcaulinodans, Azospirillum spp., Azotobacter spp., Bradyrhizobium spp., Burkholderia spp., in particular Burkholderiacepacia (formerly known as Pseudomonas cepacia), Gigasporaspp., or Gigasporamonosporum, Glomus spp., Laccaria spp., Lactobacillus buchneri, Paraglomus spp., Pisolithustinctorus, Pseudomonas spp., Rhizobium spp., in particular Rhizobium trifolii, Rhizopogon spp., Scleroderma spp., Suillus spp., Streptomyces spp.

[00134] 4) Plant extracts: products produced from plant extracts and products formed by microorganisms, including proteins and secondary metabolites, which are used or may be used as biologically active compounds:

[00135] Allium sativum, Artemisia absinthium, azadirachtin, BIOKEEPER®WP, Cassia nigricans, Celastrusangulatus, Chenopodium anthelminticum, chitin, ARMOUR-ZEN®, Dryopteris filix-mas, Equisetum arvense, FORTUNE AZA®, FUNGASTOP®, HEADS UP® (Chenopodium quinoa saponin extract), Pyrethrum / Pyrethrins, Petition 870260055028, dated 08 / 06 / 2026, p. 72 / 321 66 / 98 Quassiaamara, Quercus, Quillaja, Regalia, REQUIEM® insecticide, rotenone, riania / ryanodine, Symphytum officinale, Tanacetum vulgare, thymol, TRIACT® 70, TRICON®, Tropaeulum majus, Urtica dioica, Veratrin, Viscum album, Brassicaceae extract, in particular rapeseed powder or mustard powder, as well as bioinsecticidal / acaricidal active substances obtained from olive oil, in particular unsaturated fatty / carboxylic acids with carbon chain lengths C16-C20 as active ingredients, such as, for example, those contained in the product with the trade name FLIPPER®. Protector as a Mixing Partner (b)

[00136] A compound (a) may be combined with (b) plant protectants, such as, for example, benoxacor, cloquintoceto (-mexil), ciometrinil, cyprosulfamide, dichlormide, fenclorazol (-ethyl), fenclorim, flurazol, fluxofenim, furilazol, isoxadifen (-ethyl), mefenpir (-diethyl), naphthalic anhydride, oxabetrinil, 2-methoxy-N-({4-[(methylcarbamoyl)amino]phenyl}sulfonyl)benzamide (CAS 129531-12-0), 4-(dichloroacetyl)-1-oxa-4-azaspiro[4,5]decane (CAS 71526-07-3), 2,2,5-trimethyl-3-(dichloroacetyl)1,3-oxazolidine (CAS 52836-31-4). Relationship between Bacillus sp. (CFU) and Chemical Fungicide or Chemical Pesticide

[00137] The compound combinations according to the invention may comprise 1, 2 or even more compounds (b). Preferably, the compound combinations according to the invention comprise 1 or 2 compound(s) (b). In one embodiment, all compounds (b) are fungicides. However, if two or more compounds (b) are present, these compounds may be selected from different groups (1) to (15). For example, if one compound (b) is selected from group (1), the other compounds (b) may be selected from groups (2) to (15).

[00138] According to the invention, the expression combination Petition 870260055028, dated 08 / 06 / 2026, page 73 / 321 67 / 98 represents the various combinations of (a) and (b), for example, in a single ready-mix form, in a combined spray mixture composed of separate formulations of the single active compounds, such as a tank mix, and in a combined use of the single active ingredients when applied sequentially, i.e., one after the other in a reasonably short period, such as a few hours or days. Preferably, the order of application of compounds (a) and (b) is not essential to working the present invention.

[00139] If more than one, for example, 2 or 3, compounds (b) are present in a combination according to the invention, the weight ratio refers to the total amount of compound (b), i.e., the sum of the amount of each compound (b) present in the combination. This applies mutatis mutandis if more than one, for example, 2 or 3, compounds (a) are present.Compounds (b) may be of the same type, for example, two or more fungicides, or a combination of different types, for example, a fungicide and a biological compound or a pesticide.

[00140] If more than one, for example 2 or 3, compounds (b) are present in the combinations according to the invention, the individual compounds (b) may be present in a wide range of effective weight ratios. If, for example, 2 compounds (b) are present, which are hereinafter referred to as compounds (B1) and (B2), the effective weight ratio of B1:B2 may vary, for example, in a range of 100:1 to 1:100, preferably in a weight ratio of 50:1 to 1:50, more preferably in a weight ratio of 20:1 to 1:20. Other ratios of B1:B2 that may be used according to the present invention with increasing preference in the order given are: 95:1 to 1:95, 90:1 to 1:90, 85:1 to 1:85, 80:1 to 1:80, 75:1 to 1:75, 70:1 to 1:70, 65:1 to 1:65, 60:1 to 1:60, 55:1 to 1:55, 50:1 to 1:50, 45:1 to 1:45, 40:1 to 1:40, 35:1 to 1:35, 30:1 to 1:30, 25:1 to 1:25, 15:1 to 1:15, 10:1 to 1:10, 5:1 to 1:5, Petition 870260055028, dated 08 / 06 / 2026, p. 74 / 321 68 / 98 4:1 to 1:4, 3:1 to 1:3, 2:1 to 1:2.

[00141] Other B1:B2 ratios that can be used according to the present invention are: 95:1 to 1:1, 90:1 to 1:1, 85:1 to 1:1, 80:1 to 1:1, 75:1 to 1:1, 70:1 to 1:1, 65:1 to 1:1, 60:1 to 1:1, 55:1 to 1:1, 50:1 to 1:1, 45:1 to 1:1, 40:1 to 1:1, 35:1 to 1:1, 30:1 to 1:1, 25:1 to 1:1, 20:1 to 1:1, 15:1 to 1:1, 10:1 to 1:1, 5:1 to 1:1, 4:1 to 1:1, 3:1 to 1:1, 2:1 to 1:1.

[00142] Different weight ratios may be provided for active compounds that are not chemical fungicides or chemical pesticides, such as microbial active compounds. The colony-forming unit (CFU) is the measure of viable microbial cells, in particular fungal and bacterial cells. The ratio of a Bacillus sp. strain to a chemical fungicide or pesticide is given in bacteria CFU:g. Typically, the ratio of a Bacillus sp. strain as described herein to a chemical fungicide or pesticide is 1018 CFU:1g to 104 CFU:1g. In one embodiment, the ratio of a Bacillus sp. strain to a chemical fungicide or pesticide is 1017 CFU:1g to 105 CFU:1g. In another embodiment, a Bacillus sp. strain... As described herein for a chemical fungicide or pesticide, the concentration is 10¹⁵ CFU / 1 g to 10⁸ CFU / 1 g. In yet another embodiment, a strain of Bacillus sp., as described herein for a chemical fungicide or pesticide, has a concentration of 10¹³ CFU / 1 g to 10⁹ CFU / 1 g.In yet another embodiment, a strain of Bacillus sp. as described herein for a chemical fungicide or pesticide has a ratio of 10¹³ CFU:1 g to 10¹⁰ CFU:1 g. In one embodiment, these ratios refer specifically to ratios between Bacillus sp. strain NRRL B-67746 and a chemical fungicide or pesticide. Bacillus sp. (CFU) to Biologically Active Compound (CFU) Ratio

[00143] In the case of an active biological compound (b) being a bacterium or fungus, the amount of such active biological compound may Petition 870260055028, dated 08 / 06 / 2026, p. 75 / 321 69 / 98 to be measured in CFU. The ratio of Bacillus sp. strain to biologically active compound is typically in a range of 1000:1 CFU compound (a): CFU compound (b) to 1:1000 CFU compound (a): CFU compound (b). In another embodiment, the ratio is 100:1 CFU compound (a): CFU compound (b) to 1:100 CFU compound (a): CFU compound (b). In yet another embodiment, the ratio is 25:1 to 1:25, as well as 10:1 to 1:10. In yet another embodiment, the ratio is 4:1 to 1:4. In one embodiment, these ratios refer specifically to ratios between Bacillus spp. strain NRRL B-67746 and a bacterium or fungus. Bacillus sp. (CFU) to Biologically Active Compound (PFU) Ratio

[00144] In the case of an active biological compound being a virus, the amount of such active biological compound can be measured in PFU (plaque-forming units). The ratio of Bacillus sp. strain to active biological compound is typically in a range of 1000:1 CFU compound (a):PFU compound (b) to 1:1000 CFU compound (a):PFU compound (b). In another embodiment, the ratio is 100:1 CFU compound (a) : PFU compound (b) to 1:100 CFU compound (a) : PFU compound (b). In yet another embodiment, the ratio is 25:1 to 1:25, as well as 10:1 to 1:10. In yet another embodiment, the ratio is 4:1 to 1:4. In one embodiment, these ratios refer specifically to ratios between Bacillus spp. strain NRRL B-67746 and a virus.

[00145] In another embodiment, an active compound combination comprises (a) Bacillus spp. strain NRRL B-67746, and (b) an active compound selected from the group consisting of metalaxyl, prothioconazole, fluoxastrobin, clothianidin, Bacillus firmus I-1582, imidacloprid, Bacillus megaterium NRRL B-67357 and an LCO.

[00146] In yet another embodiment, a combination of active compounds comprises Bacillus spp. strain NRRL B-67746 and metalaxyl. Petition 870260055028, dated 08 / 06 / 2026, page 76 / 321 70 / 98

[00147] In yet another embodiment, a combination of active compounds comprises Bacillus spp. strain NRRL B-67746 and prothioconazole.

[00148] In yet another embodiment, a combination of active compounds comprises Bacillus spp. strain NRRL B-67746 and fluoxastrobin.

[00149] In yet another embodiment, a combination of active compounds comprises Bacillus spp. strain NRRL B-67746 and clothianidin.

[00150] In yet another embodiment, a combination of active compounds comprises Bacillus spp. strain NRRL B-67746 and Bacillus firmus I1582.

[00151] In yet another embodiment, a combination of active compounds comprises Bacillus spp. strain NRRL B-67746 and imidacloprid.

[00152] In yet another embodiment, a combination of active compounds comprises Bacillus spp. strain NRRL B-67746 and Bacillus megaterium NRRL B-67357.

[00153] In yet another embodiment, a combination of active compounds comprises Bacillus spp. strain NRRL B-67746 and an LCO.

[00154] In another embodiment, an active compound combination comprises (a) Bacillus spp. cepaNRRL B-67746 and (b) an active compound selected from the group consisting of thiodicarb, imidacloprid, carbendazim, thiram and Bradyrhizobium japonicum.

[00155] In yet another embodiment, a combination of active compounds comprises Bacillus spp. cepaNRRL B-67746 etiodicarb and imidacloprid.

[00156] In yet another embodiment, a combination of active compounds comprises Bacillus spp. cepaNRRL B-67746 and carbendazim and thiram.

[00157] In yet another embodiment, a combination of active compounds comprises Bacillus spp. strain NRRL B-67746 rBradyrhizobium japonicum.

[00158] Certain combinations of active compounds presented Petition 870260055028, dated 08 / 06 / 2026, p. 77 / 321 71 / 98 above may have a synergistic effect in certain compound (a) to compound (b) ratios. A synergistic effect of the active ingredients is present when the activity of the combinations of active ingredients exceeds the total activity of the active ingredients when applied individually. The expected activity for a given combination of two active ingredients can be calculated as follows (cf. Colby, SR, Calculating Synergistic and Antagonistic Responses of Herbicide Combinations, Weeds 1967, 15, 20-22): If X is the efficacy when active ingredient A is applied at an application rate of m ppm (or g / ha). Y is the efficacy when active ingredient B is applied at an application rate of n ppm (or g / ha). And the efficacy when active ingredients A and B are applied at application rates of men ppm (or g / ha), respectively, is then: X · Y 100

[00159] If the actual activity exceeds the calculated value, then the activity of the combination is superadditive, that is, there is a synergistic effect. In this case, the actually observed effectiveness must be greater than the value for the expected effectiveness (E) calculated from the formula mentioned above.

[00160] For example, the formula and analysis can be applied to an evaluation of plant growth promotion. This assay is evaluated several days after applications to the plants. 100% means plant weight that corresponds to that of the untreated control plant. Efficacy means, in this case, the additional % of plant weight compared to the untreated control. For example, a treatment that resulted in plant weights of 120% compared to the Petition 870260055028, dated 08 / 06 / 2026, page 78 / 321 72 / 98 untreated control plants would have an efficacy of 20%. If the plant growth-promoting effect of the combination (i.e., the observed efficacy for % of shoot weights of plants treated with the combination) exceeds the calculated value, then the activity of the combination is superadditive, i.e., there is a synergistic effect.

[00161] The formula and analysis can also be used to evaluate synergy in disease control or in pest control trials. The degree of effectiveness expressed as a percentage is denoted. 0% means an effectiveness that corresponds to that of control, while an effectiveness of 100% means that no disease is observed.

[00162] If the actual insecticidal or fungicidal activity exceeds the calculated value, then the activity of the combination is superadditive, that is, there is a synergistic effect. In this case, the effectively observed efficacy must be greater than the value for the expected efficacy (E) calculated from the formula mentioned above.

[00163] Another way to demonstrate a synergistic effect is the Tammes method (cf. Isoboles, A Graphic Representation of Synergism in Pesticides, in Neth. J. Plant Path., 1964, 70, 73-80).

[00164] All plants and plant parts can be treated according to the invention. In the present context, plants are understood to mean all plants and plant populations, such as wild plants or desired and undesired cultivated plants (including naturally occurring cultivated plants). Cultivated plants may be plants that can be obtained by traditional breeding and optimization methods or by biotechnological and recombinant methods, or combinations of these methods, including transgenic plants and including plant varieties that may or may not be protected by Plant Breeders' Rights. Plant parts are understood to mean all aerial and underground parts and organs of plants, such as stem, leaf, flower and root, examples of which may be Petition 870260055028, dated 08 / 06 / 2026, page 79 / 321 73 / 98 mentioned being leaves, needles, stalks, stems, flowers, fruiting bodies, fruits and seeds, and also roots, tubers and rhizomes. Plant parts also include harvested material and vegetative and generative propagation material, for example, cuttings, tubers, rhizomes, seedlings and seeds.

[00165] As mentioned above, all plants and their parts can be treated according to the invention. In a preferred embodiment, plant species and plant varieties, and their parts, that grow wild or that are obtained by traditional biological breeding methods, such as hybridization or protoplast fusion, are treated. In another preferred embodiment, transgenic plants and plant varieties that have been obtained by recombinant methods, if appropriate in combination with traditional methods (genetically modified organisms), and their parts are treated. The term plant parts or plant parts or plant parts has been explained above. The plants of the plant varieties that are in each case commercially available or in use are treated in a particularly preferred manner according to the invention.Plant varieties are understood to mean plants with new characteristics that have been cultivated either by traditional crossbreeding, mutagenesis, or recombinant DNA techniques. They can take the form of varieties, races, biotypes, and genotypes.

[00166] The treatment of plants and plant parts with the compositions according to the invention is carried out directly or by action on the environment, habitat or storage space using usual treatment methods, for example, by immersion, vaporization, atomization, misting, evaporation, dusting, fogging, dispersion, foaming, painting, spreading, injection, soaking, drip irrigation and, in the case of propagation material, in particular in the case of seeds, Petition 870260055028, dated 08 / 06 / 2026, page 80 / 321 74 / 98 In addition, by the dry seed treatment method, the wet seed treatment method, the mud treatment method, by incrustation, by coating with one or more layers and similar methods. Furthermore, it is possible to apply the active substances by the ultra-low volume method or by injecting the active substance preparation or the active substance itself into the soil.

[00167] The preferred plants are those from the group of useful plants, ornamentals, lawns, commonly used trees that are used as ornamentals in the public and domestic sectors, and forest trees. Forest trees comprise trees for the production of timber, pulp, paper, and products made from parts of the trees.

[00168] The term useful plants, as used in the present context, refers to agricultural plants that are used as plants for obtaining food, feed, ornamental plants, fuels or for industrial purposes.

[00169] Useful plants that can be treated and / or improved with the compositions and methods of the present invention include, for example, the following types of plants: grass, vines, cereals, for example, wheat, barley, rye, triticale, oats, rice, corn and millet / sorghum; beet, for example sugar beet and fodder beet; fruits, for example, pome fruits, stone fruits and soft fruits, for example apples, pears, plums, peaches, almonds, cherries and berries, for example strawberries, raspberries, blackberries; vegetables, for example beans, lentils, peas and soybeans; oilseed crops, for example rapeseed, mustard, poppies, olives, sunflowers, coconuts, palm oil, castor oil plants, cocoa and peanuts; cucurbits, for example pumpkin, cucumbers and melons; fiber plants, for example cotton, flax, hemp and jute; Citrus fruits, for example, oranges, lemons, grapefruits and tangerines; vegetables, for example, spinach, lettuce, asparagus, types of cabbage, Petition 870260055028, dated 08 / 06 / 2026, page 81 / 321 75 / 98 carrots, Allium spp., for example, onion, garlic, tomato, potato and pepper; Lauraceae, for example avocado, Cinnamomum, camphor or plants such as tobacco, nuts, coffee, cocoa, eggplant, sugar cane, tea, pepper, grapevine, hops, banana, forage crops such as alfalfa, clover, forage sorghum, latex plants and ornamentals, for example, flowers, shrubs, deciduous trees and coniferous trees.

[00170] The following plants are considered target crops particularly suitable for the application of compositions and methods of the present invention: cotton, eggplant, peat, pome fruit, stone fruits, soft fruits, corn, wheat, barley, cucumber, tobacco, vines, rice, cereals, pear, beans, soybeans, rapeseed, tomato, pepper, melon, cabbage, potato and apple.

[00171] The present invention can also be applied to any lawn, including cool-season lawns and warm-season lawns. Examples of cool-season lawns are field grasses (Poas spp.), such as Kentucky field grass (Poa pratensis L.), rough field grass (Poa trivialis L.), Canadian field grass (Poa compresa L.), annual field grass (Poa annua L.), upland field grass (Poaglaucantha Gaudin), wood field grass (Poanemoralis L.) and bulbous field grass (Poanemoralis L.) EU.); silky grass (Agrostis spp.), such as creeping silky grass (Agrostis palustris Huds.), colonial silky grass (Agrostis tenuis Sibth.), velvety silky grass (Agrostis canina L.), South German mixed silky grass (Agrostis spp. including Agrostis tenuis Sibth., Agrostis canina L. and Agrostis palustris Huds.) and redtop (Agrostis alba L.);

[00172] fescue (Festuca spp.), such as red fescue (Festuca rubra L. spp. rubra), creeping fescue (Festuca rubra L.), chewing fescue (Festuca rubra commutata Gaud.), sheep fescue (Festuca ovina L.), hard fescue (Festuca longifolia Thuill.), hair fescue Petition 870260055028, dated 08 / 06 / 2026, page 82 / 321 76 / 98 (Festu capillata Lam.), tall fescue (Festuca arundinacea Schreb.) and meadow fescue (Festuca elanor L.);

[00173] ryegrass (Lolium spp.), such as annual ryegrass (Loliummulti florum Lam.), perennial ryegrass (Lolium perenne L.) and Italian ryegrass (Lolium multiflorum Lam.);

[00174] and wheatgrass (Agropyron spp.), such as field tip grass (Agropyron cristatum (L.) Gaertn.), crested tip grass (Agropyron desertorum (Fisch.) Schult.) and western tip grass (Agropyron smithii Rydb.)

[00175] Examples of other cool-season peat grasses are beach grass (Ammophil abreviligulata Fern.), smooth brome (Bromus inermis Leyss.), timothy-like cattail (Phleum pratense L.), sand cattail (Phleum subulatum L.), orchard grass (Dactylis glomerata L.), trickling alkaline grass (Puccinellia distans (L.) Parl.) and crested dogtail (Cynosurus cristatus L.)

[00176] Examples of warm-season lawns are sagegrass (Cynodon spp. LC Rich), zoysia grass (Zoysia spp. Willd.), St. Augustine grass (Stenotaphrum secundatum Walt Kuntze), centipede grass (Eremochloa phiuroides Munro Hack.), carpet grass (Axonopus affinis Chase), Bahia grass (Paspalum notatum Flugge), Kikuyu grass (Pennisetum clandestinum Hochst. Ex Chiov.), buffalo grass (Buchloe dactyloids (Nutt.) Engelm.), bluegrass (Bouteloua gracilis (HBKw.) Lag. Ex Griffiths), seashore paspalum (Paspalum vaginatum Swartz), and oat grass (Bouteloua curtipendula (Michx. Torr.)). Cool-season lawns are generally preferred. for use according to the invention. Especially preferred are meadow grass, Bermuda grass and redtop, fescues and ryegrass. Bermuda grass is especially preferred.

[00177] In certain aspects, the compositions of the present invention are applied to the seed in about 1 χ 105a about 1 χ Petition 870260055028, dated 08 / 06 / 2026, p. 83 / 321 77 / 98 108 colony-forming units (CFU) of Bacillus spp. NRRL B67746 or a plant growth-promoting mutant strain derived from it per seed, depending on seed size. For example, for a corn seed, the application rate is about 1 x 10⁶ CFU / seed to about 1 x 10⁷ CFU / seed, and for soybeans the application rate is about 1 x 10⁵ CFU / seed to about 2 x 10⁶ CFU / seed.

[00178] When used as a soil treatment, the compositions and spore-forming bacterial cells of the present invention can be applied as a soil surface soak, applied, injected and / or applied in furrow or by mixing with irrigation water. The application rate for wet soil treatments, which can be applied at planting, during or after sowing, or after transplanting and at any stage of plant growth, is about 1 χ 1013 to about 1 χ 1016 plant growth-promoting colony-forming units (CFU) of Bacillus spp. NRRL B67746 or a mutant plant growth-promoting strain derived therefrom per hectare. In other respects, the compositions of the present invention are applied at about 1 χ 1014 to about 1 χ 1015 colony-forming units (CFU) of Bacillus spp. NRRL B67746 or a plant growth-promoting mutant strain derived therefrom per hectare.In still other aspects, the compositions of the present invention are applied to about 1 χ 1014 to about 5 χ 1014 colony forming units (CFU) of Bacillus spp. NRRL B-67746 or a plant growth-promoting mutant strain derived therefrom per hectare.

[00179] The application rate for foliar applications, such as lawn applications, is the same as that described above for soil treatment. DEPOSIT INFORMATION Petition 870260055028, dated 08 / 06 / 2026, p. 84 / 321 78 / 98

[00180] A sample of Bacillus spp. strain of the invention was deposited in the Agricultural Research Service Culture Collection located at the National Center for Agricultural Utilization Research, Agricultural Research Service, U.S. Department of Agriculture, 1815 North University Street, Peoria, Illinois 61604, USA, under the Budapest Treaty on February 14, 2019, and was assigned the following depositary designation: NRRLB-67746.

[00181] All strains described herein and having an accession number with the prefix NRRL have been deposited with the respective depository institution described above, in accordance with the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Proceedings.

[00182] These strains have been deposited under conditions that ensure that access to the culture will be available during the pendency of this Patent Application to someone determined by the Commissioner of Patents and Trademarks as having a right to such under 37 CFR § 1.14 and 35 USC §122. The filing is available as required by foreign patent laws in countries where the counterparties of the application in question or their descendants are filed. However, it should be understood that the availability of a filing does not constitute a license to practice the invention in question in derogation of patent rights granted by governmental action.

[00183] The following examples are given for purely illustrative purposes and are not limiting of the present invention. EXAMPLES Example 1: Analysis of Bacillus spp. strains in a Corn Vigor Index Platform Trial

[00184] The seed quality component responsible for performance differs between lots of high-germination seeds and is Petition 870260055028, dated 08 / 06 / 2026, p. 85 / 321 79 / 98 referred to as seed vigor or seedling vigor. Seed vigor can be affected by seed treatments. To determine the effect of NRRL B-67746 on seed vigor, maize seedling vigor tests were performed using a paper towel method with a modified protocol from the International Seed Testing Association (ISTA). Standard maize hybrid was used in these tests with a warm germination percentage of 100%. The seed lot with the highest seed vigor index is considered more vigorous (Abdul-Baki and Anderson, 1973). Two seedling vigor tests were performed.

[00185] NRRL B-67746 was compared with other Bacillus strains in the Bacillus amyloliquefaciens operational group as a seed treatment. All strains that were not commercial products were grown under the same conditions in a soy-based medium. Specifically, the strains were grown at 30 °C for 5 days until sporulation was complete using shake flasks and a soy-based medium.

[00186] In a first experiment, total broth of NRRL B-67746 and another Bacillus strain in the operational group Bacillus amyloliquefaciens (Strain 1) was applied to maize seeds at rates of 1 x 10⁶ or 1 χ¹⁰⁷ CFU per seed. For comparison, seeds were also treated with a commercial biological product based on a Bacillus strain in the operational group Bacillus amyloliquefaciens (the Commercial Biological Product), also at a rate of 1 χ¹⁰⁶ or 1 χ¹⁰⁷ CFU per seed. Water-treated seeds were used as an untreated control. In this experiment, the seedling vigor index was higher for NRRL B-67746 at a rate of 1 χ¹⁰⁶ CFU per seed, compared to the untreated control and the other Bacillus strain in the operational group, Bacillus amyloliquefaciens. At this rate, the seedling vigor index for NRRL B-67746 was similar to that of the Product. Petition 870260055028, dated 08 / 06 / 2026, page 86 / 321 80 / 98 Commercial Biological. At a rate of 1 χ¹⁰⁷ CFU per seed, NRRL B67746 showed the highest seedling vigor index compared to all other treatments, which was 70% higher than the untreated control. See Table 1 for the results. Table 1 - Seed treatments Treatments Seedling Vigor Index % Increase Under Control Untreated control (water treatment only) 12840.83 - Commercial Biological Product (1 x 10⁶ CFU / seed) 14490.62 13.0 Commercial Biological Product (1 x 10⁷ CFU / seed) 15280.97 19.0 NRRL B-67746 (1 x 10⁶ CFU / seed) 14913.30 16.0 NRRL B-67746 (1 x 10⁷ CFU / seed) 21807.52 70.0 Strain 1 (1 x 10⁶ CFU / seed) 9511.14 -25.0 Strain 1 (1 x 10⁷ CFU / seed) 11003.87 -14.0

[00187] In a second experiment, the seeds were treated with (i) a standard chemical coating consisting of a fungicide and an insecticide (referred to in this example as the chemical base) or (ii) with the chemical base and NRRL B-67746 or the Commercial Biological Product, each applied at a rate of 1 χ 106CFU per seed.

[00188] Five seeds for each treatment, with ten replicates each, were planted on autoclaved germination paper (Anchor Company, Minnesota, USA) in a completely randomized design and incubated in a growth chamber at 28 °C. After 7 days, the number of germinated seeds was counted and the percentage of the total seeds in each group that germinated was calculated. Seedling length was measured by taking the length of the part Petition 870260055028, dated 08 / 06 / 2026, page 87 / 321 81 / 98 aerial and root per plant. The seedling vigor index was calculated using the following formula: germination (%) x seedling length (cm).

[00189] The Commercial Biological Product and NRRL B-67746 were compared to a commercial chemical seed treatment. In this experiment, as in the last one, NRRL B-67746 outperformed both the Commercial Biological Product and the control for seedling vigor index. See the results in Table 2 below. Table 2 - Chemical-Based Seed Treatment Treatments for Vigos de Muda Index % Increase Under Control Control (Chemical base only) 30842.74 - Commercial Biological Product 33094.81 7.0 NRRL B-67746 36097.73 17 Example 2: Analysis of Bacillus spp. strains for initial vigor in soybeans and corn.

[00190] In a greenhouse experiment, corn and soybean seeds were treated with NRRL B-67746 or other Bacillus strains from the Bacillus amyloliquefaciens operational group in order to evaluate their effect on promoting plant growth. The treatments were an untreated control and four different strains, including NRRL B67746, strain 1, another strain from the Bacillus amyloliquefaciens operational group (Strain 2), and the Commercial Biological Product. Whole broth cultures of NRRL B-67746, strain 1, and strain 2 were prepared as described above in Example 1. Each was applied to seeds at a rate of 1 χ¹⁰⁶ CFU / seed. The untreated control (UTC) consisted of seeds treated with sterile deionized water.

[00191] The seeds were planted in sandy loam soil, in 2.5-liter square pots with 12 replicates per variety. A randomized block design was used. Throughout the course of Petition 870260055028, dated 08 / 06 / 2026, page 88 / 321 In the 82 / 98 experiment, the plants were watered from above as needed and fertilized on days 7 and 14 with 20-20-20 fertilizer at 1 g / L, 10 mL / pot. The pots were removed from the trays and placed in a completely randomized design directly on the greenhouse bench. The greenhouse chamber was regulated to 23.89 to 26.67 °C with a photoperiod of 14 / 10 hours. Twenty-one days after planting, plant growth promotion was evaluated by cutting the shoots and measuring leaf area with a portable LI-3000C leaf area meter (LI-COR® Biosciences, Lincoln, Nebraska, USA). The average leaf areas of soybean and corn treated with NRRL B-67746 were significantly larger than untreated control seeds or seeds treated with strain 1 or strain 2. The Commercial Biological Product exhibited similar leaf area in corn and a slightly larger leaf area than NRRL B-67746 in soybean. The results are shown in Table 3 below. Table 3 - Results of Plant Growth Promotion Treatment Corn harvest (Total leaf surface area cm2 / plant) n = 12 Soybean harvest (Total leaf surface area cm2 / plant) n = 12 Untreated control 45.07 48.03 Commercial Biological Product 50.37 58.98 NRRL B-67746 50.45 55.07 Strain 1 43.53 45.95 Strain 2 42.02 43.25 Example 3: Nodule Mass and Plant Growth after Treatment with Bradyrhizobium and NRRL B-67746

[00192] Biological nitrogen fixation by the soybean symbiont Bradyrhizobium japonicum is an important biofertilizer input for soybeans in North and South America. Therefore, it is important to evaluate whether an added biological treatment impacts the nodulation efficiency provided by Bradyrhizobium as assessed by nodulation mass. Petition 870260055028, dated 08 / 06 / 2026, page 89 / 321 83 / 98 of the nodule and overall plant growth. In another experiment, soybean seeds were treated with a chemical base consisting of an insecticide and a fungicide typical for North America (NA) or South America (SA) applied in combination with a commercially available Bradyrhizobium inoculant capable of biological nitrogen fixation. The plants resulting from this treatment were compared to plants from seeds treated with the same chemical base, Bradyrhizobium, and a total broth culture of NRRL B-67746, grown as described in Example 1 above. The Bradyrhizobium inoculant and B-67746 were each applied at a rate of 1 x 10⁶ CFU / seed. After 28 days of growth, several plant characteristics were evaluated. Plants treated with NRRL B-67746, Bradyrhizobium, and the chemical base showed increased plant height, leaf area, and average root surface area compared to those treated with the chemical base and Bradyrhizobium alone. Table 4 - Nodule mass and plant growth characteristics after treatment with a base treatment + / - NRRL B 67746 Treatment Mass % of Height % of Area % of Area % of freshness n-to plant n-to surface n-to surface n-to of Under , 28 Under í-cie Under í-cie Under nodu- Control days Average control Average control Control los o-le after o-le of o-le of o-le (g / plant leaf root n-ta) plant (cm2 / plant (cm2 / plant (cm) plant) plant) Base 0.10 9.95 72 47.66 Chemistry (NA)+Bradyrhizobium Petition 870260055028, dated 08 / 06 / 2026, page 90 / 321 84 / 98 Treatment Fresh mass of nodules (g / plant) % Increase Under Control Plant height, 28 days after planting (cm) % Increase Under Control Average leaf surface area (cm2 / plant) % Increase Under Control Average root surface area (cm2 / plant) % Increase Under Control Chemical Base (NA)+Bradyrhizobium + B-67746 0.11 10% 10.2 3% 74 3% 45.45 -5% Chemical Base (SA)+Bradyrhizobium 0.20 14.4 72 135 Chemical Base (SA)+Bradyrhizobium + B-67746 0.22 10% 17% 18% 111% 54% 135% 0% Example 4 - qPCR studies to identify the presence of NRRL B-67746 in soybean nodules

[00193] Soybean plants were treated with 1 χ 10⁶ CFU / mL of a commercially available Bradyrhizobium inoculant, alone or in combination with NRRL B-67746 at 1 χ 10⁶ CFU / mL. Soybean nodules were randomly collected from inoculated plants after four weeks. The collected nodules were surface sterilized with a 1% bleach solution for 5 minutes, followed by 70% ethanol for one minute, and then rinsed with water. The nodules were passed over a flame for sterilization and then rinsed three times with sterile distilled water. The nodules were rapidly agitated in 100 pL of water and 100 pL of water was seeded to check for microbial growth or contamination. The presence of NRRL B-67746 within the soybean nodules was determined by crushing the nodules separately in microtubes. Petition 870260055028, dated 08 / 06 / 2026, page 91 / 321 85 / 98 sterile 1.5 mL samples were used, followed by DNA extraction and qPCR using primer sets designed to be specific for NRRL B-67746 and Bradyrhizobium. Table 5 shows the detection of NRRL B67746 in several nodules tested separately. Table 5 - Detection of NRRL B-67746 in Nodules Treatment Contamination (Y / N) Nanodroplet Concentration (ng / pL) Bradyrhizobium Detection (Y / N) NRRL B-67746 Detection (Y / N) NRRL B-67746 N 35.57 YY NRRL B-67746 N 27.88 YY NRRL B-67746 N 28.76 YY NRRL B-67746 N 2.983 Y Below Cutoff NRRL B-67746 N 79.65 YY NRRL B-67746 N 2.629 Y Below Cutoff Control N 235.8 YN Control N 304 YN Control N 294.3 YN Example 5: Improving Nitrogen Fixation and Assimilation Efficiency in Soybean Plants

[00194] Soybean seeds were treated with NRRL B-67746 and a commercially available Bradyrhizobium japonicum inoculant and tested to determine if such treatment improved nitrogen fixation and assimilation efficiency in soybean plants. Whole broth cultures of NRRL B-67746 were grown by transferring a colony from a plate to 50 mL of tryptic soybean broth (TSB) in a 250 mL baffle flask. The inoculated flask was incubated at 30 °C and 220 RPM for 24 hours. Then, 1 mL of this seed flask was transferred to 50 mL of Schaeffer TSB medium in a 250 mL baffle flask and incubated at 30 °C and 220 RPM for 72 hours. A small portion of this sample was evaluated to determine colony-forming units. Soybean seeds were treated Petition 870260055028, dated 08 / 06 / 2026, page 92 / 321 86 / 98 with 1 χ 106 CFU of total broth culture of B-67746 per seed. A 1:100 dilution of the Bradyrhizobium strain culture was applied via irrigation directly to the seed during planting. Control seeds were treated with the Bradyrhizobium potion only. Nitrogenase Method

[00195] Twenty-five days after planting, roots of two-week-old soybean seedlings were harvested by cutting the entire root system (above the primary root). The roots were washed with water and dried on paper towels. The roots were placed in a 50 mL Falcon tube and covered with a rubber septum. 5 mL of acetylene were injected into the tube. The samples were incubated for 1 h before gas chromatography (GC) injection. 10 pL of the gas from the empty space in the tube was injected into the GC. Ethylene production was monitored at 0 h, 1 h, and 3 h of acetylene incubation. The results are provided in Table 6 below. Seeds treated with NRRL B-67746 showed significantly higher nitrogenase activity compared to the Bradyrhizobium-based treatment. Table 6 - Nitrogenase activity for seeds treated with NRRL B-67746 Medium Soybean Variety SE B-67746 + Bradyrhizobium Variety 1 237.1825927 109.4159 Bradyrhizobium only Variety 1 87.15976517 32.6298 B-67746 + Bradyrhizobium Variety 2 77.54834969 34.57229 Bradyrhizobium only Variety 2 46.42325835 1.728181 Ureides method Extraction

[00196] Fresh six-week-old soybean plants were harvested, and the nodule, root, stem, and petiole were separated. Each plant part was ground in a mortar using liquid nitrogen. 500 mg of freshly ground samples were mixed in 200 µL of 0.5 N NaOH. Petition 870260055028, dated 08 / 06 / 2026, page 93 / 321 87 / 98 and 300 pL of water. The samples were heated to 100°C for 8 minutes. After cooling, 200 mL of 0.65 N HCl were added and the mixture was heated for an additional 8 minutes at 100°C. After cooling, the mixture was centrifuged for 15 minutes at 17,000 g. Color Development

[00197] 100 mL of supernatant and 500 mL of water were mixed with 100 mL of phenylhydrazine and the mixture was left to stand for 30 minutes or more at room temperature. The tubes were cooled to 0 °C in an ice water bath and 500 mL of concentrated HCl pre-cooled to -20 °C and 100 mL of ferricyanide solution were added. The tubes were placed at room temperature and the color was read at 535 nm after 15 minutes. The results are shown in FIG. 1. Soybean seedlings treated with NRRL B-67746 showed significantly higher ureide content in several plant parts when compared to the baseline treatments. Example 6: Field Trials in Corn

[00198] Over three years, field tests were conducted in maize to compare the yield-enhancing capabilities of various Bacillus strains in the Bacillus amyloliquefaciens operational group. All non-commercial strains were cultured at 30 °C for 5 days until sporulation was complete using shake flasks and a soy-based medium.

[00199] The resulting total broths were applied to maize seed along with a chemical base treatment or a chemical and biological base treatment, as applicable per assay. In Year 3, a preservative was added to the total broth before its application to the maize seed. The total broths were applied to the seeds at the following rates: 1-2 χ 10⁶ CFU / seed for years 1 and 2 and 2 χ 10⁶ CFU / seed for year 3. The treated maize seeds were planted and cultivated during the normal season until Petition 870260055028, dated 08 / 06 / 2026, p. 94 / 321 88 / 98 harvest.

[00200] In each trial, seeds treated with the strains established in the tables below were compared to a treatment that had all the same components except the strain. Typically, there were four plots per trial, but in some trials in Year 2, there were three plots per trial. RCBD (randomized complete block design) was used for all trials. Outlier plot data were removed from the trial data, such as plots with extremely low yield or extreme outliers based on the yield range per trial. Table 7, below, shows the performance of NRRL-B-67746 compared to other strains of the same operational group when applied on a chemical basis. The results are based in part on modeling of the raw data. The model estimates accounted for spatial variation and stochasticity within the fields and were produced by linear mixed models with restricted maximum likelihood.This is a standard method used in many studies and produces more accurate results than simply summarizing raw data. Some raw data is also presented to show the differences between the raw data and the data generated through modeling. For example, the raw data shows a large yield gain for strain 5, but the modeled data is more predictive as it takes into account the low number of trials for strain 5 and field variations. Although the yield gains for B-67746 are numerically different from the other treatments, the results are not statistically significant. However, this is quite common when comparing multiple trials over several years, even with modeling, due to differences within the fields and between trials and years. Therefore, Table 7 also shows the Consistency between trials, which is the rate at which the treatment delivered. Petition 870260055028, dated 08 / 06 / 2026, page 95 / 321 89 / 98 yield increase relative to the control (chemical baseline or biological reference chemical baseline). Consistency 0.5 and Consistency 2.5 are the rates at which the treatment gave a yield increase of 0.5% or 2.5%, respectively, compared to the control. This is a common way for agronomists to analyze the effectiveness of various treatments. Predicted Consistency is the modeled version of these raw data. Confidence intervals (CI) are also provided in Tables 7 and 8 for predicted consistency. The lower 95% CI indicates that the yield gain for new trials would not be less than this rate, with 95% confidence. The higher 95% CI indicates that the yield gain in new trials would not be above this rate, with 95% confidence. Table 7 Strain to 2 B6774 6 Strain to 1 Strain to 3 Chemical base to Strain to 4 Biological or commercial product Strain 5 Strain to 6 Number of Trials 63 58 50 29 68 21 21 10 10 Consistency 0 (%) 63.5 52.4 57.1 80 80 Consistency 0.5 (%) 41.3 55.2 36 31 0 23.8 23.8 20 20 Consistency 2.5 (%) 23.8 24.1 12 10.3 0 4.8 9.5 Consistency (90%). 62.5 71.6 63.8 60.5 N / A 58.4 66.4 63.2 66.4 Lower 95% CI for predicted consistency 0 (%) 52.9 62.3 53.1 46.1 N / A 41.5 43.8 38.8 Upper CI for predicted consistencies 71.4 79.6 73.6 73.6 N / A 73.9 80.2 83.1 85.2 Petition 870260055028, of 08 / 06 / 2026, p. 96 / 321 90 / 98 0 (%) Average yield gain (gross) 1.23 9 2.63 5 -0.69 2 1.32 7 0 -0.05 1 2.159 11.59 7 3.83 6 Standard error of yield gain (gross) 9.01 6 9.63 3 9.63 4 9.31 3 8.739 9.17 7 8.223 5.891 5.92 Average yield gain (modeled) 1.42 5 2.13 1 1.16 1 1.10 3 0 0.58 5 1.092 0.433 1.32 9 Standard error of yield gain (modeled) 5.94 8 5.92 6 6.46 9 6.81 5 5.484 6.48 6.48 5.029 5.03 7

[00201] Table 8, below, shows the performance of NRRL-B-67746 compared to other strains of the same operational group when applied on a chemical and biological reference basis. The same type of data is presented as in Table 7, except that gross yield gains are not provided. Table 8 Biological Chemical Basis B-67746 Strain 2 Strain 1 Number of trials 70 32 16 16 Consistency 0 (%) 0 46.9 43.8 56.2 Consistency 0.5 (%) 0 28.1 18.8 25 Consistency 2.5 (%) 0 3.1 6.2 0 Predicted Consistency 0 (%) N / A 56.7 48.4 57.2 Lower 95% confidence interval for predicted consistency 0 (%) N / A 42.9 29.8 37.9 Upper 95% confidence interval for predicted consistency 0 (%) N / A 69.7 67.3 74.9 Average yield gain (modeled) 0 0.379 -0.158 0.318 Petition 870260055028, dated 08 / 06 / 2026, page 97 / 321 91 / 98 Biological Chemical Basis B-67746 Strain 2 Strain 1 Standard error of yield gain (modeled) 6.151 6.247 5.877 5.886 Example 7: Yield Benefit in Corn Field Trials

[00202] Corn field trials were conducted over five years (including the three years evaluated in Example 6) to assess the effect of the NRRL B-67746 strain on corn yield performance. In years 1 and 2, NRRL B-67746 was grown at 30 °C for 5 days until sporulation was complete using shake flasks and a soybean-based medium. In years 3 and 4, NRRL B-67746 was grown under the same conditions for 2 days using a bioreactor. In year 5, NRRL B-67746 was grown under the same conditions for 2 days using a bioreactor and a yeast extract-based medium.

[00203] The resulting total broths were applied to hybrid maize seeds along with a base fungicide and insecticide treatment at a rate of 1–2 x 10⁶ CFU / seed for years 1 and 2; 2 x 10⁶ CFU / seed for years 3–5. An additional rate of 1 x 10⁷ CFU / seed was also used in Year 5. In years 3–5, a preservative was added to the total broth before its application to the maize seeds. Hybrid maize seeds treated only with the base fungicides and insecticides were included in the trials as controls. Treated hybrid maize seeds were planted and grown in 4-row plots 30–40 feet long each year in a variety of maize-growing geographic locations following standard agricultural practices until harvest. The trials utilized a randomized complete block design. Each trial consisted of different treatments. Typically, there were four repetitions for each treatment, including site controls.A germplasm was tested in each trial each year, although the germplasm may... Petition 870260055028, dated 08 / 06 / 2026, page 98 / 321 92 / 98 change from year to year. The relative maturity of the germplasm tested was combined with the geographical location.

[00204] At harvest, corn plants in the two middle rows in each 4-row plot were harvested for yield measurements to avoid edge effects. Yield measurements from individual plots were combined. Data from plots with outlier values ​​were removed from the trial data, such as plots with extremely low yields or extreme outliers based on the yield range per trial. Table 9 presents the results of year- and location analysis of yield changes (delta) for corn plants grown from hybrid corn seed treated with the NRRL B-67746 strain compared to control plants treated only with base pesticides. The results were based in part on modeling the raw data. The model estimates took into account spatial variation and stochasticity within and between fields, and were produced by linear mixed models with restricted maximum likelihood.This is a standard method used in many studies and produces more accurate results than simply summarizing raw data. Table 9 - Yield increase in corn plants grown from seeds treated with NRRL B-67746 compared to plants grown from control seeds. Locations Yield Delta* (Acre / Acre) Win Rate** (%) p-value Number of Trials All 2.0 61 0.09 147 *: Yield delta: represents the change in yield in acres per acre compared to the control treated with basic pesticides. **: Win rate: % of fields where the treatment yield was higher than the control yield.

[00205] As shown in Table 9, NRRL B-67746 resulted in a yield gain of 2 alqueires / acre out of a total of 147 Petition 870260055028, dated 08 / 06 / 2026, page 99 / 321 93 / 98 trials over five years showed a 61% gain rate compared to the control treated only with the base pesticide. Example 8: NRRL B-67746 Improved nutrient uptake in maize plants grown in controlled environments

[00206] To evaluate the effect of NRRL B-67746 on nutrient uptake, hybrid maize seeds treated with total broth of NRRL B-67746 at a rate of 2 χ 106CFU per seed or water (as a control) over a base fungicide and insecticide treatment were planted in sandy soil in 5-inch-tall pots and grown in a greenhouse or growth chamber in two separate studies. Plants were grown in a greenhouse with a 16-hour daytime and 8-hour nighttime photoperiod, daytime temperature of 29 to 33 °C and nighttime temperature of 20 °C, and relative humidity of 52 to 59%; or in a growth chamber with a photoperiod of 16 hours during the day and 8 hours at night, a daytime temperature of 28 °C and a nighttime temperature of 18 °C, and a relative humidity of 55%. The plants were watered by subirrigation at least once a day and fertilized with a 20-20-20 fertilizer twice: at the initial V3 stage and at the final V3 stage.The experiments used a randomized complete block design and contained 16 plants per treatment.

[00207] The second fully expanded leaf from the top of each plant was harvested at the V3 stage from plants grown in a growth chamber and at the V4 stage from plants grown in a greenhouse. Pooled samples were processed, divided into 4 replicates, and subjected to nutrient analysis using standard methods known in the art (for nitrogen assay: http: / / www.elementar.de / en / products / nprotein-analysis / rapid-n-exceed.html; for other nutrients, Havlin, JL, and PN Soltanpour. 1980. Method of digesting plant tissue with nitric acid for use with inductively coupled plasma spectrometry. Com. Soil Sci. Plant Anal. 11 (10): 969-980. Modification with addition of Petition 870260055028, dated 08 / 06 / 2026, page 100 / 321 94 / 98 hydrogen peroxide during digestion, determined using inductively coupled plasma optical emission spectrometry (ICP-OES)). In general, maize plants grown from seeds treated with NRRL B-67746 exhibited increased uptake of all nutrients compared to control plants grown from seeds treated with water and the base pesticides, as shown in Table 10. Significant increases in total nitrogen, calcium, and manganese content were consistently observed in both studies, while significant increases in the uptake of sulfur, magnesium, zinc, iron, copper, and boron were also observed in one of the studies. Table 10 - Enhanced nutrient uptake in corn plants grown from seeds treated with NRRL B-67746 compared to plants grown from control seeds. Controlled Environment % Increase Under Control Total Nitrogen Phosphorus Potassium Sulfur Calcium Magnesium Zinc Iron Manganese Copper Boron Greenhouse 12* 6 3 3 21** 13 9 7 28* 0 8 Growth Chamber 16** 13 14 35* 17* 26* 28** 33* 22* 32* 43* *: p-value < 0.1 **: p-value < 0.2 Example 9: NRRL B-67746 Improves nutrient absorption in soybean plants grown in controlled environments.

[00208] To evaluate the effect of NRRL B-67746 on nutrient uptake, soybean seeds treated with total broth NRRL B-67746 at a rate of 2 χ 106CFU per seed or water (as a control) over a base fungicide and insecticide treatment were planted. Petition 870260055028, dated 08 / 06 / 2026, page 101 / 321 95 / 98 in sandy loam soil in 5-inch-tall pots and grown in a greenhouse or growth chamber in two separate studies. Plants were grown in a greenhouse with a 16-hour daytime and 8-hour nighttime photoperiod, daytime temperature of 29–33°C and nighttime temperature of 20°C, and relative humidity of 52–59%; or in a growth chamber with a 16-hour daytime and 8-hour nighttime photoperiod, daytime temperature of 28°C and nighttime temperature of 18°C, and relative humidity of 55%. Plants were irrigated by subirrigation at least once a day and fertilized with a 20-20-20 fertilizer twice: at the initial V3 stage and at the final V3 stage. The experiments used a randomized complete block design and contained 16 plants per treatment.

[00209] The second fully expanded leaf from the top of each plant was harvested at the V3 stage for plants grown in a growth chamber and at the V4 stage for plants grown in a greenhouse.Pooled samples were processed, divided into 4 replicates, and subjected to nutrient analysis using standard methods known in the art (For nitrogen assay: http: / / www.elementar.de / en / products / nprotein-analysis / rapid-n-exceed.html; for other nutrients, Havlin, JL, and PN Soltanpour. 1980. Method of digesting plant tissue with nitric acid for use with inductively coupled plasma spectrometry. Com. Soil Sci. Plant Anal. 11 (10): 969-980. Modification with addition of hydrogen peroxide during digestion, determination using inductively coupled plasma optical emission spectrometry (ICP-OES)). In general, soybean plants grown from seeds treated with NRRL B-67746 exhibited greater uptake of all nutrients compared to control plants grown from seeds treated with water and the base pesticides, as shown in Table 11. Significant increases in total nitrogen, potassium, calcium, manganese, sulfur, magnesium, zinc, and iron contents were observed in a Petition 870260055028, dated 08 / 06 / 2026, page 102 / 321 96 / 98 of the studies. Table 11 - Improvement in nutrient absorption in soybean plants grown from seeds treated with NRRL B-67746 compared to plants grown from control seeds. Controlled Environment % Increase Under Control Total Nitrogen Phosphorus Potassium Sulfur Calcium Magnesium Zinc Iron Manganese Copper Boron Greenhouse 22** 13 25** 19** 20** 21** 11** 24** 12** 30 13 Growth Chamber 9 2 5 4 2 2 12 18 6 5 2 **: p-value < 0.2 Example 10: NRRL B-67746 Improved root growth in maize and soybean plants grown in controlled environments.

[00210] Corn and soybean seeds treated with NRRL B67746 total broth at a rate of 2 χ 106CFU per seed or water (as a control) on top of a base fungicide and insecticide treatment were planted and grown in a greenhouse or growth chamber as described in Examples 9 and 10. The experiments used a randomized complete block design and contained 16 plants per treatment.

[00211] Whole plants were harvested at the V3 stage in the growth chamber or the V4 stage in the greenhouse and thoroughly washed with water to remove any soil residue from the roots. The roots of each plant were collected and weighed. The results are summarized in Table 12. Root biomass is expressed as grams of fresh root weight. The control represents plants grown from seeds treated with water on top of a base fungicide and insecticide treatment. B-67746 represents plants grown from seeds treated with strain B-67734 on top of the treatment with Petition 870260055028, dated 08 / 06 / 2026, page 103 / 321 97 / 98 fungicide and insecticide base. Treatment with B-67746 significantly improved the root biomass of maize plants grown in greenhouses and growth chambers (Table 12). Similar improvement was also observed for soybean plants, although the improvement for plants grown in growth chambers was numerical. Table 12 - NRRL B-67746 Improved Root Biomass in Corn and Soybean Plants Harvest in Controlled Environment Treatment Medium Fresh root biomass (g / plant) Standard Error p-value (Comparison with control) Corn GH Control 10.89 0.39 B-67746 12.36 0.76 0.1 Growth Chamber Control 1.86 0.1 B-67746 2.43 0.13 2.00 χ 10-3 Soybean GH Control 4.32 0.17 B-67746 5.1 0.19 5.00 χ 10-3 Growth Chamber Control 0.13 0.01 B-67746 0.15 0.01 0.26 Example 11: B-67746 Increased Phosphate Solubilization Inorganic

[00212] NRRL B-67746 was cultured in liquid LB medium at 30°C and 400 rpm for 24 hours. After incubation, 50 pL aliquots of the B-67746 culture were added to each well of a 96-well deep block filled with 950 pL of sterile NBRIY medium (glucose 10 g / L, MgSO4 · 7 H2O 0.1 g / L, KCl 0.2 g / L, MnSO4-H2O 0.002 g / L, NaCl 0.2 g / L, (NH4)2SO4 0.5 g / L, bromophenol 0.025 g / L) containing 5 g / L of tricalcium phosphate or 5 g / L of ferric phosphate. The 96-well blocks were incubated in a shaker at 30°C and 400 rpm with 85% humidity for 72 hours. At the end of the incubation period, the blocks were sealed with plate film and centrifuged at 4700 rpm for 10 hours. Petition 870260055028, dated 08 / 06 / 2026, page 104 / 321 98 / 98 minutes. A 200 µL aliquot of the supernatant from each well of the block was transferred to a well of a 96-well Nunc microplate. The absorbance of the mixture at OD600 was measured using a plate reader. The experiment was repeated twice, each time with 16 replicates per sample. Uninoculated culture medium was used as a control.

[00213] As shown in Table 13, B-67746 was able to solubilize two different sources of inorganic phosphate compared to the control without B-67746, as indicated by a reduction in OD600 absorbance. Table 13 - Enhanced Solubilization of NRRL B-67746 Inorganic Phosphate Treatment Type of Phosphate Average Absorbance at OD600 Standard Deviation Control Ferric phosphate 1.3464 0.2174 Tricalcium phosphate 1.5017 0.2089 B-67746 Ferric phosphate 0.5688 0.1108 Tricalcium phosphate 1.2483 0.0417

[00214] Unless otherwise defined, all technical and scientific terms in this document have the same meaning as commonly understood by someone skilled in the art to which this invention pertains. All publications, patents, and patent publications cited are incorporated by reference herein in their entirety for all purposes.

[00215] It is understood that the invention described is not limited to the specific methodology, protocols and materials described, as these may vary. It is also understood that the terminology used in this document is for the purpose of describing particular embodiments only and is not intended to limit the scope of the present invention, which will be limited only by the appended claims. Petition 870260055028, dated 08 / 06 / 2026, p. 105 / 321

Claims

1 / 2 CLAIMS 1. Composition, characterized in that it comprises a biologically pure culture of Bacillus spp. strain NRRL B-67746, wherein the composition further comprises a Bradyrhizobium inoculant, a fungicide, an insecticide, a nematicide or a biologically active compound.

2. Composition according to claim 1, characterized in that it further comprises an agriculturally acceptable vehicle.

3. Composition according to claim 1, characterized in that it comprises at least 1 x 10⁵ CFU per ml of Bacillus spp. NRRL B-67746.

4. Composition according to claim 1, characterized in that said biological active compound is one or more lipo-chito-oligosaccharides.

5. A method for treating a plant to increase plant growth, characterized in that the method comprises applying to the plant, a part of the plant and / or a locus of the plant, a composition comprising Bacillus spp. strain NRRL B-67746.

6. Method according to claim 5, characterized in that the composition comprises at least 1 x 10⁵ CFU per ml of Bacillus spp. NRRL B-67746.

7. Method, according to claim 5 or 6, characterized in that it comprises applying the composition to the seed, preferably wherein the composition is applied at a rate of 1 χ 10⁵ to 1 χ 10⁸ colony forming units (CFU) of the NRRL B-67746 strain per seed.

8. Method, according to claim 5, characterized in that the composition is applied to the soil at a rate of 1 χ Petition 870260055028, dated 08 / 06 / 2026, page 106 / 321 2 / 2 1013 to 1 χ 1015 colony forming units (CFU) per hectare of the NRRL B-67746 strain.

9. A method according to any one of claims 5 to 7, characterized in that the plant is selected from the group consisting of cotton, corn, sorghum, soybean and beet.

10. Seed, characterized in that it is coated with a composition, as defined in claim 1. Petition 870260055028, dated 08 / 06 / 2026, page 107 / 321

Images